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ABSTRACT
B-cell antigen receptor (BCR) [engagement by antigen/signalling] contributes to 
Chronic lymphocytic leukaemia (CLL)-cell selection and survival. This 
signalling pathway has been investigated and the main Src family kinase (SFK) 
involved has been identified as Lyn, as in normal B cells. Expression of another 
SFK Lymphocyte specific tyrosine kinase (Lck) has also been described in CLL 
cells but the factors leading to the expression of this kinase, which is essential for 
T cell antigen receptor signalling, and its contribution to CLL cell survival have 
not been previously investigated. This study confirms the presence of Lck 
mRNA and protein in CLL cells as previously shown but uses highly purified 
cells to ensure that there was no contamination of T cell-specific Lck affecting 
the quantification as was thought to be the case in some B-l cell studies. The 
levels of protein vary from 20 to 256pg per pg of total cellular protein and do not 
correlate with CLL prognostic markers or the amount of Lck mRNA. The 
regulation of the expression of the protein was investigated and suggested that 
the mechanism differs from that of T cells. It was shown that expression of Lck 
protein cannot be stimulated in CLL using IL-2 and crosslinking of the BCR, 
which can induce Lck protein in normal B cells. Incubation of CLL cells for 48 
hours with an Lck inhibitor induced apoptosis in all CLL cases to some extent, 
but to a greater degree in unmutated (UM) than mutated cases (p<0.01). 
Stimulation-induced survival of CLL cells by CpG, anti-IgM or CD40 ligand 
was also reduced by the Lck inhibitor. The specificity of the Lck inhibitor for 
Lck and not other Src family kinases was confirmed by analysis of the activating 
tyrosine residues in Lck (Y394) and Lyn (Y396) following treatment of CLL 
cells with the inhibitor. The mechanism of Lck-induced survival was 
investigated and it was shown that treatment of CLL cells with the Lck inhibitor 
decreased phosphorylation of ERK, IKK and Akt which contribute to CLL-cell 
survival in response to BCR engagement. Pro and anti-apoptotic proteins were 
also investigated following treatment with the Lck inhibitor and cleavage of Bcl- 
xL and a reduction in Mcl-1 levels were observed. This study shows that Lck 
has a pro-survival role in CLL, especially in UM cases, and would therefore be a 
potential therapeutic target either with a specific targeted therapy or using a 
general Src kinase inhibitor such as Dasatinib which would also inhibit Lyn.
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Chapter 1
General introduction
1.1 Overview
The subject of this thesis is the role of the Src-family kinase (SFK) 
Lymphocyte specific tyrosine kinase (Lck) in the pathogenesis of Chronic 
Lymphocytic Leukaemia (CLL). Lck was originally found to be expressed 
in T cells [1] where it plays a crucial role in their development and function 
[2], The enzyme was later found to be also expressed in subsets of normal 
and malignant B cells, including CLL cells [3, 4]. The function of Lck has 
been clearly defined in T cells and its equivalent role in B cells has been 
mainly ascribed to another SFK Lyn [5,6]. The contribution of Lck to the 
development and function of normal or malignant B cells remains to be 
defined.
1.2 Cell of origin in CLL
1.2.1 Haematopoietic cell differentiation
All classes of blood cells are derived from hematopoietic stem cells 
(HSCs) in adults, partly through progressive loss of differentiation 
potentials for other cell lineages. Once the HSC receives signals to undergo 
differentiation, there is a gradual loss of self-renewal ability. The
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traditional view of the decision between the two lineages has been revised 
in recent years. New models of haematopoiesis have been fonned due to 
the identification of progenitors with diverse cell fates [7-11].
In addition to transcription factors, increasing evidence suggests that 
microenviromnents in the bone marrow may play a role in lymphoid 
specification and commitment.
Hematopoietic cells can be separated into two major lineages: the 
lymphoid lineage which includes T, B, and natural killer (NK) cells, and 
the myeloid lineage comprised of erythrocytes, megakaryocytes, 
granulocytes, and monocyte/macrophages [12].
1.2,2 Lymphoid versus myeloid cell fate selection
The identification of distinct lymphoid and myeloid progenitor cells 
[known as the common lymphoid progenitor (CLP) [13] or common 
myeloid progenitor [7] (CMP)] supported a model whereby the two 
lineages develop independently downstream of HSCs (figure 1.1a). 
However, more recent work using FACS analysis to identify different 
progenitor cell populations has challenged this traditional view, and 
allowed a new developmental pathway model to be formed as shown in 
figure 1.1b. Both models support differentiation from CD34 positive 
multipotent progenitor cells (MPPs). The model in figure 1.1b is now
2
favoured because FACS analysis of CD34 positive MPPs showed that this 
population is far more heterogeneous in terms of antigen expression than 
was originally thought.
Dendritic cell
Figure 1.1 Summary of the current model of lymphoid versus myeloid 
fate decision [141.
Lineage commitment to CMPs appears to be dependent upon expression of 
the transcription factor GATA-1. With respect to differentiation to the CLP 
a series of steps seems to be required; the first of these steps involves
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expression of Flt3 which appears to direct cells to differentiate into the 
LMPP (lymphoid multipotent progenitor cells). The second step involves 
expression of the transcription factor PU-1 and this assists the 
differentiation of cells into the granulocyte-macrophage progenitors 
(GMP). The final step of differentiation to CLP requires the expression of 
the Ikaros gene. The CLP gives rise to either T, B or lymphoid dendritic 
cells.
1.2.3 B cell differentiation
Commitment of CLPs to the B lineage is controlled by E2A family 
transcription factors, and expression of the components that are required 
for antigen receptor gene rearrangement (RAG/TdT genes). Expression of 
the IgH and L chain genes and the mb-1 gene responsible for production 
of Iga (part of the B cell receptor complex) are seen as signs of 
irreversible differentiation.
B lymphocytes express clonally diverse cell surface immunoglobulin (Ig) 
recognising specific antigenic epitopes. B cell development begins in the 
bone marrow and then finishes in the secondary peripheral lymphoid 
tissue [15]. Within the bone marrow pro B cells differentiate to pre B 
cells and then to immature B cells (figure 1.2). Rearrangement of Ig 
genes causes surface expression of a pre-B cell receptor composed of Igp
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heavy and surrogate light chains. The presence of this receptor is 
necessary for both further differentiation of the cell as well as clonal 
selection. Rearrangement of variable, diversity and joining (VDJ) gene 
segments occurs during the transition of pre B cells to immature B cells 
which express the final mature BCR structure on their surface. VDJ 
recombination is necessary to give antigen binding diversity to the 
developing antibody expressing clones. At this point in development, B 
cells must pass a checkpoint that ensures self reactive cells do not 
develop further because 75% of human early immature B cells are self­
reactive [16]. Editing of the BCR [17, 18] and deletion of self-reactive 
clones [19] are involved in this selection process. If a cell passes this 
selection checkpoint then it is able to exit the bone marrow as a 
transitional B cell. These cells can then eventually progress into mature 
follicular B cells or marginal-zone B cells. Further development can also 
occur during an immune response when antigen-specific B cells 
differentiate into either plasma cells capable of secreting antibodies or 
memory B cells. This maturation and selection procedure is summarised 
in the following diagram:
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Bone marrow
Pre-BCR Mature BCR
Pro-BCR ^7 TVvpreB 1 Surrogate
____v r light
Calnexin TP '■ -I chains
-lea
Pro-B cell Pre-B cell Immature B cell
Figure 1.2. Summary of the development of B cells taken from (20|.
Naive cells in the bone marrow enter the periphery and can then undergo 
maturation upon encounter with antigen.
The early stages of B cell development are regulated by at least 10
transcription factors (TFs) [15]. E2A, EBF and Pax5 are the main TFs
responsible for B-lineage commitment and differentiation. Pax-5 deficient
pro-B cells have the capacity to adapt non-B-lineage fates and can develop
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into other haematopoietic lineages due to the role of Pax5 in activation of 
genes responsible for B-cell development and repression of genes involved 
in non-B lineage development [21].
1.2.4. The cell of origin in CLL
The cells which give rise to CLL have not been identified. However, 
certain assumptions can be made about the B cell population that is likely 
to support the genesis of CLL. During differentiation B cells are either 
negatively or positively selected through interaction with cognate 
antigens. Negative selection takes place at an earlier stage of maturation 
and involves cells undergoing apoptosis due to high-affinity interaction 
with self antigens [22, 23]. However, some cells can be positively 
selected by reaction with low affinity self antigens at low concentrations. 
These cells give rise to a distinct lineage of CDS positive B cells known 
as B-l cells [24]. The remaining surviving cells give rise to B2 cells with 
specificity for exogenous antigens of microbial or other origin [25].
The currently held view is that B-l cells found at locations such as 
peritoneum and marginal zone of the spleen are the most likely cells of 
origin of CLL. This view is supported by gene expression profiling 
studies which show that the malignant cells have a common genotype 
that resembles normal mature memory B cells [26]. The B-l origin is
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further supported by the CD5 positivity of CLL cells, and by their 
specificity for low affinity self antigens and structurally similar antigens 
of microbial origin [27]. As I have discussed above, the gene segment 
usage that is used in CLL cells shows that the spectrum of these antigens 
is relatively narrow and that a substantial majority of CLL cells share 
specificity for the same antigens [28, 29]. This excludes a random usage 
of these segments and favours the proposition that CLL cells have been 
positively selected by their cognate antigens.
CLL cell maturation frequently involves interaction with T-independent 
antigens of the type known to be responsible for development of B-l 
cells. At least in mouse, the signalling generated by these antigens 
requires expression of Lck [30].
1.3. Chronic Lymphocytic Leukaemia
Leukaemias are cancers of the cellular component of blood, and can arise 
from any of these components (i.e. lymphocytic or myelogenic) at 
potentially any stage of their differentiation. Leukaemias can be divided 
into either acute or chronic forms based on the speed of disease 
progression. CLL is a leukaemia of mature B lymphocytes that is defined 
by a slow accumulation of malignant cells in the blood, bone marrow and 
lymphoid tissues.
8
CLL is a prevalent disease that typically affects people over the age of 60, 
and affects men more than women [31]. CLL is characterised by a clonal 
expansion of mature malignant CD5, CD 19 and CD23 positive B cells that 
have reduced membrane levels of IgM, IgD and CD79b [32, 33]. Other 
molecular markers and gene expression profiles demonstrate that CLL 
cells have a phenotype [34] and genotype [26] of mature activated memory 
B cells. Another characteristic of CLL cells is that they are locked into the 
GO stage of the cell cycle and are largely unresponsive to mitogenic 
stimulation [35].
The clonal expansion of CLL cells was originally attributed primarily to 
prolonged in vivo survival of these cells due to a defect in apoptosis [36]. 
However, the use of deuterium labelling has recently been used to 
demonstrate an equal importance of cell proliferation to the clonal 
expansion of CLL cells. In this study it was suggested that the balance 
between proliferation in growth centres and cell death outside of these 
centres governs progression of the disease. Thus, a combination of 
proliferation and resistance to apoptosis is likely to be responsible for 
disease progression. This notion is supported by a further study showing 
that CLL cell proliferation is reduced when compared to that of normal B 
cells [37]. Despite a considerable amount of research into the pathobiology 
of CLL, the exact events leading to oncogenic transformation in the 
malignant cells remain uncharacterised.
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CLL is a disease that can progress differently in different patients; some 
patients surviving for many years without the need for therapy, whilst 
others have a fatal disease that progresses rapidly despite treatment. This 
heterogeneity in progression was defined by the Rai [38] and Binet [39] 
staging systems which are the basis for prognosis assessment. In these 
systems patients are classified according to different parameters. These 
parameters include white blood cell count, cell doubling time, and 
infiltration of bone marrow and secondary lymphoid organs resulting in the 
suppression of function. Rai stage 0 and Binet stage A patients have an 
average predicted survival of 15 years. Intermediate cases are Rai stages I 
or II and Binet stage B; these cases have a median survival of 5 to 7 years. 
High risk patients are classified as Rai stage III or IV and Binet stage C 
and survive on average for less than 3 to 4 years [40].
Prognosis of the potential for CLL to progress is evident also from recently 
identified molecular and immunophenotypic traits. The traits that are the 
most powerful predictors of disease progression include mutation of the 
variable region encoded by the gene for the immunoglobulin heavy chain 
(IgVH), expression of proteins such as CD38 and ZAP70 [41] and the 
presence of certain cytogenetic abnormalities involving chromosomes 
13ql4, llq23, 17pl3, 6q21 and 12ql3 [42]. Currently, decisions on 
disease prognosis are made on the basis of both the Rai and Binet clinical 
staging criteria plus the molecular markers listed above [41].
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I will now discuss how these different molecular markers of disease
prognosis contribute to the pathobiology of CLL.
1.4.1 Factors proposed to play a role in the pathogenesis of CLL
1.4.1.1 The role of the B cell antigen receptor
The usefulness of determining IgVH mutation status in CLL disease 
prognosis was first described in 1999 [43, 44], and has since been 
corroborated several times. These studies defined CLL cases as having 
unmutated IgVH genes if the VH sequence within the malignant cells did 
not differ by more than 2% from the germ-line sequence [44]. Thus CLL 
cases which have less than 2% somatic mutation have a poor prognosis 
when compared to cases where the mutation is greater than 2%.
Classically, somatic mutation of IgVH genes occurs within germinal 
centres at the rate of KT3 to 1 O' 4 mutations per base pair per generation [45, 
46] and involves the presentation of antigens by B cells to cognate helper T 
cells which then provide soluble and cell-contact stimuli which assist B 
cell proliferation and survival [47] (so called T-dependent antigen 
response). Based on the role of the germinal centre in providing the 
environment for somatic mutation to take place it was originally thought 
that CLL might comprise 2 diseases; one which arose from cells which had 
umnutated IgVH genes and likely had not entered the germinal centre, and
11
one which had mutated IgVH genes and therefore had passed through the 
genninal centre [48].
However, it has been noted that under some circumstances, in nonnal B 
cells, IgVH mutation can take place outside germinal centres and in the 
absence of T cells [49-51]. This model probably reflects CLL because 
analysis of global gene expression has shown that CLL cases bearing 
mutated and umnutated IgVH genes are largely similar to each other in 
their gene expression profiles, and that this likely results from a common 
cell of origin rather than from cells that are at different stages of 
differentiation.
Analysis of IgVH mutational status in CLL also revealed that the 
malignant cells use a characteristic repertoire of Ig genes in the final 
assembly of the antigen receptor expressed on the cell surface. These genes 
code for the VDJ segments of the antigen binding domain of Ig and give 
diversity to the antigen binding characteristics of the antibody through 
recombination. The biased usage of particular VDJ genes in CLL has led to 
the hypothesis that antigen binding to the BCR is an important component 
of CLL pathogenesis. For example, cells that utilise the VH3-21 gene 
segment for recognition of antigen have a particularly unfavourable disease 
prognosis likely due to the prevalence of this autoantigen in the body [27]. 
The difference that IgVH mutation makes in determining disease prognosis
12
is likely played out in antigen specificity of the BCR expressed on the 
malignant cells of CLL. Herve et al [52] recently showed that antibodies 
derived from umnutated CLL were polyreactive whereas those derived 
from mutated CLL were not. Furthermore, this same study also showed 
that mutation of the IgVH sequence within antibodies derived from 
mutated CLL back to the gennline sequence restored polyreactivity of 
these antibodies. Based on this evidence it is easy to hypothesise a role for 
BCR engagement in the pathogenesis of CLL.
Thus, preferential positive selection and expansion of CLL-cell clones 
likely involves alterations in BCR signalling in comparison with the cells 
that are negatively selected through interaction with antigen. Generally, 
BCR signalling in CLL cells is strongly attenuated in comparison with 
signalling in normal B cells. This could be the consequence of chronic 
antigenic stimulation resulting in different degrees of cell anergy, and to 
specific changes in gene expression profiles favouring clonal expansion of 
these cells [53]. Chronic stimulation by antigen is a consequence of the 
arrest of CLL cells at a pre-plasma-cell stage of maturation resulting in the 
failure of the cells to fully differentiate in vivo and secrete significant 
amounts of antibody required for the clearance of the antigen. Although 
these chronically stimulated cells can be anergised with respect to some 
responses such as Akt activation, the chronic stimulation may maintain 
activity of several other signalling pathways required for cell survival [53].
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Thus, such anergised CLL cells contain constitutively phosphorylated 
MEK 1/2, ERK 1/2 and IkBo; together with an increase in activated NF-AT 
[53].
In addition to the role of the BCR, CLL cases with umnutated IgVH genes 
are likely to have additional features that contribute to unfavourable 
prognosis. Some insight into these additional features is provided by 
frequent co-expression of ZAP-70 and CD38 in these cells which may 
provide the signals for their accelerated clonal expansion [54].
1.4.1.2 The role of CD38
CD38 is a 42kDa type II transmembrane glycoprotein that is expressed on 
various haematopoietic cells, including normal B and T cells [55], and also 
on non-haematopoietic cells [56, 57]. CLL cases where expression of 
CD38 can be detected on 30% or more of the malignant cells, and where 
these same cells contain IgVH sequences that retain germline or close to 
germline configuration typically have a poor disease prognosis [44, 58]. 
This is because CD38 expression is associated with CLL cells which are 
more rapidly proliferating [54, 59]. The exact role of CD38 in CLL 
pathogenesis is unclear, but may be due to the capacity of this protein to 
catalyse ADP ribosylation and modulate intracellular calcium levels [56].
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1.4.1.3 The role ofZAP70
ZAP70 is a non-receptor tyrosine kinase strongly expressed in T cells and 
NK cells [60]. This protein is either absent or expressed at a very low 
levels in normal B cells [61] but the expression of this protein can be 
upregulated in B cells undergoing the germinal centre reaction [62]. The 
presence of ZAP70 in CLL cells is an indicator of unfavourable prognosis 
[63] and is strongly correlated with cases where the IgVH genes remain 
unmutated. Measurements of the expression of this protein in the malignant 
cells of CLL is sometimes used as a simple surrogate for the more costly 
and time-consuming measurements of IgVH mutation [64, 65]. The role of 
ZAP70 in BCR signalling will be discussed below.
1.4.1.4 Cytogenetic abnormalities
hi addition to the use of the genotypic and phenotypic attributes listed 
above for disease prognosis in CLL, the presence of particular 
chromosomal aberrations within the regions 13ql4, llq23, 17pl3, 6q21 
and 12ql3 can also be used. Deletion of llq23 and 17pl3 are associated 
with aggressive CLL because the genes that are affected are ATM and 
p53. The proteins that are encoded by these genes are responsible for 
regulating cell response to DNA damage, therefore, drugs which affect 
DNA, such as the nucleoside fludarabine™ which is commonly used to 
treat CLL, are ineffective. On the other hand, deletion of 13ql4 is a
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favourable prognostic indicator possibly due to its effect on the 
expression of microRNAs such as miR-16-1 and miR-15-a [66].
1.4 Intracellular signalling in B cells.
T and B cell development and function are principally regulated by signals 
generated through interaction of their respective antigen receptors (TCR 
and BCR) with antigen [67, 68]. Antigen receptor-generated signals have 
been shown to be initiated through activation of Lck in T cells [69] and 
Lyn in B cells [5]. These signals then branch into a number of pathways 
which regulate selection, maturation, function and survival of the cells.
1.4.1 Src Family Kinases
There are 8 different SFKs expressed in human cells, these are; Lck [1], 
lyn [70] fyn [71], src [72], yes [73], fgr [74], hck [75] and blk [76]. These 
enzymes are non-receptor protein-tyrosine kinases that have been 
implicated in regulation of metabolism, survival, proliferation, 
differentiation and migration of cells belonging to different lineages [77, 
78]. SFKs range in size from 52 to 62 kDa and all are composed of eight 
functional regions. The eight regions are: a myristoylated site, a unique 
region, a src homology (SH) 4 domain, an SH3 domain, an SH2 domain, a 
linker region, a kinase/catalytic domain and a regulatory domain [79]. The 
basic stracture of SFKs is shown in figure 1.3.
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Figure 1.3. The structure of Src family kinases.
The regions most relevant for activation of SFK enzymes and for their 
interaction with substrates are the SH2 and SH3 domains. These regions 
form the regulatory domain of SFKs and maintain a closed inactive 
conformation through intra-molecular protein-protein interactions when the 
kinase is at rest. These motifs also regulate substrate specificity by 
mediating inter-protein interactions. The SH2 domain is -100 amino acids 
long and interacts with phosphotyrosine motifs of substrate proteins [80] as 
well as with the inhibitory phosphotyrosine site on the kinase itself. The 
SH3 domain is -50 amino acids long and binds to proteins that contain 
proline rich motifs related to the PXXP consensus [81, 82].
An additional important feature of all SFKs is the presence of conserved 
inhibitory and activating tyrosine residues. The inhibitory tyrosine residue 
is contained within the C terminus of the SFK and, when phosphorylated, 
maintains the protein in a restrained inactive confonnation through 
interaction with the SH2 domain of the protein. The activating residue is 
located within the kinase domain and, when phosphorylated, facilitates 
enzymatic activity.
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1.4.2 Unique region of Src family kinases
SFKs have a similar domain arrangement, but the N-terminal region of all 
family members is the most divergent and has been termed the unique 
domain. This domain directs fatty acid acylation which occurs as the 
protein is translated [77]. N-terminal myristoylation is a permanent 
modification that directs SFKs to the cholesterol-rich membrane rafts [83], 
whereas palmitoylation of SFKs within this region is reversible [84, 85]. 
The unique domain of SFKs also provides additional interaction and 
phosphorylation sites that are thought to be involved in the specific 
targeting and regulation of each enzyme. For example, in T cells the 
unique domain of Lck has been shown to be associated with the 
cytoplasmic tails of CD4 and CDS [86]. For the puiposes of this thesis we 
will concern ourselves only with Lck.
1.5 Function and expression of Lck
1.5.1 The role of phosphorylation in regulating Lck function
As with other SFKs, phosphorylation of Lck plays an important role in its 
function. Activation of Lck in T cells involves CD45-dependent 
dephosphorylation of the inhibitory phosphotyrosine (Y505). This 
dephosphorylation results in a structural change/unfolding of the protein 
that is followed by autophosphorylation in the active site (Y394). The 
unfolding of the protein also enables the binding of substrates and other 
molecules (figure 1.4a) [87].
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The refolding of Lck into its deactivated form occurs via 
dephosphorylation of Y394 and rephosphorylation of Y505. 
Dephosphorylation of the activating phosphotyrosine in Lck is suggested to 
be mediated by CD45 [88-90], PEP (proline-, glutamic acid-, serine-, and 
threonine-rich (PEST) domain-phosphatase) [91], protein tyrosine 
phosphatase (PTP)-PEST [92], and SH2 domain-containing phosphatase 1 
(SHP-1) [93]. Rephosphorylation of the inhibitory tyrosine in Lck is 
mediated by C-terminal src kinase (Csk) [94] (figure 1.4b). As mentioned 
above, the phosphorylated Y505 binds to the SH2 domain of Lck, blocking 
substrate access to the enzyme. In addition, the SH3 domain associates 
with the proline rich region within the linker domain of the protein [82]. 
The culmination of these two interactions is to force the catalytic domain 
into a state where the residues responsible for phosphorylation are no 
longer in their optimal configuration [95]. This is illustrated in figure 1.4.
Inactive
Y394
pY505
Figure 1.4. Activation and deactivation of Lck (modified ffom[96]).
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Active Lck can be further phosphorylated on serine residues by protein 
kinase C (PKC) and by extracellular regulated kinase (ERK). PKC and 
ERK catalyse the phosphorylation of serine 42 and 59 within the unique 
region of the protein [97, 98]. This results in a shift in the apparent 
molecular weight of the protein from 56kDa to 60kDa when analysed by 
SDS-PAGE [99-101]. This appearance of the 60kDa form is taken as proof 
that Lck has been serine phosphorylated on least one of the serine 42 or 59 
sites [102, 103]. The function of serine phosphorylation is postulated to 
regulate the ability of Lck to interact with protein tyrosine phosphatases 
such as SHP-1, and therefore act in a positive feedback fashion to stabilise 
the activity of Lck [104, 105]. Serine phosphorylation of Lck is also 
thought to mark the protein for ubiquitination and destruction via 
proteasomal degradation [96] (figure 1.4.b).
1,5.2 Tissue expression of Lck
Lck is primarily expressed in cells of haematopoietic origin, and, in 
particular, in T and NK cells [106]. However, Lck can also be found in a 
variety of other normal and malignant cells. In normal cells, the expression 
can be cell-maturation or activation dependent. For example, human and 
murine B-2 cells express Lck as immature cells, but not as quiescent 
mature cells [107]. However, stimulation of B cells in the germinal centre 
has been reported to induce the expression of this protein in these cells 
[108]. Additionally, Lck has been found in mouse peritoneal CD5+ B-la
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cells, but not in the CD5+ B-l cells located in the marginal zone of the 
spleen. This difference is reported to depend upon different specific 
microenvironmental stimuli at the two locations [109].
With respect to Lck expression in malignant cells, Lck is found in tumours 
of the breast [110], lung [111] and colon. Lck is also expressed in B cell 
malignancies such as DLBCL, mantle cell lymphoma and B-ALL [108, 
112].
1.5.3 Transcriptional regulation of Lck
The expression of Lck during T and B cell development and activation by 
stimuli such as antigen-receptor activation and IL-2 is primarily regulated 
by transcription [113]. The human Lck gene is located on chromosome 
lq35-34.3 and has 12 exons distributed across ~14kb of genomic DNA. 
There are 2 promoters that are responsible for regulating expression of the 
gene, a proximal and a distal promoter. This leads to 2 main types of 
transcripts [114] which have been further diversified based on length [115]. 
Activation of the proximal, type I, promoter occurs in T-cell leukaemia cell 
lines and non-lymphoid neoplasms such as colon carcinoma [111]. 
Activation of this promoter is thought to originate from the absence of a 
translational repressor [116].
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Activation of the distal, type II, promoter which is 35 kilobases upstream 
of the coding region of the Lck gene, occurs in mature peripheral T cells 
and at low levels in myeloid cell lines [115]. Malignant lymphoid cells 
have been shown to contain both transcripts [115].
1.5.4 Lck signalling
The most extensively studied role of Lck is in T cells where this enzyme is 
involved in cell activation and IL2 production in response to TCR 
engagement, hi these cells, Lck initiates signalling via phosphorylation of 
immuno-receptor tyrosine activation motifs (ITAMS) [117] within CD3 
and the TCR^ chain which allows recruitment of zeta-associated protein 
kinase of 70kDa (ZAP70) to the TCR [118]. iTAM-bound ZAP70 is then 
tyrosine phosphorylated by Lck [119] allowing ZAP70 to phosphorylate 
substrates such as SLP76 and LAT leading to activation of the subsequent 
steps of the TCR signalling cascade [120]. This is summarised in figure 
1.5.
In response to certain stimuli, active Lck also associates with CD38 and 
leads to endocytosis of this protein. This is thought to result in the 
production of cyclic ADP ribose and subsequent increase in intracellular 
calcium levels leading to NF-AT activation [121].
In addition to its role in T cell activation, Lck also plays a role in the
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Figure 1.5. The role of Lck in TCR signalling.
23
induction of tolerance upon protracted TCR signalling. The induction of 
tolerance by Lck could involve phosphorylation and recruitment of CDS 
[122, 123] and c-Cbl to the TCR signalosome. In this model CDS 
contributes to tolerance by recruiting SHP-1 phosphatase to oppose the 
action of protein tyrosine kinases [123], including Lck. c-Cbl, on the other 
hand, contributes to tolerance via its ubiquitin ligase activity, leading to 
ubiquitination and proteasomal degradation of several signalling 
components including Lck itself [124, 125].
Although it has been demonstrated that Lck is expressed in B cells, its role 
within these cells is not clear. One report has indicated that Lck expression 
confers hyporesponsiveness to B-l cells undergoing BCR stimulation in 
the peritoneum [109]. However, these findings are contrasted by another 
study reporting that Lck is necessary for sustained BCR signalling in these 
same cells [126]. Meanwhile, a third study has indicated that 
hyporesponsiveness of B-l cells to BCR stimulation has nothing to do with 
Lck expression at all [127]. Thus, there is a lack of consistent evidence to 
support a direct role for Lck in BCR signalling.
1.5.5 The presence of Lck in CLL cells
In 1991, Abts et al [128] investigated the expression of Lck mRNA in 21 
CLL samples using northern blot analysis and found that all samples 
contained transcripts for this gene. Normal B cells from the peripheral
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blood of healthy donors were also investigated in this study but these did 
not contain any Lck transcripts. Lck protein expression in CLL cells was 
later confirmed in subsequent studies by western blot analysis [4, 129- 
131]. Some of these studies also used protein kinase assays to confirm the 
presence of active Lck in CLL cells, and to further show that stimulation of 
these cells with SAC/anti-IgM caused a change in the expression level and 
the formation of a higher molecular weight species of Lck. However, some 
doubt has been expressed about the ability of CLL cells to express Lck 
[127, 132],
1.6. Lck in B-l cells
B-l cells were originally distinguished from conventional B cells (B2) due 
to the expression of CDS [133], a glycoprotein expressed on the surface of 
T cells that is likely to regulate signals emanating from the TCR. B-l cell 
development is antigen driven and potentially reflects selection by thymus- 
independent self antigens [109]. Maintenance of the B-l population 
appears to be also dependent on BCR signals, because this population is 
affected when mutations are present in proteins that participate in 
signalling via the BCR [134]. Further work on B-l cells has revealed that 
there are two subpopulations within this group; B-l a cells which are 
characterised by their expression of CDS, and B-lb cells which do not 
express this antigen [135, 136].
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Another characteristic feature of B-l cells is Lck expression. A role for 
Lck in B-l cell physiology is implicated in a publication by Ulivieri et al 
[126]. Here it was shown that B-l cells developed normally in Lck"7' mice, 
but that the BCR signalling in these cells was defective. This shows that 
Lck is not required for B-l cell development, but required for effective 
BCR-induced signal transduction in these cells.
Alternatively, Lck may be required to confer the BCR hyporesponsiveness 
seen in CD5+ B-l cells. In this way, Lck appears to be involved in the 
maintenance of the unique function of these cells [109]. Chronic, low-level 
BCR stimulation, such as encounter with ubiquitous self-antigen is 
sufficient to induce CD5 expression [137, 138]. Lck expression however 
appears to require additional cues or signals which may be provided by 
environmental factors. Dal Porto et al [109] hypothesise that continued 
antigen exposure induces CDS expression, regardless of the locale of the 
cells, but the peritoneum and pleural cavity provides a unique 
microenvironment in which prolonged residency causes phenotypic change 
of the B-l cells such as Lck expression. Splenic B-l cells do not express 
Lck; however upon entry to the peritoneum they can be induced to express 
this enzyme. In Lck deficient mice Dal Porto et al [109] showed that B-l 
cell development is normal but peritoneal CD5+ B-l cells are no longer 
hyporesponsive.
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1.7 BCR signalling
As discussed above, Lck is described to play a role in either facilitating or 
downregulating BCR signalling. To understand any potential role of Lck in 
BCR signalling we must first understand how the BCR transfers its signal 
in normal B cells.
Engagement of the BCR induces receptor oligomerisation and 
phosphorylation of a non-covalently associated signalling unit, the Iga/p 
heterodimer (otherwise known as CD79ot/f3 heterodimer). These proteins 
contain IT AMs, and are the target of the SFK Lyn [139]. Phospho-Iga/p 
are then able to recruit and activate Syk [140] and phosphatidylinositol 3 
kinase (PI3K) either through direct interaction with their SH2 domains, or 
through interaction with adaptor proteins such as BCAP [141]. Activated 
PI3K generates phosphatidylinositol trisphosphate (PIP3), which then 
recruits and activates Bruton’s tyrosine kinase (Btk) [142, 143] as well as 
PDK1 and Akt [144-146], In parallel, Syk phosphorylates the adaptor 
protein BLNK, which then acts as a scaffold to facilitate the 
phosphorylation of PLCy2 [147] by Btk and Syk [148, 149]. Activated 
PLCy2 hydrolyses PIP2 to inositol trisphosphate (IP3) and diacylglycerol 
(DAG). IP3 stimulates release of intracellular Ca2+, which then together 
with DAG activates PKCp. The latter kinase stimulates the NFkB pathway 
by interacting with the CARMA1-Bell0-MALT1 complex to ultimately
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activate IkB kinases (IKKs) [150, 151], as well as the JNK pathway [152]. 
DAG has an additional function in activating RasGRPs and lead to 
activation of the ERK pathway [153]. This pathway is illustrated in figure 
1.6.
NFkB
Figure 1.6. B cell antigen receptor-induced sinnallinn in normal B
cells.
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Variation in this pathway has been noted between normal and anergic B 
cells [20]. For example, activation of the NFkB, Akt and JNK pathways 
have become uncoupled from the BCR in some models of B cell anergy 
[154-159]. Such uncoupling is thought to be mediated by chronic 
activation of SHIP-1, Dok and PKC8 [20].
Anergy seems also to play a role in BCR signalling in CLL cells. BCR 
crosslinking has been shown to stimulate the signalling pathways leading 
to activation of ERK, Akt and NFkB, but not the JNK pathway [160]. 
Moreover, in CLL cases expressing highly mutated IgVH sequences 
signalling to all pathways including the release of intracellular calcium is 
attenuated [161].
1.8. The potential role of Lck in CLL
The cellular components that have been proposed to play a role in 
attenuated BCR signalling in CLL cells include changes in expression or 
function of enzymes and adaptors which together form the BCR 
signalosome. These components include among others CD5 [162], c-Cbl 
[163] and Lck. Lck may play a role in the altered BCR signalling of CLL 
cells, possibly through its association with CD5 as has been proposed for 
peritoneal B-l cells in mice, and in T cells. Porto et al [109] found that, in 
mice, Lck was required for the hyporesponsiveness of the BCR seen in
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CD5+ B-l cells. In T cells, Lck has been shown to be necessary for CD5 
Y429 and Y463 phosphorylation [164] which is responsible for attracting 
SHP1 and downregulating TCR signalling. Considering that CDS is 
expressed on CLL cells, it is therefore possible that Lck might perform a 
similar function. This is supported by studies showing that CDS can be 
upregulated on conventional B cells that have been exposed to chronic 
antigenic stimulation in vivo, or by in vitro stimulation with anti-IgM and 
a soluble CD40 ligand [165]. CDS expression on these cells exerts a 
negative feedback on BCR signalling as shown by reduced proliferative 
capacity and inhibition of intracellular calcium release following further 
BCR stimulation [166],
Renaudineau et al [167] showed that stimulation of CDS with specific 
antibodies resulted in apoptosis of the malignant cells from a subset of 
CLL cases. The signalling in the cases that underwent apoptosis involved 
association of CDS with the CD79a/CD79b components of BCR and the 
translocation of this complex to lipid rafts.
Lck may contribute to the disease progression of CLL through its role in 
positive signalling from proteins such as CD38 and ZAP70. These proteins 
are markers of poor prognosis in CLL; this might be particularly important 
with respect to ZAP70 expression in CLL cells because this protein is a 
major substrate of Lck in T cells [119]. Whether this could lead to further 
progression of signalling in CLL cells remains to be seen. However,
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although the function of ZAP70 in CLL has not been clearly defined, it is 
known that this molecule facilitates BCR signalling [168].
Lck participation in cell stimulation may also involve interaction with 
CD38. As stated above, CD38 is a prognostic marker in CLL where it is 
routinely measured using FACS analysis. CD38 and Lck are physically 
associated in T cells and CD38 ligation increases tyrosine kinase activity 
of the CD38-associated Lck leading to activation of interleukin-2 gene 
transcription [169]. Figure 1.7 shows a summary of the proposed role of 
Lck in CLL cell survival.
Downstream 
signalling. 
MARK, RISK, 
NF-kB pathways
Figure 1.7. The theoretical role of Lck in CLL based on its function 
in T cells and B-l cells.
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1.9. Overall aims of the thesis
At the beginning of these studies expression of Lck in CLL cells had not 
been fully characterised. Therefore, the first aim of this work was to 
establish Lck expression in populations of purified CLL cells. Having 
shown that Lck is indeed expressed by CLL cells, I then sought to 
investigate how the expression of this protein is regulated. The second 
aim of this work was to establish a role for Lck in CLL pathophysiology. 
Thus, in the first instance I sought to establish a role for Lck is protecting 
CLL cells from spontaneous apoptosis. Secondly, I investigated a role for 
Lck in BCR signalling in CLL cells.
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Chapter 2
Expression of Lck in CLL cells
2.1 Introduction
Work in this laboratory and the work of others [4] showed the presence of 
Lck protein in CLL cells. However, this was questioned in some other 
studies [132] suggesting that Lck is either not expressed in all CLL-cell 
clones, or that the expression is highly variable and depends upon stimuli 
to which some cells are not exposed.
CLL cells are thought to originate from B-l cells and, in mice, only 
peritoneal B-l cells, but not splenic B-l cells, express Lck [30]. As Lck 
expression can be induced in normal B cells by antigen receptor 
stimulation [113] there is a possibility that the Lck-expressing CLL-cell 
clones develop under the influence of specific antigens and possibly also 
other stimuli that are present in the peritoneum but not in the marginal zone 
of the spleen.
Recently Lck expression was also found in germinal centre B cells [108] 
where it is induced by antigen and has an anti-apoptotic role. However, 
when these germinal centre cells give rise to plasma or memory cells, Lck
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expression is down regulated since in the absence of stimulation these last 
two mature B cell types do not express this enzyme.
If it is assumed that Lck does play a non-redundant role in a particular 
subgroup of CLL, it would be important to establish how variable is its 
expression in different CLL-cell clones, how this expression is induced and 
what the contributions of gene transcription, translation and post 
translational modification are in the regulation of its expression.
An insight into the mechanisms involved in Lck expression in CLL cells 
can be obtained from the type of Lck franscripts present. These transcripts 
are produced from distinct promoters which are activated either during cell 
maturation or cell stimulation by some not yet fully identified stimuli 
[115]. The level of the Lck protein can also be primarily regulated by 
mRNA translation or by post-translational modification involving 
activation-dependent proteasomal degradation [96].
Lck mRNA production can be initiated from 2 separate promoters that 
result in the heterogeneity of the transcripts regarding the length and 
sequence of the 5’ untranslated region (UTR). The actual coding region is 
however the same between the two types of the transcript which means that 
there is no functional difference between the translated proteins. Since the 
stimuli which initiate translation from the two promoters are different, it is
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important to establish which transcript(s) are present in CLL, as this may 
identify the mechanism(s) that lead to the production of Lck in the 
malignant cells of this disease.
The type of transcript present in different cells depends on both cell type 
and stimuli to which a particular cell is exposed. Thus, the activation of 
the type I (proximal) promoter has been found in T cell leukaemia lines 
as well as in non-lymphoid neoplasms such as colon carcinoma. The type 
lb transcript resulting from the activation of this promoter is present at a 
low level in B cell lines and is increased in malignancies of 
haematopoietic immature cells, such as AML [115].
The type II (distal) promoter is located 35 kilobases upstream of the coding 
region. Expression of the type II transcript is linked to the phenotype of 
activated cells and is upregulated during developmental transitions 
associated with antigen receptor signalling in both B and T cells [3]. This 
transcript is also present in presumably stimulated, mature, peripheral T 
and B cells as well as at the low levels in myeloid cell lines. The type Ha 
form (figure 2.1) is the major fonn of Lck mRNA present in human T 
cells. Lymphoid cells of a malignant origin contain both type I and II 
hanscripts [170].
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The aim of this chapter was to determine factors that regulate Lck 
expression at the level of mRNA, including usage of different promoters 
and the importance of translation in determining the level of Lck protein in 
CLL cells. Since it is well established that the level of Lck is also affected 
by post-translational modifications [96] this chapter also includes 
experiments in which Lck is activated either through BCR stimulation or 
PKC activation, followed by Western blot analysis of changes in 
electrophoretic mobility and amount of Lck protein caused by 
phosphorylation and proteasomal degradation.
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2.2 Materials and methods
2.2.1 Cell isolation and culture
Peripheral blood samples were obtained from patients previously 
diagnosed with CLL, Hairy Cell Leukaemia (HCL) or Mantle Cell 
Lymphoma (MCL) after they gave informed consent and with the approval 
of the Liverpool Research Ethics Committee. The clinical and biochemical 
characteristics of all the samples used in this study are summarised in 
Table 1.2. Data for ZAP70 and CD38 were obtained by FACS while IgVH 
gene sequencing data was obtained as detailed before [171] and the 
information then stored on the departmental database. The majority of 
CLL cases used in this study had White blood cell counts (WBC) higher 
than 50x109/L to limit the influence of non-CLL cells, specifically T cells 
which contain high levels of Lck protein. In experiments where purity of 
over 90% CLL cells was required, such as PCR and quantification of CLL- 
specific Lck protein, samples were negatively purified as detailed in 
section 2.2.4.
Mononuclear cells were obtained by centrifugation (500rcf, 30 minutes, 
room temperature) on Lymphoprep (Ficoll-Paque; Nycomed, Oslo, 
Noiway). Cells were then washed in PBS and slowly resuspended in a 4°C 
solution of RPMI (Sigma-Aldrich, Gillingham, UK) /10% fetal calf serum
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(FCS; Biosera, Ringmer, UK) /10% DMSO (Sigina-Aldrich). Aliquots of 
1ml were then transferred to cryotubes (Nuncbrand, Fisher Scientific, 
Loughborough, UK) and frozen at -80°C for one week and then finally 
cryopreserved in liquid nitrogen. Normal T and B cells were obtained from 
buffy coat preparations (British Transfusion Service, Liverpool, UK) 
which were processed and cryopreserved as for malignant samples.
Cryopreserved CLL, HCL and MCL cells were thawed rapidly at 37°C in a 
waterbath and then diluted on ice to a volume of lOmls by the slow 
addition of 9 mis of 4°C RPMI medium supplemented with 0.5% (w/v) 
BSA (Sigma-Aldrich), 2mM L-glutamine, lOOunits/ml penicillin and 
lOOpg/ml streptomycin (Invitrogen, Paisley, UK), from now on referred to 
as culture media. It is essential that this addition of media to lOmls is a 
gradual process due to the osmotic pressure, which if it were to change too 
rapidly would cause the CLL cells to lyse. Cells were then pelleted by 
centrifugation at 4°C for 5 minutes at 500rcf and supernatant discarded. 
The pellet was then resuspended in lOmls of culture medium and 
centrifuged as above. These 2 wash steps ensure that the DMSO is 
removed from the ceil suspension as it is cytotoxic at temperatures above 
4°C. The pellet was this time resuspended in 1ml of culture medium and 
the number of cells counted using a haemocytometer (Fischer Scientific) 
and trypan blue (Sigma) to allow assessment of viability as the trypan blue 
dye can only be excluded from the live cells which therefore appear clear
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and the dead cells appear blue. The cells were then diluted to 2xl06/ml, 
based on the live cell count, and 1ml of this cell suspension added to a well 
of a 24 well tissue culture plate (Nuncbrand, Fisher Scientific). Wells of 
these plates were pre-coated with a 95% ethanolic solution of 12mg/ml 
poly(2-hydroxyethylmethacrylate) (polyHEMA; Sigma-Aldrich) in order 
to avoid the effects caused by the adhesion of these cells to the bottom of 
the wells [172]. Cells were then left to ‘recover’ for 1 hour before time 0 
(TO) of culture when stimuli/inhibitors were added.
Normal B cells were cultured in the polyHEMA-coated plates as for CLL, 
HCL and MCL cells but in RPMI medium supplemented with 10% PCS 
(Biosera), 2mM L-glutamine, lOOunits/ml penicillin and lOOpg/ml 
streptomycin . The Jurkat cell line was taken from liquid nitrogen storage, 
made up to 10ml with the above media and spun as for CLL cells. Cells 
were resuspended in media and cultured in T25 tissue culture flasks 
(Becton Dickinson, CA). All cells were cultured in a 37°C incubator 
(HeraCell, FisherScientific) with 5% CO2.
2.2.2 Inhibitors and stimuli
All inhibitors were dissolved in DMSO and stored at -20°C. The Lck 
inhibitor (4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2d] pyrimidin-7-yl- 
cyclopentane) was used at IpM, U0126 was used at lOpM, lactacystin was 
used at 2.5pM, actinomycin D was used at 811M, cycloheximide was used
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at lOjiM, flavopiridol was used at 2pM, RO-32-432 was used at lOpM and 
bisindolylmaleimide I was used at either 1 or 10|iM and all were purchased 
from Calbiochem (Merck Biosciences, Nottingham, UK). Bryostatin-1 was 
used at 25nM and was purchased from Alexis Biochemicals (Enzo Life 
Sciences, Exeter, UK). The PKC/3II inhibitor (LY379196) used at IpM 
was kindly provided by Lilly Research Laboratories (Indianapolis, IN). 
PMA (phorbol 12-myristate 13-acetate) and bryostatin were purchased 
from Sigma-Aldrich.
F(ab’)2 fragments of goat anti-human IgM (Jackson ImmunoResearch 
Laboratories; Stratech, Soham , UK) were used at a final concentration of 
lOpg/ml for crosslinking/stimulating the BCR. Interleukin-2 (Cell 
Signaling Technology; New England Biolabs, Hitchin, UK) was cultured 
with cells at 100 international units (IU)/ml.
2.2.3 Western blotting
2xl06 cells were pelleted by centrifugation at 500g for 5 minutes at 4°C, 
washed 2 times in cold Phosphate buffered saline (PBS) (Fisher Scientific) 
to remove contaminating BSA and lysed in 100|nl clear sodium dodecyl 
sulphate (SDS) lysis buffer (1% SDS, 10% glycerol, 5mM EDTA, 50mM 
Tris pH6.8). Lysates were sonicated for 5 seconds using a microson 
ultrasonic cell disrupter and ultrasonic convertor (Scientific Laboratory 
Supplies, Nottingham, UK) in order to shear DNA and then heated to 96°C
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for 5 minutes using a Grant hotblock (Scientific Laboratory Supplies) to 
aid denaturation. Determination of the exact concentration of protein 
present in the lysates was carried out using the DC protein assay (Bio-Rad, 
Hemel Hempstead, UK) which works in a similar way to the Lowry 
protein determination method [173]. Lysates were prepared containing 
lO/xg total protein by addition of the relevant quantity of cell sample 
lysates, clear SDS lysis buffer and finally laemelli buffer [174] to allow 
addition of /3-mercaptoethanol (Sigma-Aldrich) which must be absent from 
the lysis buffer during protein determination as this reducing agent affects 
the assay, but present in the final buffer to break disulphide bridges within 
proteins. These lysates were then loaded onto 10% polyacrylamide gels 
prepared using the Bio-Rad system (Bio-Rad) and subjected to 30mA 
electrophoresis for 1 hour using a poweipack (Bio-Rad). lOpl of 
BenchMark Prestained protein ladder (Invitrogen) was used as a molecular 
weight marker to allow assessment of the extent of migration of the 
samples through the gel and to allow identification of proteins according to 
size. Following completion of electrophoresis, the gel was subjected to 
transfer to allow protein present in the gel to be transferred onto immobilon 
membrane (Millipore, Watford, UK) using the Bio-Rad Trans-blot system 
in transfer buffer (Geneflow, Fradley, UK) for 1 hour at 400mA using a 
powerpack(Bio-Rad). Immobilon membrane blots were blocked overnight 
for 1 hour and antibodies prepared in 5% non-fat powdered milk (Tesco)
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dissolved in Tris buffered saline (lOmM Tris.HCl pH7.4, 0.1M sodium 
chloride) with 0.1% Tween-20 (TBST).
Following blocking of the blots, they were incubated in the 5% milk/TBST 
mixture containing the relevant primary antibody. The following primary 
antibodies were used: anti-Lck mouse monoclonal (Santa Cruz 
Biotechnology; Insight Biotechnology, Middlesex, UK), anti-ZAP70 
mouse monoclonal (Upstate, Milton Keynes, UK) and anti-/? actin mouse 
monoclonal antibody (Sigma-Aldrich). Blots were then washed for 1 hour 
in TBST to remove unbound antibody and reduce non-specific binding, 
replacing with fresh TBST every 15 minutes. The blots were then 
incubated for 1 hour in 5% milk/TBST mixture containing the relevant 
secondary antibody at a concentration of 80ng/ml (1:5000 dilution). The 
following secondary antibodies were used: Goat anti-rabbit horseradish 
peroxidise (HRP) conjugated antibody and goat anti-mouse HRP- 
conjugated antibody (Santa Cruz Biotechnology
Blots were then washed as above for 1 hour in TBST and antibody bound 
to proteins in the blots visualised using an LAS-1000 chemiluminescence 
and fluorescent imaging system machine (Fuji, Tokyo, Japan) for 
measurement of chemiluminescence after treatment of the membrane with 
enhanced chemiluminescence reagent (Millipore) or ECL-Plus (Amersham 
Biosciences, Chalfont, UK). The peroxidase-conjugated anti-mouse or
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anti-rabbit antibody bound to the primary antibody specific for the protein 
of interest oxidises luminol in the ECL reagent, emitting light at a peak 
wavelength of 428nM which is then detected by the machine and displayed 
as an image which can be analysed and densitometry earned out using the 
AIDA image analyser software package (Raytek Scientific Ltd, Sheffield, 
UK).
Stripping of membranes was earned out when a blot had to be reprobed 
with an antibody produced in the same species. Membranes were incubated 
at 65°C in stripping buffer containing 62.5mM Tris-HCL (pH 6.8), lOOmM 
/3-mercaptoethanol and 2% SDS for 30 minutes in a waterbath. Membranes 
were washed in TBST for 30 minutes and then blocked in 5%milk/TBST 
as detailed above. Membranes were then reprobed with the desired 
antibody as above.
2.2.4 Purification of ceils
Negative purification of cells was used in order to avoid stimulating the 
target cells as may occur during positive purification (i.e. CD 19 
purification of CLL cells). Purification of CLL, MCL and HCL samples 
involved incubation of 1x107 cells in 40pl of 4°C degassed purification 
buffer (PBS pH7.2, 0.5% BSA, 2mM EDTA) for 20 minutes in the 
presence of 20pl of each of the following FITC-conjugated antibodies 
CD3, CD14 and CD16 (BD biosciences); these antibodies label T cells,
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monocytes, macrophages, neutrophils and NK cells. Cell/antibody 
suspensions were then centrifuged at 500g for 3 minutes at 4°C, washed in 
the purification buffer, centrifuged again and resuspended in 80pl 
purification buffer. 20|al of anti-FITC magnetic beads (Miltenyi Biotech, 
Bisley, UK) were then added to each sample. Cell/magnetic bead solutions 
were incubated at 4°C for 15 minutes then pelleted as above, washed in 
purification buffer, resuspended in 40pl purification buffer and applied to a 
MiniMACS column (Miltenyi Biotech) in a magnetic bracket (Miltenyi 
Biotech) for 5 minutes. This causes the CDS, CD 16 or CD 14 positive cells 
with the beads attached to remain in the column and allow collection of the 
unlabelled CD 19 positive malignant cells that flow through the column. 
Three repetitions of 1ml of buffer were added to the column to aid the flow 
through and collection of the CLL cells in a universal. After this 
purification procedure CLL, HCL and MCL purity was always greater than 
96% B cells as analysed by anti-CD19, CD3, CD16 and CD14 FACS 
analysis (as detailed in methods section 2.2.6).
Normal T cells were purified from buffy coat prepamtions using the same 
method but with anti-CD 19, CD 16 and CD 14 MACS beads instead. 
Normal B cells were negatively purified using the same column method 
but utilising two steps. The first step involved incubation of cells with anti- 
CD3 MACS beads and application to the column to remove a large 
proportion of the T cells in the sample. This produces a smaller population
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of cells in which the B cells make up a larger proportion and so use of a 
commercially available B cell isolation kit (Miltenyi Biotec) is less costly. 
The B cell isolation kit contains CD2, CD 14, CD 16, CDS 6, CD43, and 
CD235a (glycophorin A) antibodies conjugated to biotin and anti-biotin 
beads. After incubation of the antibody mix with the cells, addition of the 
beads and then application to the magnetic MACS column, as for the CLL 
purification, a population of >97% normal B cells are collected in the form 
of column flow-through. Non-B cells, i.e., T cells, NK cells, monocytes, 
dendritic cells, granulocytes, platelets, and erythroid cells remain in the 
column.
2.2.5. Quantification of Lck protein
3x107 CLL cells were thawed as described in section 2.2.1 and 
immediately resuspended in purification buffer without the 1 hour recovery 
incubation at 37°C. Cells were purified (section 2.2.4) and purity of the 
resulting population assessed by FACS analysis. All purified samples were 
>95% CD 19 or CD20 positive indicating that contaminating T, NK, 
monocytes, macrophages and neutrophil cells had been removed. Cell 
suspensions were counted and were then divided to produce pellets for 
RNA extraction of ~lxl07 cells and the remaining cells were used to assess 
Lck protein quantities. Protein determination was earned out and lOpg 
total protein from each lysate was subjected to Western blotting. A 
recombinant GST-tagged Lck protein (Santa cruz Biotechnology) of 0.5, 1
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or 4ng concentration was also loaded on the gel to allow calculation of the 
amount of Lck protein in the lysates as opposed to using densitometry 
utilising actin as a loading control which would be less reliable.
2.2.5 Polymerase chain reaction (PCR)
All RNA extraction, reverse transcription and PCR protocols are 
performed using RNase/DNase free equipment, including eppendorphs 
(Anachem) and filter pipette tips (Anachem). Total RNA was extracted 
from purified CLL, HCL and normal T and B cells with the RNeasy mini 
kit (QIAGEN, Crawley, UK) according to the manufacturer's instructions. 
Briefly, IxlO7 cells were lysed in 600^1 of the provided RLT buffer and 
then centrifuged at 18000g through a QIAshredder spin column (QIAGEN) 
to shear the DNA. The flow through was then mixed 1:1 with 70% ethanol 
and added to an RNeasy spin column. Once centrifuged through the 
column at 8000g, the RNA (now bound to the column membrane) is first 
washed by adding 700/d of the provided RW1 wash buffer. The spin 
column is centrifuged at 8000g and the flow-through is discarded. Next, 
500/xl of the provided RPE buffer is added to the column and once again 
the column is centrifuged at 8000g. The RPE wash step is then repeated 
but the centrifugation step is increased to 2 minutes to dry the spin column 
of any remaining ethanol. The 2ml collection tube is then replaced with a 
1.5ml collection tube and 50fi\ of RNase free water is used to elute the pure 
RNA from the spin column by centrifuging at SSOOOg for 1 minute. RNA
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concentration and purity was measured at 260/280nm using a NanoDrop 
machine (Thermoscientific from Labtech International Ltd., Ringmer, 
UK).
l/ig of purified RNA was reverse transcribed to cDNA in a 20^1 reaction 
containing 1 pi (200U) Molony murine leukemia virus (M-MLV) reverse 
transcriptase (Promega, Southampton, UK), Ipl (500ng) oligo(dT)i5 
primer (Promega), Ipl of lOmM dNTPs (Promega), 0.5pi (25U) 
Recombinant RNasin® Ribonuclease Inhibitor (Promega) and 4pl M- 
MLV 5x reaction buffer (Promega). Initially, the RNA was added to the 
oligo(dT)i5 primer, made up to 13.5pl with H20, and heated to 70°C for 5 
minutes. Samples were then cooled on ice and the remaining reagents 
were added. The reaction is then incubated at 37°C for 1 hour followed by 
heating at 65°C for 10 minutes to deactivate the reverse transcriptase 
enzyme.
The Lck specific PCR primers were; transcript I forward (PI): 5’- 
GGATCCCAGGATCTCACAATC-3’, transcript II forward (PII): 5’- 
GGACCATGTGAATGGGGCCAGAGG-3’, reverse primer for both 
transcripts (PHI): 5’-GCACCTCAGAGCCATTTCG-3’ (Eurofins MWG 
Operon, London, UK) and were taken from [115]. Primers were received 
in lyophilized form, and were reconstituted to lOOpmol/pl in H20 and then 
diluted to provide a 20pmol/pl working stock.
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All semi-quantitative PCR reactions were performed on ThermoHybaid 
PxE 0.5 machines (Thermoscientific) and contained: 16.75j.l1 H20, 5jli1 5x 
Green GoTaq Flexi buffer (Promega), 1.5 pi 25mM MgCl2 (Promega), 
0.5pl of each of the forward and reverse primers (final concentration 
0.4pmol/jil), 0.5pl lOmM dNTPs (200pM final concentration), 0.5pl of the 
cDNA template and 0.25pl GoTaq DNA polymerase (Promega). The 
optimised PCR conditions were 10 minutes at 95°C followed by 30 cycles 
of 94°C denaturation, 67°C annealing and 72°C extension for 30 seconds 
each. PCR products were subjected to agarose gel electrophoresis (1% gel 
at 140 constant volts for 1 hour) in the presence of ethidium bromide and 
visualised using a Fujifilm FLA-5000 (Fuji). A 1% agarose gel contains 
1.5 grams of agarose (Web Scientific Ltd, Crewe, UK) boiled until 
dissolved in lOOmls of H20 in a conical flask using a microwave. 15mls of 
lOx Tris-acetate-EDTA (TAE; Sigma) buffer was then added followed by 
35mls H20 and 1.5/d of a lOmg/ml ethidium bromide solution (Sigma). 
The suspension was mixed, poured into a horizontal gel plate and two 20 
well combs were placed into the gel and left to set for 20mins. The combs 
were then removed, the gel placed in a running tank (Scie-Plas, Fisher 
Scientific) and lx TAE buffer containing lOOpg/ml ethidium bromide was 
added. 5 pi of the PCR reaction was loaded into each lane and the first and 
last lane of every gel contained lOpl of lOObp ladder (New England 
Biolabs). Gels were visualised using a Fluorescent Image Analyser FLA- 
5000 (Fujifilm from Raytek Scientific Ltd., Sheffield, UK).
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2.2.6 Quantitative Real-time PCR
Primers were designed using sequence information on the NCBI Entrez 
nucleotide database (records NM_001042771.1 and NM_005356.3, Homo 
sapiens lymphocyte-specific protein tyrosine kinase transcript variant 1 
and 2 respectively as detailed in the appendix). Primers were designed to 
amplify the coding region and would therefore amplify Lck transcripts 
initiated from both the proximal and distal promoter, therefore giving a 
reflection of the amount of total Lck mRNA present. The forward primer 
sequence was S’-GAGGCTGTGCTGGAAGGAG-S’ and the reverse 
primer sequence was 5’-TGTGGTCTCAGGAAATGGGAG-3’ (Eurofins 
MWG Operon); the product has a length of 383 nucleotides. qRTPCR 
reactions were performed in Mx3000P 96-well qPCR plates (Agilent 
Technologies, South Queensfeny, UK) with 8x strip optical caps (Agilent 
Technologies) on a Stratagene Mx3005P qPCR machine (Agilent 
Technologies). Each PCR reaction comprised of 0.25pl cDNA template, 
0.5jil (lOpmol) of each forward and reverse primer, 11.25pl H20 and 
12.5pi 2x DyNAmo SYBR Green qPCR master mix (New England 
Biolabs). Optimised PCR reaction conditions were 10 minutes at 95°C 
followed by 45 cycles of 95°C denaturation, 67°C annealing and 72°C 
extension for 30 seconds each. The products were measured using a 7 
second 81°C read step at end of each cycle. A final dissociation read 
section (multiple product reads from 55-95°C) at the end of the PCR 
verified the correct product amplification read temperature. To further
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confirm the specificity of the primers and the presence of only 1 PCR 
product of 384 bp in length, 5 pi of the PCR reaction was mixed with Ipl 
6x Orange G loading buffer (1.5grams Ficoll 400 (Sigma), Orange G Dye 
(Sigma) dissolved in lOmls H2O) and was ran on a 1.5% agarose gel.
2.2.7 Fluorescent activated cell sorter (FACS) analysis
The purity of the CLL cell populations was determined by flow cytometry 
using a Becton Dickinson FACSCalibur machine and FITC-labelled anti 
CDS, CD 19 or CD20 antibodies and IgG controls (BD Biosciences). Lck 
was detected using an unlabelled rabbit primary antibody (Santa Cruz 
Biotechnology) and a phycoerythrin (PE) labelled secondary antibody 
(Invitrogen). When analysing surface expressed proteins, 1x106 cells were 
incubated for 20 minutes on ice, in the dark, with lOpg/ml final 
concentration of antibody. When analysing internal proteins, such as Lck, 
1x106 cells were fixed using 4% paraformaldehyde (Sigma-Aldrich) for 20 
minutes, then permeabilised using 0.1% TX100 (Sigma-Aldrich) for 5 
minutes, and the free paraformaldehyde was quenched using 50mM 
glycine (Sigma-Aldrich) for 5 minutes. The cells were then resuspended in 
the antibody at lOpg/ml final concentration in lOOpl PBS and incubated as 
above. The cells were centrifuged at 500g for 5 minutes at 4°C and washed 
using lOOpl PBS between each incubation step. Cells were finally 
resuspended in lOOpl PBS to which lOOpl FACS flow (BD biosciences) 
was added. This sample was then analysed by FACS analysis.
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2.2.8 Cell survival analysis
1ml of 2xl06/ml cells in culture media were incubated with various 
stimuli in the presence or absence of IjaM of the Lck inhibitor for 48 
hours and the relative proportion of alive or dead cells assessed using a 
3,3-dihexyloxacarbocyanine iodide/propidium iodide (DiOC6/PI) 
apoptosis assay. 4x105 cells were harvested from culture in 200pl culture 
medium and added to 200pi of 80nM DiOC6/PBS (Sigma-Aldrich). This 
was then incubated at 37°C for 20 minutes. 400pl of lOpg/ml PBS/PI 
(Sigma-Aldrich) solution was added and incubated on ice, in the dark, for 
30 minutes. DiOCe is a marker of membrane integrity and alive cells are 
DiOCfi positive and fluoresce on the FL1 wavelength of the FACS 
machine. Early apoptotic cells do not contain as much DiOC6 and are 
negative of FL1 fluorescence. Apoptotic cells are also FL1 negative but 
have bound PI to the exposed DNA and are therefore FL2 positive.
2.2.9 siRNA
1 x 106 CLL cells were resuspended at a concentration of 2 xl06 per ml 
and treated with 1 OOnM of either Lck-specific siRNA (Ambion; Applied 
Biosystems, Warrington, U.K), a mixture of 4 SMARTselection-designed 
siRNAs targeting Lck (Dharmacon RNA Technologies; Thermo Fisher 
Scientific), or nonspecific control siRNA ( Silencer negative control #1 
siRNA, Ambion). siRNA was diluted in 100pi culture medium and pre­
incubated with 6pl HiPerFect Transfection Reagent (QIAGEN) for 10
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minutes at room temperature to allow formation of transfection complexes. 
These siRNA-HiPerFect complexes were then added dropwise into the cell 
suspension with gentle swirling of the plate to allow uniform distribution 
of the transfection complexes. Cells were then cultured for 48 hours before 
harvesting and analysis of protein content by SDS-PAGE and Western blot. 
In addition, in the case of the experiments where 2 hits of siRNA were 
used, the cells were washed after 48 hours, resuspended in fresh culture 
media and subjected again to the siRNA treatment. Cells were cultured for 
a further 48 hours and then analysed as above. A control FITC-labelled 
siRNA (Ambion) was used to assess the transfection rate of the CLL cells 
and this was analysed using FACS analysis and showed an average uptake 
of 88%.
2.2.10. Statistical analysis
SPSS or Excel were used to analyse the statistical significance of data. 
The Mami-Whitney U or Students T test was used and p<0.05 was 
considered statistically significant. All averages are expressed as the 
mean +/- the standard deviation.
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2.3 Results
2.3.1 Expression of Lck mRNA in CLL cells
The results of the RT-PCR analysis into the presence of Lck mRNA in 
CLL, Jurkat, HCL and normal B cells are shown in figure 2.1a and 2.1b.
Figure 2.1a is obtained by using transcript 1 primers that amplify 
transcripts initiated from the proximal, type I promoter. This figure shows 
the amplification of 3 bands; transcription product lb (165bp) which is the 
expected product that is transcribed from the type I promoter (Figure
2.1 .d), and products la (263bp) and prela (567bp) which are likely to be 
splice variants of the transcript from the type I promoter. These products 
have been noted in a previous publication investigating Lck expression 
[115], and could be expected to be present based on the structure of the lck 
gene. Thus, the la and lb products are clearly present in the Jurkat T cell 
line, whereas they are absent in normal peripheral B cells and in HCL cells. 
In CLL cells the la and lb products were variably present depending on the 
case used. All of the cases used in this study expressed the prela product.
Figure 2.1b is obtained by RT-PCR using transcript II primers that amplify 
transcripts initiated from the distal promoter [115]. All cases of CLL, as
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Figure 2.1 The presence of the different transcripts in CLL cells, 
Jurkat T cell line, normal peripheral blood B cells and HCL cells.
CLL, HCL and normal peripheral B cells were highly purified. cDNA was 
subjected to PCR using either transcript I (part a) or II (part b) specific 
primers (as detailed in section 2.2.5) or actin primers (part c). PCR 
products were run on a 1.5% agarose gel. The size of different products are 
shown in relation to a lOObp DNA ladder. Part d is a schematic of the gene 
structure and PCR products for transcription from both type I and type II 
promoters. Results are representative of two experiments.
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did Jurkat T cells, contained the expected 180bp PCR product (IIA). This 
product is only weakly present in normal peripheral B cells and HCL cells. 
The band designated IIB is present in cases CLL1 and CLL6 and the Jurkat 
cell line. The identity of this band has been confirmed by sequencing, and 
is derived from the Lck transcript [115]. The more pronounced band 
observed in case CLL6 and in normal B cells migrates to a similar position 
on the gel (fig 2. lb) and could be a primer-dimer.
Taken together, the above results demonstrate the presence of Lck mRNA 
in CLL cells. These results further suggest that transcription of the Lck 
gene to generate mature mRNA takes place from the distal promoter, and, 
in some cases of CLL, also from the proximal promoter.
2.3.2 Quantification of total Lck mRNA
In order to assess if the amount of Lck protein is regulated at the 
transcriptional or post-transcriptional level and if the levels of Lck mRNA 
correlate with the amount of Lck protein, quantitative real time PCR 
(qRTPCR) was used. Primers were designed to amplify product from the 
coding region of the gene and would therefore amplify transcripts initiated 
from both the distal and proximal promoters.
Purified CLL cells from cases that contained different levels of Lck protein 
(as assessed by Western blotting in figure 2.3) were selected. Normal T
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cells and B cells purified irom 3 different buffy coat samples were also 
analysed to allow comparison. One HCL case was used as an example of a 
cell type that contains veiy low levels of Lck protein (figure 2.3).
Figure 2.2 shows the qRTPCR results of the different cell types and 
includes analysis of whether levels of mRNA correlate with levels of 
protein. CLL cells contained significantly more Lck mRNA than normal B 
cells (pO.OOl). The levels of Lck mRNA in CLL cells were very similar 
to normal T cells (p=0.921). HCs contained the lowest levels of Lck 
mRNA, even lower than that expressed in the normal B cells. This low Lck 
mRNA expression of HCL is to be expected based on the result in figure 
2.3 that shows that these cells contain very low levels of Lck protein.
We next examined Lck protein expression in different CLL cell clones.
2.3.3. Expression of Lck protein in CLL cells
To examine Lck protein expression in CLL we first compared Western 
blots of Normal T and B cells, the malignant cells of hairy-cell leukaemia 
(HCL) and mantle-cell lymphoma (MCL) cells with those of purified CLL 
cells. Figure 2.3 shows that T cells and CLL cells express easily detectable 
amounts of Lck protein, whereas HCL cells do not. B cells from normal 
peripheral blood contain very low levels of Lck protein that may represent
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Figure 2.2. Levels of Lck mRNA in CLL and normal T cells are 
similar and are higher than the levels in normal B cells and HCL cells.
A; Amount of Lck mRNA normalised to GAPDH in 14 CLL cases, l 
HCL, 3 normal peripheral blood T cell samples and 2 normal peripheral 
blood B cell samples. One CLL is an outlier represented on the boxplot as 
a single dot which contained 20.5 arbitrary units of Lck mRNA. Statistical 
significance was determined by the Mann-whitney U test. B; correlation of 
Lck mRNA levels with protein expression in 14 CLL samples. Statistical 
significance was determined by assessment of linear regression using 
Excel.
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the B-l cell population. MCL cells variably expressed Lck depending on 
the case. These results were reproducible using different antibodies to Lck 
(data not shown). Thus, in agreement with Majolini et al [4], our results 
demonstrate that CLL cells express Lck protein.
We next examined Lck expression in the lysates of 45 different CLL 
clones where the malignant cells had been highly purified. Figure 2.3 
shows that Lck expression in a selection of these cases varied dramatically. 
To quantitate the levels of Lck protein in CLL cells we used a Western 
blot-based technique whereby Lck levels in CLL cell lysates were 
estimated against standard amounts of recombinant Lck protein. Figure 2.3 
shows that there was a linear relationship between 0.5 and 4ng of total 
loaded recombinant Lck. Lck expression in CLL cell lysates was estimated 
from lOpg of total cellular protein and is reported as pg Lck/pg total 
cellular protein. This method was reproducible using mouse anti-Lck 
(Santa Cruz clone 3A5) and rabbit anti-Lck (Cell Signaling clone 73A5) 
antibodies (Figure 2.3). Table 2.1 shows the amount of Lck protein in the 
malignant cells from each CLL clone tested. We found that there was a 
range of Lck expression from 20 to 256 pg/pg total cellular protein. 
Interestingly, a comparison between Lck protein and mRNA levels in CLL 
cells shows that despite the very large variation in protein, there is 
relatively small variation in mRNA. Moreover, the levels of Lck mRNA do 
not correlate with the levels of protein (Figure 2.2B). These data suggest
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Figure 2.3. Expression of Lck protein in CLL, HCL, Mantle cell 
lymphoma (MCL) and normal peripheral blood T and B cells. All cell 
types were purified by removal of contaminating cells using negative 
purification (methods section 2.2.4) prior to lysis, protein determination 
and Western blotting. Actin was used as a measure of sample loading and 
the actual amount of Lck in different samples in C and E were calculated 
by comparison with 0.5, 2 or 4ng of recombinant Lck protein standard 
(Lck std). The analysis of the standards are shown in D and F. Results are 
representative of two experiments.
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CLLcase UMP!/M) c-Abl (pg/mg) ZAP70 (relative) Lyn (relative) WBC IgVH mut gene usage dan stage
CLL35 20 2 30.21 142 0.4 3-48/ M
CLL30 32 17 9.84 240 0.0 5-51/ A
CLL36 40 68 27.91 118.5 3.6 3-73/ M
CLL37 42 19 4.30 242 12.3 3-53/ G
CLL38 49 87 17.76 126.5 0.0 3-09/ M c
CLl 39 52 43.68 184 0.0 3-30/ M
CLL40 55 44 29.74 183 0.3 2-70/ M
CLL 41 58 7.7 23.3 1.35 3-48/ M A
CLL 22 58 58 23.00 155 5.4 4-34/ G
CLL 29 61 5.63 158 8.9 4-34/ M C
CLL 42 65 15.4 412 0 DPS M
CLL43 75 8.4 86.8 1.09 3-66/ M B
CLL 44 75 10.1 49.3 . . A
CLL 33 81 17.2 382 0 DP8 M
CLL 45 101 7.5 215 4.47 4-43/ M AO
CLL 46 107 25 39.34 128 3.2 3-48/ M
CLL47 109 23 32.37 116 6.1 3-23/ G A
CLL 48 110 24.7 8.5 3-13/ M AO
CLL 49 111 16.3 66.4 11.11 3-48/ M C
CLL 17 117 43.36 427 0.0 1-18/ M B
CLL 50 123 61 29.50 124.7 0.0 1-69/ M
CLL 51 123 42.54 11.5 147 0 4-34/ M A
CLL 52 127 16.1 124 6.12 V3-49 G B
CLL 53 138 101 9.33 110.7 8.9 4-34/ G
CLL 54 142 31 29.10 187 0.0 4-31/ M B
CLL 55 145 13.9 182 6.45 1-69/ M B
CLL 56 149 57 41.06 266 0.3 3-49/ M
CLL 57 168 20.9 . 0.35 1.46 M
CLL 58 170 10 10.23 210 8.6 3-09/ M B
CLL 59 181 59 9.43 18 165 4.6 4-34/ M
CLL 60 182 49 42.20 127 0.0 1-69/ M
CLL61 185 165 4.56 4-34/ M A
CLL 62 185 103 42.08 71.5 . .
CLL 63 187 32 8.19 165 4.6 4-34/ M
CLL 64 187 10 54 6.12 3-72/ M
CLL 65 189 15 3.29 196 3.1 3-30/ M
CLL 66 196 11.7 127 _ . B
CLL 67 199 85 4.24 150 5.2 3-48/ M
CLL 68 211 9.9
CLL 69 213 11.32 98.8 4.4 3-07/ M A
CLL 70 219 82 6.73 175 6.6 1-69/ M
CLL 71 222 12.9 174 1.75 4-59/ M A
CLL 72 236 82 14.80 105 1.8 4-59/ M
CLL73 256 31 26.97 12 76.6 1.7 4-61/ M Bll
Fable 2.1 Levels of Lck, ZAP70 or Lyn protein and characteristics of 
the cases used. Levels of Lck are expressed as pg/pg total cellular lysate in 
comparison to a recombinant standard. Lyn and ZAP70 levels are 
expressed as arbitrary units in comparison to jft-actin. WBC is the whole 
blood cell count of the sample (expressed as 10ycells/litre).
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that post-translational regulation of Lck expression may be important in 
CLL cells.
A previous study has shown that the SFK Lyn is overexpressed in CLL 
cells [132]. Figure 2.4 shows that in contrast to the considerable variability 
of Lck expression between CLL cell clones, Lyn expression was relatively 
consistent. This suggests that the mechanisms that control Lck and Lyn 
protein expression in CLL cells are different.
ZAP70 is a major substrate of Lck in T cells. CLL cells also express 
ZAP70, but the expression of this protein varies between malignant cell 
clones [63]. In particular, high expression of ZAP70 is associated with low 
levels of IgVH mutation. To investigate the possibility that Lck and ZAP70 
expression in CLL cells may be similarly controlled, we next compared the 
expression of these two proteins in the malignant cells of the CLL clones 
we analysed. Figure 2.4 shows, in agreement with the work of others [65], 
that ZAP70 expression varied between CLL cases. Moreover, our data also 
agree with the published results of others; ZAP70 expression was higher in 
CLL cases with unmutated IgVH (Figure 2.4.B.). However, when we 
correlated ZAP70 expression with that of Lck we found there was no 
significant relationship (figure 2.4.C.).
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Figure.2.4. Comparison of Lck protein levels with ZAP70 and Lyn. 17
representative CLL cases negatively purified were subjected to Western 
blotting for Lck, ZAP70, Lyn or /3-actin as a loading control (A). 
Densitometry was perfonned and the amount of each protein was 
normalised to actin and comparison of the levels with each other and with 
markers of disease such as IgVH mutation were made. B; IgVH versus 
ZAP70 levels and C; Lck protein versus ZAP70.
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ZAP70 expression is a useful marker for CLL disease prognosis because 
CLL-cell clones bearing unmutated IgVH genes generally express high 
levels of this protein. When we compared Lck expression in CLL-clones 
bearing umnutated IgVH genes with those bearing mutated IgVH genes we 
found no significant difference (Figure 2.5A). This result was expected 
based on the previous finding that there was no significant correlation 
between ZAP70 and Lck.
We next examined Lck expression in CLL clones bearing different VH 
gene segments. Figure 2.5B shows that Lck expression could not be 
correlated with particular gene usage. Furthermore, a comparison of Lck 
expression in CLL cells that had undergone Ig class switch showed no 
difference in protein expression between IgM and IgG bearing cases 
(figure 2.5C). Finally, we compared Lck expression with white blood cell 
count. This analysis showed no correlation between Lck expression and 
tumour burden in CLL (Figure 2.5D).
Taken together, the above results show a wide variation in Lck expression 
between CLL cell clones that has no relation to prognostic indicators of 
disease. This suggests that Lck is likely not to have value in CLL disease 
prognosis. Furthermore, the above data provide no hint to the processes 
that drive Lck expression in CLL cells.
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IgVH mutation
300
Iggene usage and mutational status
WBC
Figure 2.5. Comparison of Lck protein levels with markers of CLL 
disease prognosis. A; IgVH mutation defined as unmutated (UM) if the % 
deviation from the germline sequence is <2. B, immunoglobulin gene 
usage and mutational status. C, Immunoglobulin class (note only 1 IgA 
case was analysed). D; whole blood cell count (WBC).
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2.3.3.1 Detection of Lck in CLL cells by flow cytometry
To further explore Lck protein expression in CLL cells, and to confirm the 
results generated by Western blot, I used flow cytometry. This method has 
the advantage of being able to examine the appropriate cell population in 
unpurified cell preparations. The major disadvantage of this technique is 
that protein expression is semi-quantitative and small differences are not 
easily distinguishable.
Figure 2.6 shows that Lck can be detected by FACS analysis in both T and 
B cells in CLL cell samples. Furthermore, this figure also shows that the 
majority of Lck positive cells in the CLL cases are B cells. These data 
validate the Western blot analysis of Lck expression in CLL cells.
During our experiments examining Lck protein expression in CLL cells, I 
often observed the appearance of a slower migrating minor band in some 
but not all of the CLL cases I analysed (Figure 2.7, CLL cases 10 and 16 
versus 2 and 21). Several reports have indicated that the appearance of 
such a band is associated with serine/threonine phosphorylation of Lck. 
This post-translational modification of Lck seemed to be important and 
was therefore further investigated in the second part of this Chapter.
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Figure 2.6. Expression of Lck protein in CD 19 and CD3 positive cells 
in non-purified CLL samples. FACS analysis of cells stained with anti- 
Lck antibody and either CD 19 or CD3 was perfonned on whole, non- 
purified, CLL samples to compare the amount of Lck expressed in CD 19 
positive B cells and CDS positive T cells (methods section 2.2.7). 
Representative of 5 CLL cases.
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2.3.4 Investigation into the mechanism and function of Lck serine
phosphorylation in CLL cells.
2.3.4.1 Appearance of the slower migrating Lck band is associated
with the stimulation of CLL cells with PMA and signalling through the
BCR
It is well established that activated Lck can be phosphorylated on serine 42 
and 59 by enzymes such as PKC and ERK which results in the generation 
of an Lck band of apparently larger molecular size (60kDa). This band has 
been designated p60 [100]. In T cells the appearance of the p60 band is 
often taken as an indication of Lck activation because of its association 
with engagement of the TCR [175]. Appearance of the p60 band can also 
be stimulated using PMA, but whether this indicates full activation of Lck 
is not clear.
Figure 2.7 shows Western blots of Lck in four CLL samples, two in which 
the 60kDa band was constitutively present (CLL10 and CLL16) 
presumably because of in vivo cell stimulation, and two that did not contain 
this band (CLL2 and CLL21). When the cells were stimulated by PMA this 
caused a rapid shift of a large proportion of the p56 band to the 60kDa 
position regardless of whether or not the cells already contained this slower 
moving band. Incubation for 1 hour with either the specific PK.C/3 
inhibitor (LY379196) or a general inhibitor of PKCs (Ro32-0432) caused
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Figure 2.7. Lck migration shift in response to PMA is PKC dependent
A. 4 CLL samples were cultured with a PKC beta inhibitor (LY379196) at 
IpM, a PKC general inhibitor (Ro-32-0432) at lOpM for 55 minutes with 
or without PMA at lOOnM for 5 a further minutes to stimulate PKCs. 
Lysates were subjected to Western blotting for Lck (as detailed in methods 
section 2.2.3). B. 2 CLL cases were preincubated with the same inhibitors 
(as for A) for 55 minutes and then stimulated with lOOnM PMA for 5 
minutes and then Western blotted for Lck and actin. Results are 
representative of two repeat experiments.
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no clear reduction of the constitutively present 60kDa band (figure 2.1 A). 
These results suggest that the mechanisms regulating the shift in Lck 
mobility in resting CLL cells might be different from those that are 
stimulated by PMA to result in the slower migrating band.
To investigate the nature of the PMA-induced shift in Lck mobility I tested 
the effect of the above PKC inhibitors on the induction of this shift (figure 
2.7B). In these experiments a lower percentage polyacrylamide gel was 
used to analyse the Lck shift than was used in figure 2.7A. Reducing the 
acrylamide concentration allowed for better separation of the Lck bands 
and resulted in the appearance of a third band migrating above p60. The 
appearance of this band is reported to indicate phosphorylation of Lck at 
both serine 42 and 59 [97]. Pretreatment of CLL cells with LY379196 
inhibited the appearance of this higher molecular weight band, whereas 
pretreatment with Ro32-0432 inhibited the appearance of both bands. 
These results suggest that the PMA-induced shift in Lck mobility is 
partially mediated by activation of PKC(3, but that the majority is likely to 
be mediated by other, possibly novel, isoforms of PKC.
The above data suggest that Lck may associate with PKCs, where these 
latter enzymes are responsible for serine phosphorylation of activated Lck. 
However, in some studies Lck has been found to be associated with and 
phosphorylated by ERK [175]. It is therefore possible that Lck activation
69
may also involve ERK and that either PKC or ERK, or both, are involved 
in post-translational modification of Lck. Since both ERIC and PKC play a 
role in BCR signalling, the appearance of the p60 band in response to BCR 
cross-linking on CLL cells in the presence of PKC and MEK inhibitors 
was studied next.
Figure 2.8B shows that BCR stimulation of CLL cells induces appearance 
of the p60 Lck band. Pretreatment of the cells with inhibitors of PKC 
(Ro32-0432 or bisindolylmaleimidel, both used at lOpM), or the MAP 
kinase pathway (U0126), or of Lck itself inhibited the formation of this 
band. These results confirm a role for PKC and ERK in the BCR-induced 
change in Lck mobility, and further suggest that BCR mediated activation 
of Lck may also be involved. As demonstrated for PMA-induced p60 
formation, PKC{3 and possibly also PKCs may play small roles because 
treatment of CLL cells with IpM bisindolylmaleimidel, which inhibits 
these PKC isoforms at this concentration, partially inhibited the 
disappearance of the p56 band.
To investigate the role of ERK we analysed the level of phosphorylation of 
this protein in response to BCR crosslinking as a function of the 
appearance of the p60 band of Lck. Figure 2.8A shows that BCR 
engagement induced an increase in the level of pERK in all the cases
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Figure 2.8. Unstimulated p60Lck is present in CLL cases with high 
baseline pERK levels and increases in response to BCR crosslinking in 
a PKC, MEK and Lck-dependent manner. A. Levels of Lck, 
phosphorylated ERK (pERK), total ERK and jS-actin in four CLL cases 
subjected to 5, 30 or 60 mins of lOpg/ml anti-IgM stimulation(XL). 
Representative of two experiments. B. One CLL clone (CLL8) was pre­
incubated with the indicated inhibitor for 1 hour, then stimulated with 
F(ab,)2 anti-IgM at lOpg/ml final concentration for 30 minutes (+ BCR 
XL). The general PKC inhibitor Ro-32-0432 was used at a lOpM 
concentration (RO) and the PKCe-specific inhibitor bisindolylmaleimidel 
at concentration of 1 or lOpM (BIS 1/10). The MEK inhibitor U0126 was 
used at 1 OpM in order to inhibit ERK activation and the Lck inhibitor used 
at 1 pM. Representative of five cases.
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tested. This increase was apparent at 5 minutes following addition of the 
crosslinking antibody, and was maintained over the 1 hour duration of the 
experiment. Appearance of the p60 Lck band only became apparent at 30 
minutes following BCR stimulation. These results demonstrate a time 
delay between the kinetics of ERK phosphorylation and the appearance of 
the p60 Lck band. The reason for this time delay is unclear, but it suggests 
that active PKC and ERK must be brought into the proximity of Lck in 
order for the p60 Lck band to be formed and that this is a secondary effect 
of BCR crosslinking.
Interestingly, the presence of the p60 Lck band in resting CLL cells 
seemed to be associated with high levels of pERK (Figure 2.8A). Based on 
the above results, and on the known role of the BCR in CLL pathobiology 
[53], the appearance of the p60 band may be the result of prior stimulation 
of the CLL cells in vivo.
2.3.4.2 Formation of the p60 Lck band in CLL cells is associated with
serine phosphorylation
Previous reports have indicated that Lck can be phosphorylated on serine 
42 and 59 and that this results in the generation of the p60 Lck band [97, 
100]. I next investigated whether the stimulated appearance of this band in 
CLL cells was also associated with serine phosphorylation.
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Figure 2.9. Amino acid sequence of Lck highlighting the serine 42 and 
59 PKC and MAPK phosphorylation consensus sequences.
Figure 2.9 shows a schematic of the amino acid sequence of Lck that 
includes the phosphorylation sites at serine 42 and 59 (highlighted in 
yellow). Analysis of the peptide sequence surrounding serine 42 shows that 
this is a consensus phosphorylation sequence for PKC, while the peptide 
sequence surrounding serine 59 corresponds to the consensus 
phosphorylation sequence for ERK (red boxes) [97]. Since formation of 
the p60 Lck band in response to PMA or BCR crosslinking can be 
inhibited by U0126 and Ro32-0432 these data indicate that 
phosphorylation at serine 42 and 59 of Lck are likely to occur in CLL cells.
To investigate actual serine phosphorylation of Lck I used an anti-phospho 
serine antibody that specifically recognises serine that is phosphorylated in 
the context of a PKC consensus substrate sequence. I first investigated the 
effects of PKC activation on Lck phosphorylation. Figure 2.10 shows that 
stimulation of CLL cells with the PKC agonist bryostatin resulted in the 
appearance of the p60 Lck band in whole cell lysates. Figure 2.10 also
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shows that the anti-PKC substrate antibody innnunoprecipitated protein 
bands that were reactive with the Lck antibody. Pretreatment of CLL cells 
with IpM bisindolylmaleimidel resulted in the partial inhibition of 
bryostatin-stimulated p60 formation in whole cell lysates, and complete 
inhibition of the top band within the anti-PKC substrate 
immunoprecipitates. Taken together, these results indicate that bryostatin 
stimulates the formation of the p60 Lck band in CLL cells through PKC- 
mediated serine phosphorylation of Lck.
I performed the same experiment with U0126 to investigate the role of 
ERK. Figure 2.1 OB shows that the treatment of CLL cells with U0126 
resulted in a reduction in the molecular weight of the Lck reactive band 
that was immunoprecipitated with the anti-PKC substrate antibody from 
bryostatin stimulated CLL cells. This indicates that active ERK is likely to 
contribute to the phosphorylation of Lck in CLL cells. Figure 2.1 OB also 
shows that treatment of CLL cells with lOpM bisindolylmaleimidel results 
in the complete inhibition of anti-PKC substrate antibody 
immunoprecipitation of Lck reactive bands from bryostatin treated CLL 
cells. This corresponds to the complete inhibition of p60 Lck formation in 
whole cell lysates.
I also analysed Lck phosphorylation using an antibody that recognises 
phosphoserine in the context of an ERK consensus substrate sequence.
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Figure 2.10. Lck from brvostatin-treated CLL cells is a substrate of PKC
A. 1 CLL case incubated with 50nM bryostatin in the presence or absence of 
bidindolylamalemide for 1 hour. Cells were pelleted and subjected to 
immunoprecipitation (IP) with anti-PKC or anti-MAPK substrate antibodies, 
then western blotted for Lck to identify Lck phosphorylated on serine by PKC 
or ERK. Whole cell lysates (WCL) were subjected to western blotting for Lck 
or pERK. B. As for A but cells were stimulated with lOpg/ml of F(ab,)2 anti- 
IgM for Ihour in the presence or absence of lOpM of U0126 or lOpM BisI 
and then subjected to immunoprecipitation of whole cell lysates examined for 
Lck. Results are representative of two experiments.
Thus, activation of CLL cells with bryostatin resulted in the generation of 
an anti-Lck reactive band that could be immunoprecipitated with an anti- 
MAPK substrate antibody. Treatment of CLL cells with 1 pM bisl prior to 
bryostatin stimulation did not affect this immunoprecipitation, likely 
because the presence of IpM bisindolylmaleimidel did not affect pERK 
levels (figure 2.10A).
Finally, I investigated the mechanism of BCR-induced p60 Lck formation. 
Figure 2.10 shows that the anti-PKC substrate antibody could 
immunoprecipitate an anti-Lck-reactive protein when CLL cells had been 
stimulated through the BCR. The results generated with the anti-MAPK 
substrate antibody were less clear.
Taken together, the results from the above section demonstrate that the 
appearance of the p60 Lck band is associated with serine phosphorylation 
of Lck. Moreover, the results also strongly suggest that PKCs and ERK 
are likely to be involved in mediating this phosphorylation of Lck.
2.3.4.3. Formation of the p60 Lck band is potentially also associated
with ubiqiiitinviation of Lck.
In T cells formation of the p60 Lck band is associated with ubiquitinylation 
of Lck [96]. I therefore investigated whether this process could also be 
taking place in stimulated CLL cells (figure 2.11).
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Figure 2.11. BCR XLing induces an increase in smears that react with 
a ubiquitin antibody from Lck immunoprecipitates. 1 CLL clone was 
incubated with lOpg/ml F(ab’)2 anti-IgM (BCR-XL) or 50nM bryostatin 
for 1 hour. Ubiquitinylated Lck was assessed either by 
immunoprecipitating with an anti-ubiquitin antibody and probing for Lck 
(A), or immunoprecipitating with an anti-Lck antibody and Western 
blotting with the anti-ubiquitin antibody (B). Results are representative of 
three experiments performed on two CLL cases.
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Figure 2.11. A shows that anti-Lck reactive proteins could be 
immunoprecipitated from lysates of BCR and bryostatin-stimulated CLL 
cells using an antibody that recognises ubiquitin. Several of the reactive 
bands migrated with the same mobility as the p60 and higher molecular 
weight Lck bands observed in whole cell lysates. When I did the converse 
experiment and immunoprecipitated Lck from CLL cell lysates and 
performed Western blots with the anti-ubiquitin antibody, I found weaker 
reactivity and the amount of smears indicating polyubiquitmtylation of 
proteins was low even in the whole cell lysates (Figure 2.1 IB). However, 
BCR crosslinking or bryostatin stimulation resulted in the appearance of 
bands in the anti-Lck immunoprecipitates that were reactive with ubiquitin 
antibodies in Western blots. These bands showed a mobility that was 
similar to that of the p60 Lck band. Analysis of whole cell lysates with the 
ubiquitin antibody showed the appearance of high molecular weight 
smears within the stimulated cell lysates, and this is indicative of 
ubiquitinylated proteins [96]. Taken together, these results suggest that 
CLL cells, like T cells, are likely also to ubiquitinylate Lck in response to 
stimulation.
2.3.4.4. Kinetics of Lck phosphorylation during prolonged CLL
incubation with bryostatin
Ubiquitinylation of proteins is often associated with degradation of these 
modified proteins within the proteasome. A role for ubiquitinylation in the
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degradation of Lck in stimulated T cells has already been demonstrated 
[96]. Since our data suggest that Lck was being ubiquitinylated during 
BCR and bryostatin stimulation of CLL cells, it was important to 
investigate whether this led to Lck degradation within these cells.
I initially investigated Lck degradation following activation and the 
reappearance of the enzyme by Western blot analysis. Figure 2.12 shows 
that addition of bryostatin to the cells caused an immediate conversion of a 
part of p56 Lck to the p60 form. In the upper case in the figure (CLL15), 
this conversion was almost complete during the first 4 hours of stimulation 
so that the residual p56 band became almost invisible. After this point, the 
density of the p60 band was progressively reduced in parallel with the 
progressive reappearance of the p56 band at 4, 24 and 48 hours. At 72 
hours, the 60kDa Lck was no longer present and the density of the p56 
band had largely recovered and by 120 hours this band even exceeded the 
level seen in the control unstimulated CLL cell samples.
In the lower case in 2.12A (CLL16), the conversion of p56 Lck to p60 
form followed a similar pattern as in CLL15. However the recovery of the 
p56 band was slower than in CLL15 and the p60 band was still present at 
later stages of the incubation with bryostatin. Bryostatin activates PKC 
whereby activated PKC becomes ultimately degraded by proteasomal 
degradation. Judging from the difference in kinetics of the appearance and
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Figure 2.12. Bryostatin or F(ab,)2 anti-IgM causes a change in 
electrophoretic mobility and amount of Lck during prolonged 
incubation of CLL cells. A. cells from 2 CLL patients (CLL15 and 
CLL16) were incubated with bryostatin at a final concentration of 25nM 
for 120 hours and examined at indicated times for Lck expression by 
Western blotting. Results are represenative of two experiments on a total of 
four cases. B. CLL 8 was stimulated with 10jUg/ml anti-IgM for the 
indicated times and analysed for Lck SDS-PAGE migration as in A. Time 
0 denotes the time taken to pellet, wash and lyse the cells after the addition 
of bryostatin or anti-IgM. Representative of two repeat experiments.
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disappearance of p56 and p60 bands in clone CLL15 and CLL16 it would 
appear that PKC activity persisted in CLL16 for a considerably longer time 
than in clone CLL15.I also examined the kinetics of p60 Lck formation in 
BCR-stimulated CLL cells. Figure 2.12B shows that stimulation of CLL 
cells with BCR crosslinking resulted in the generation of the p60 band. The 
presence of this band was apparent at 1 and 2 hours, but then decreased at 
4h, almost disappeared at 8h, but then reappeared at 24h, where it remained 
for the rest of the experiment. Interestingly, and in contrast to the results 
observed with bryostatin, the level of the p56 band of Lck decreased in the 
BCR-stimulated CLL cells at the 48h and 72h time points. Also, BCR 
crosslinking never stimulated the complete disappearance of the p56 Lck 
band, whereas bryostatin (or PMA) almost always did.
The above induced changes in Lck mobility could either be due to 
ubiquitinylation, degradation and de novo synthesis of Lck, or to a cycle of 
protein phosphorylation and de-phosphorylation. If the observed kinetics of 
appearance and disappearance of the two bands indicates Lck degradation 
and resynthesis, then the rapid protein recovery indicates de novo synthesis 
through stimulation of Lck translation rather than transcription. This 
resynthesis also indicates that bryostatin-activated PKC may not only be 
involved in the regulation of Lck expression through phosphorylation and 
degradation, but also through regulation of Lck synthesis.
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In order to investigate if the p60 Lck band is proteasomally degraded upon 
bryostatin treatment, the proteasome inhibitor lactacystin was used. CLL 
cells are particularly susceptible to lactacystin-induced apoptosis [176] and 
I found that this was the case for most of the CLL samples I used in my 
studies. However, I found two cases that did not undergo quite as dramatic 
an induction of apoptosis and would, therefore, allow an experiment 
investigating the effects of lactacystin on the p60 Lck band to go forward 
(figure 2.13). Since bryostatin induces PKC downregulation through 
proteosomal degradation, the treatment of CLL cells with lactacystin will 
also preserve PKC levels within the treated cells. This persistent presence 
of active PKC would likely contribute to Lck phosphorylation, and 
consequently cause an increase in the level of the p60 Lck band 
independent of any effect on Lck degradation. To eliminate this problem I 
included bisindolylmaleimidel in my experiments as a general PKC 
inhibitor.
Figure 2.13A shows that 24 and 48 hours incubation with bryostatin 
produced the expected shift of the p56 Lck band to the p60 position. This 
accumulation of the p60 Lck band was almost completely abrogated by the 
addition of lactacystin in the two CLL cases shown. This disappearance of 
the p60 Lck band induced by lactacystin is unlikely to be due to the 
cytotoxicity of this reagent on CLL cells because this reagent reduced CLL 
cell viability by approximately 50% in the two cases that I used, and
82
2-lhr 48hr
m m 
°p °? 
5 1
QC !£'op ^ O
J^
CLL75
Lck
A.
CLL38
Lck
actm
Figure 2.13 Lactacystin treatment decreases the bryostatin-induced 
formation of p601ck. 2 CLL cases were pre-incubated with 2.5pM 
lactacystin or lOpM bisindolylmaleimidel for 1 hour before addition of 
25nM bryostatin to the relevant wells. A; Cells were pelleted, lysed in clear 
SDS sample buffer, protein detennination carried out and lOpg total 
protein subjected to Western blotting for Lck and then the blot reprobed 
with an anti /3-actin antibody as a loading control. B; apoptosis assay 
showing percentage alive cells (DiOC6 positive, PI negative) after 24 or 48 
hours incubation with 25nM bryostatin (BRY), 2.5pM lactacystin (LAC) 
and lOpM bisindolylmaleimidel (BISI). Results represent one experiment.
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because this reduction in cell viability is not matched by a proportional 
decrease in p60 Lck band density. Since lactacystin treatment did not result 
in maintenance of the p60 Lck band but instead fostered the appearance of 
the p56 Lck band, there is a suggestion that the appearance of the p60 Lck 
band resulting from bryostatin treatment does not necessarily lead to 
proteomic degradation of Lck.
The inclusion of bisindolylmaleimidel in these experiments reduced CLL 
cell viability to near zero levels. Therefore, the effect of BisI and 
lactacystin on Lck mobility cannot be interpreted.
An alternative method for showing the fate of the p60 Lck band would be 
to treat the cells with siRNA targeting Lck. Knockdown of Lck mRNA 
would mean that if p561ck were to reappear after the shift to p601ck then 
this could not be due to newly synthesised protein and must therefore be 
due to dephosphorylation of p601ck. However, although I tried this 
procedure several times, using techniques such as nucleofection or reagent- 
mediated transfer, this did not result in a decrease in Lck protein levels. To 
show that my method was working a FITC-labelled siRNA was used to 
confirm the uptake of siRNA into the cells. Figure 2.14C shows that CLL 
cells incorporated the FITC-siRNA. Figure 2.14A shows that despite using 
two different siRNA (from Ambion and Qiagen) specifically designed to 
knock down Lck mRNA, there was no change in Lck protein expression,
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Figure 2.14. Lck and c-Abl targeted siRNA treatment of two CLL
cases. Cells were subjected to 2 hits of siRNA at a concentration of lOOnM 
for a total of 96 hours. Amount of Lck (A) or Abl protein (B) following 
siRNA treatment of two CLL clones. C. FACS plot showing uptake of a
positive control FITC-labelled siRNA(H) in >85% of cells in comparison
to the untransfected cells (■). Representative of two experiments.
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even if CLL cells were incubated for up to 96h. Similar results were 
generated using another siRNA (a mixture of 4 different siRNA in a 
preparation called Smartpool™ siRNA from Dhannacon). In contrast, 
siRNA targeting c-Abl resulted in a small decrease in c-Abl protein 
expression (Figure 2.14B), and replicates the results of experiments already 
perfonned in this department [177]. This persistence of Lck protein in the 
cells after siRNA treatment is presumably due to a very slow Lck protein 
turnover in CLL cells that have been deprived of external stimuli, or to an 
inability of the Lck siRNA to properly reduce Lck mRNA levels.
Therefore, inhibitors of transcription and translation were used to 
investigate the possibility that the p56 Lck band is newly synthesised 
protein. I used two inhibitors of gene transcription, actinomycin D and 
flavopiridol, and one inhibitor of protein translation, cycloheximide. Like 
lactacystin, these reagents are very cytotoxic to CLL cells [178-182]. 
Ideally, these inhibitors should have been used in 24 - 48 hour incubations 
in the presence of bryostatin, but, in order to limit the effect of these 
inhibitors on CLL cell viability, relatively short incubation times were used 
(4 and 12 hours).
Figure 2.15 shows that flavopiridol and cycloheximide were active in CLL 
cells and resulted in the downregulation of Mcll expression. This result 
was expected based on the reliance of Mcll on new transcription and
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Figure 2.15 Use of transcription and translation inhibitors to 
investigate the fate of the p60 band of Lck. 2 CLL cases were incubated 
with or without 25nM bryostatin (BRYO), 2pM tlavopiridol (FLAY) or 
8nM of actinomycin D (ActD) for 4 hours. At the 4 hour timepoint lOpM 
cycloheximide (CYC) was added and the culture was continued for a 
further 8 hours. A. Western blotting for Lck, Mcl-1 as a positive control for 
the action of tlavopiridol or /3-actin as a loading control. B. The effect of 
the different inhibitors on CLL cell survival after 12 hours (CLL 75 black 
bars, CLL 38 grey bars) of incubation was assessed by a DiCXyPI 
apoptosis assay. Representative of two experiments.
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translation in order to maintain its expression levels, and confirms 
previously published results [183]. Actinomycin D seemed only to work in 
the upper CLL case but not in the lower one.
With respect to Lck, incubation of bryostatin-treated CLL cells with 
flavopiridol and cycloheximide resulted in a decrease in intensity of the 
p60 band and reappearance of the p56 band. The effect I observed with 
respect to flavopiridol at 4h is not due to the cytotoxicity of this reagent 
because its removal from CLL cultures at this time point is reported to 
reverse the events leading to the induction of apoptosis [184]. At the 12h 
time point flavopiridol had a considerable cytotoxic effect (Figure 2.15), 
so the effects of this agent on Lck cannot be interpreted. Nevertheless, the 
disappearance of the p60 Lck band and the strong presence of p56 Lck 
band at the 4h time point is reminiscent of the results generated with 
lactacystin. The fact that flavopiridol induced strong downregulation of 
Mcll but did not largely affect Lck suggests that Lck protein is turned over 
at a much slower rate in CLL cells than is Mcll, and that stimulation of the 
cells with bryostatin does not change this turnover.
However, with cycloheximide the disappearance of the p60 Lck band did 
not correspond to the same strong reappearance of the p56 Lck band as 
was observed with flavopiridol at 4h. This result is noteworthy because it is
not associated with induction of significant cell death, and suggests that at 
least some protein synthesis contributes to the reappearance of p56 band.
Taken together, the results of this section suggest that the appearance of the 
p56 Lck band in CLL cells following bryostatin treatment is partially due 
to de-novo protein synthesis. The disappearance of the p60 Lck band may 
not be totally due to proteosomal degradation because lactacystin failed to 
maintain the presence of this form of Lck. Thus, p60 is likely also to be a 
target of protein phosphatases, whereby p56 is generated through the 
dephosphorylation of p60.
2.3.4 Expression of Lck protein is differentially affected by BCR
crosslinking and IL-2 stimulation in different CLL cell clones
Lck expression can be induced in normal B cells through stimulation of 
these cells with BCR crosslinking and IL-2 [113]. To examine whether the 
same mechanisms also operated in CLL cells, 4 different CLL cell clones 
and normal peripheral blood B cells were incubated for 72 hours with 
either anti-IgM or IL-2 or a combination of both stimuli. The results of this 
experiment are shown in figure 2.16.
Thus, in agreement with Taieb et aPs results [113], combined IL2 
stimulation and BCR crosslinking for 72 hours increases Lck protein 
expression in normal B cells. However, it should be noted that IL-2 alone
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Figure 2.16. IL-2 and BCR stimulation do not up-regulate Lck protein 
in CLL cells. Normal peripheral blood B cells or the cells from 4 CLL 
cases were cultured with 10pg/ml anti-IgM, lOOIU/ml IL-2 or both for 
72hrs. Lysates were subjected to Western blotting with an anti-Lck 
antibody. The darkness of the Lck bands in case CLL9 with very high 
protein expression was reduced using computer image software (AIDA 2D 
densitometry) to show the decrease in protein upon BCR stimulation that 
was not clear in the upper, original image, due to overexposure. Result is 
representative of two experiments.
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was sufficient to induce Lck protein, and that combination of IL-2 and anti- 
IgM had only a small additional effect. A similar result showing that IL-2 
stimulation of T cells induces an upregulation of Lck protein levels has 
been reported [185].
In contrast to the results generated for normal B cells, the pattern of CLL 
cell response to these stimuli varied from case to case, and was different 
from the response of normal B cells. If the Lck expression in untreated cell 
was very low (CLL20) then BCR crosslinking alone induced a small 
increase in Lck. In CLL23 and CLL34 that express intermediate levels of 
Lck in unstimulated control cells, the incubation of cells with any of above 
stimuli alone or in combination had no clear effect on Lck expression. 
However in CLL9, which had a very high level of Lck, the amount of Lck 
protein was reduced rather than increased when the BCR was cross-linked 
by anti-IgM, and the degree of this reduction was strongly potentiated in 
cells stimulated by the combination of anti-IgM and IL-2.
It would appear therefore that, depending on the level of Lck expression, 
CLL cells either do not respond to the stimuli that increase the expression 
of this protein in normal B cells or, contrary to what is seen with normal B 
cells, the high levels of Lck present in some CLL cells is actually reduced 
upon cell stimulation by anti-IgM and IL2. This decrease in Lck upon BCR 
cross-linking could be due both to activation of PKC and/or ERK, which
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are shown to phosphorylate Lck, and to its ubiquitinylation which would 
direct it to proteasomal degradation.
2.4 Discussion
The presence of Lck mRNA in CLL cells was shown by others [4, 128], 
and now confirmed in the present study (figure 2.1a and 2.1b). Moreover, 
the present study was the first attempt to characterise all possible 
transcripts in CLL cells that are generated from both the proximal (type I) 
and distal (type II) promoter.
The results showed that, like some other lymphoid cells of malignant 
origin [115], CLL cells contain both type I and type II Lck mRNA 
transcripts. The more dominant type II transcript is in normal mature 
lymphocytes associated with antigen receptor signalling [3]. Therefore the 
finding of this transcript in CLL cells supports the published data showing 
that these cells are mature, antigen-activated cells. In addition, CLL cells 
contain variable levels of type IA and B transcripts which are normally 
associated with cells undergoing malignant transformation. The IIA and IB 
transcripts that were amplified by the primers I used are the correct size for 
the expected products. However, having analysed the complete sequence 
of the Lck gene on the Entrez Nucleotide database it would appear that the 
IA and pre-IA products as assigned by Rouer et al [115], may represent a 
sequence containing introns due to either contamination with DNA or the
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presence of a mature unspliced version of mRNA which would possibly 
not be translated into a functional protein.
Although there was some difference in the expression of different 
transcripts between different CLL cases, the PCR method used was not 
sufficiently quantitative to correlate Lck mRNA expression with other 
phenotypic and functional features of CLL cells. Ideally, the levels of the 
different transcripts would require analysis by quantitative real-time PCR 
(qRT-PCR). However, the multiple sizes of products fonned from the 
amplification of the transcripts present in CLL cells would give a number 
of peaks which makes qRT-PCR unsuitable for quantitative analysis of Lck 
transcript expression from the different promoters.
A different set of primers were designed to amplify a sequence in the 
coding regions of both transcript 1 and 2 which could be used for qRT- 
PCR and therefore would allow for quantification of Lck mRNA. CLL 
cases analysed were selected based on Lck protein expression as assessed 
by western blotting (figure 2.3). Normal T and B cells and one 
representative HCL sample, that contained very little Lck protein, were 
also analysed. CLL cells, even those that contain very low levels of Lck 
protein, contain levels of Lck mRNA that are similar to the levels seen in 
normal T cells. When I compared Lck mRNA with protein levels I found 
that these two parameters were not correlated in the CLL cases I analysed
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(R =0.033). That is, CLL cells from cases expressing high levels of Lck 
protein had levels of Lck mRNA which were similar' to those expressed in 
CLL cells from cases expressing low levels of Lck protein. This result 
suggests that the turnover of Lck protein is likely to be very slow in CLL 
cells that allows for a steady build up over time.
The data presented in this chapter confirm published work showing Lck 
protein expression in normal and malignant B cells [4, 126], hi most cases, 
expression of Lck in these cells will depend upon the stage of maturation 
or the degree of activation [3]. With respect to CLL cells, these may vary 
with respect to either maturation or activation, or both, so it can be 
expected that differences in the level of Lck expression between different 
clones will be observed. I used highly purified CLL cells in my analysis to 
confirm the presence of Lck, and further show that Lck expression is 
widely variable between CLL cell clones. It is unlikely, however, that 
levels of Lck protein have a prognostic value because they did not correlate 
with established markers of disease prognosis such as IgVH mutation and 
ZAP-70 expression.
The malignant HCs shown in figure 2.4 did not contain Lck protein 
although they had detectable Lck mRNA (figure 2.1 and 2.2). Also, other 
HCL cases tested during the course of this study (n=6) either completely 
lacked Lck or contain very low levels of this protein. Since HCs are
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arrested at closely similar maturation stage as CLL cells [186, 187], the 
absence of Lck in these cells made them an ideal negative control for the 
subsequent studies of the role of Lck in CLL signalling and survival. In 
contrast to HCL cells, the expression of Lck in MCL was variable (n=5, 1 
representative case shown in figure 2.3) confirming recently published data 
[108]. 4 of the MCL cases had a very low level of Lck protein, but one 
case shown in figure 2.3, had moderate levels of this kinase. This level was 
comparable to the amount of Lck present in some CLL clones.
In addition to regulation by transcription and translation, the levels of Lck 
protein in T cells are also known to be controlled post-translationally by 
activation, followed by ubiquitination and proteasomal degradation. The 
activation of Lck in CLL cells, as assessed by migration in SDS-PAGE 
gels to the 60kDa level, was observed in the present study in anti-IgM 
treated cells and cells treated by the PKC activators PMA and bryostatin. 
In this respect, CLL cells resemble T cells in their ability to modify the 
mobility of Lck on Western blots. We further show that CLL cells induce 
formation of the p60 Lck band through serine phosphorylation that is likely 
catalysed by activation of PKC and of ERK. This was demonstrated by the 
use of specific inhibitors of PKC and MEK; these inhibitors blocked the 
formation of the p60 Lck band that was induced in CLL cell stimulated by 
BCR crosslinking and PMA/bryostatin. Moreover, we also demonstrate 
that Lck can be irmnunoprecipitated by antibodies that recognise phospho-
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serine within the consensus recognition sequences of PKC and ERK. 
Serine 42 and 59 of Lck are contained within such recognition sequences 
[97], suggesting that our ability to immunoprecipitate Lck with these 
antibodies is due to recognition of serine phosphorylated Lck and not to 
co-immunoprecipitation of Lck with other serine-phosphorylated proteins. 
Our ability to directly immunoprecipitate Lck with PKC- and ERK- 
substrate specific phospho-serine antibodies is also demonstrated by the 
molecular weight of the immunoprecipitated Lck, which had a mobility 
corresponding to that of the p60 Lck band.
I also show that Lck can be ubiquitinylated in CLL cells. Ubiquitinylation 
of proteins is an important process whereby they are tagged for 
proteosomal degradation, and/or for targeting the protein into another 
cellular compartment. Polyubiquitinylation normally results in proteosomal 
degradation of proteins, whereas monoubiquitinylation can result in the use 
of a particular molecule for further signalling. In T cells, TCR engagement 
induces polyubiquitinylation and proteosomal degradation of Lck [96]. In 
my experiments I was unable to show that Lck was degraded within the 
proteosome of CLL cells due to the high cytotoxicity of lactacystin. 
However, the results of the experiments using flavopiridol (to inhibit 
protein transcription) and cycloheximide (to inhibit protein translation) 
suggest that Lck protein in CLL cells is degraded at a far slower rate than
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is Mcll, and that this rate of degradation is not affected by formation of the 
p60 band.
Taken together, the results of this Chapter demonstrate the CLL cells 
express Lck mRNA and protein. The data in this Chapter also show that 
Lck can be post-translationally modified by PKC and ERK in CLL cells 
undergoing activation stimuli, but that this modification does not affect the 
rate at which Lck is degraded in the cell.
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Chapter 3
The role of Lck in CLL cell cytoprotection
3.1 Introduction
The function of Lck in normal B cells and CLL cells has so far not been 
investigated in depth, mainly because of the long lasting uncertainty 
whether this enzyme is expressed in these cells at all. In addition, many 
functional responses which are in T cells regulated by Lck are in B cells 
dependent on Lyn. Thus, in normal B cells as well as in CLL cells the 
focus so far was on Lyn as the principal SFK that initiates signalling 
responsible for antigen-mediated selection, maturation and clonal 
expansion of these cells.
Having shown that the comparatively high levels of Lck protein present in 
CLL samples originates from malignant CLL cells and not from 
contaminating T cells, the next step was to investigate whether this enzyme 
has any non-redundant, specific functional role in CLL cells not shared by 
other SFKs. Because the most important factors responsible for clonal 
expansion of CLL cells are those involved in cell proliferation and 
survival, and since CLL cells do not proliferate in vitro, it was decided to
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examine first whether specific inhibition of Lck affects CLL cell viability 
in in vitro cultures.
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3.2 Materials and methods
3.2.1 Cell isolation and culture
CLL and HCL samples were obtained and cultured as described in 
methods section 2.2.1
3.2.2 Inhibitors and stimuli
All inhibitors were dissolved in DMSO, aliquoted and stored at -20°C. PP1 
(Biosource; Oxford Biosystems, Wheatley, UK) was always used at lOpM. 
The Lck inhibitor (4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2- 
d]pyrimidin-7-ybcyclopentane) was used at 1 pM, , lactacystin was used at 
5pM, RO-32-432 was used at lOpM and bisindolylmaleimide I was used at 
either IpM or lOpM, and all were purchased from Calbiochem. The 
caspase inhibitor (Z-Val-DL-Ap-fluoromethylketone) which was used at 
500nM was purchased from Bachem (St Helens, UK).
F(ab’)2 fragments of goat anti-human IgM were used at a final 
concentration of lOpg/ml for crosslinking/stimulating the BCR (Jackson 
ImmunoResearch Laboratories). CpG stimulation utilised 0.5 or 5pg/ml 
ODN2006 (5,-TCGTCGTTTTGTCGTTTTGTCGTT~3’) and ODN2006 
control (5 ’ -TGCT GCTTTT GT GCTTTT GTGCTT-3’) oligonucleotides 
(InvivoGen; Autogen Bioclear, Caine, UK) for human Toll-like receptor 9 
(TLR9) stimulation. CD40 ligand (CD40L) was supplied with an enhancer
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in a soluble human recombinant set from Alexis biochemicals. The CD40L
was incubated with the enhancer in cell culture media at 37°C for 30 
minutes and then added to the cells at a final concentration of 200ng/ml 
ligand and 1 jig/ml enhancer.
3.2.3 Western blotting
As described in 2.2.3. In addition, blots were blocked in 5% milk dissolved 
in TEST for analysing the expression of proteins, or 5% ESA in TEST for 
analysis of phosphorylated proteins. Antibodies were prepared in TEST 
containing either 5% milk powder or 5% ESA as for blocking of blots.
The following primary antibodies were used: anti-Lck mouse monoclonal, 
anti-pERK mouse monoclonal, anti ERK rabbit polyclonal and anti-Mcl-1 
rabbit polyclonal (Santa Cruz Biotechnology). Anti-pY416Src, anti- 
pSer473Akt mouse monoclonal, anti Bcl-xL rabbit polyclonal, anti-c-IAPl 
rabbit polyclonal antibody, anti-cIAP2 rabbit polyclonal antibody, anti- 
pIKK rabbit polyclonal, anti-PARP mouse monoclonal, anti-BIM rabbit 
polyclonal and anti-XIAP rabbit polyclonal antibodies were purchased 
from Cell Signaling Technology. Anti-p21WAFl (clone DCS-60.2) 
mouse monoclonal antibody was obtained from Biosource. Anti p27 
antibody was purchased from ED transduction laboratories. The following 
secondary antibodies were used: Goat anti-rabbit horseradish peroxidise
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(HRP) conjugated antibody, goat anti-mouse HRP-conjugated antibody 
(Santa Cruz Biotechnology).
3.2.5 Immunoprecipitation
IxlO7 cells in media were pelleted at 500g for 5 minutes at 4°C and then 
lysed in 1ml of 4°C RIPA lysis buffer (PBS, 20mM Tris, 316mM NaCl, 
2mM EGTANa2, 2% XX-100, 0.02% SDS) containing phosphatase and 
protease inhibitors (ImM PMSF, protease inhibitor cocktail set III-EDTA 
free (Calbiochem) 1:100 dilution to produce a final concentration of ImM 
AEBSF, 800nM aprotinin, 50pM bestatin, 15pM E-64 protease inhibitor, 
20jiM leupeptin and 10pM pepstatin A). Lysates were then incubated for 
15 minutes on ice to allow complete lysis of the cells. Lysates were then 
centrifuged at 18000g for 10 minutes to pellet unlysed material. 900jil of 
supernatent was transferred to a new eppendorph and then incubated 
overnight at 4°C with 5pg of immunoprecipitating antibody, followed by 1 
hour incubation with 30 pi protein A/G beads (Invitrogen). Protein-A/G 
immuno-complexes were pelleted by centrifugation at 18000g for 10 
minutes, then washed 3 times with 4°C RIPA lysis buffer. Samples were 
boiled in 30pi 2xSDS laemelli sample buffer, run on a polyacrylamide gel 
and subjected to Western blotting.
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3.2.6 Cell survival analysis
1ml of 2xl06/ml cells in culture media were incubated with various 
stimuli in the presence or absence of IpM of the Lck inhibitor for 48 
hours and the relative proportion of alive or dead cells assessed using a 
3,3-dihexyloxacarbocyanine iodide/propidium iodide (DiOCc/PI) 
apoptosis assay.
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3.3 Results
In chapter 2, I used siRNA in an attempt to inhibit Lck mRNA and 
decrease protein expression in CLL cells (figure 2.14). Although I could 
show that the technique had the potential of working, particularly with 
proteins such as c-Abl, I found Lck protein expression in CLL cells was 
not affected by the presence of siRNA. This meant that any assessment of 
Lck function in CLL cells had to be derived from comparison with HCL- 
cells serving as negative controls, and on the specificity of a commercially 
available inhibitor of Lck activity.
3.3.1 Lck in CLL cells is specifically inhibited at luM concentration of
an inhibitor of Lck activity
Due to the close structural homology of the active site of SFKs it had to be 
assumed that inhibitors targeting this site are relatively non-specific. It was 
therefore necessary to confirm that the 4-Amino-5-(4-phenoxyphenyl)-7H- 
pyrrolo[3,2-d]pyrimidin-7-yl-cyclopentane, (from now on referred to as the 
Lck inhibitor) employed in this study, is indeed specific for Lck at the 
concentrations used.
Figure 3.1 shows the structure of the Lck inhibitor. This compound is 
reported to have an IC50 for Lck that is about 3000 fold lower than for c- 
Src and 26 fold lower than for Lyn [188]. Nevertheless, particular attention 
had to be paid to the possibility that this inhibitor also inhibits Lyn, since it
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has been shown that this kinase is highly expressed in CLL cells and has an 
important function in CLL cell survival [132],
Figure 3.1 Structure of the Lck inhibitor
Figure 3.2 shows the effect of cell incubation with the Lck inhibitor on 
active site phosphorylation of Lck and Lyn in non-stimulated and BCR- 
stimulated CLL cells. To demonstrate specificity of these effects, the SFKs 
were first immunoprecipitated from cell lysates by an antibody which 
recognises pY416 in the active site of Src (anti-active Src). This antibody 
also crossreacts with active-site phosphotyrosines in Lck (pY394) and in 
Lyn (pY396), as well as in other SFKs. The immunoprecipitates were then 
analysed by Western blot using specific anti-Lck (A) and anti-Lyn (B) 
antibodies. Thus, the anti-active Src antibody immunoprecipitated Lck as a 
doublet in unstimulated CLL cells. This shows that Lck is constitutively 
active in these cells. Stimulation of CLL cells with BCR crosslinking
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Finure 3.2. The Lck inhibitor primarily inhibits the activity of Lck.
CLL cells (CLL9) were pre-incubated with the Lck inhibitor at IpM for 1 
hour and then stimulated with F(ab’)2 anti-IgM at lOpg/ml final 
concentration for 30 minutes. The cells were then washed, pelleted and 
lysed in a RIPA buffer followed by immunoprecipitation (methods section 
3.2.5) by an anti-pY416 antibody which recognises autophosphorylation of 
the active site specific tyrosine of Src as well as Lck and Lyn. 
Immunoprecipitates were then subjected to Western blotting for Lck (A) or 
Lyn (B). C; As for B, but increasing concentrations of the Lck inhibitor 
(1 pM, 8pM or 16pM as in figure 3.2) were used.
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resulted in a shift in molecular weight of the anti-Lck bands that were 
immunoprecipitated with the anti-active Src antibody. This shift in 
molecular weight corresponds to the appearance of the p60 Lck band in the 
whole cell lysate and therefore reflects the additional serine 
phosphorylation of Lck that results in CLL cells from BCR stimulation. 
Pre-treatment of resting or BCR-stimulated CLL cells with the Lck 
inhibitor resulted in a strong reduction in the intensity of Lck-reactive 
bands. This suggests that the Lck inhibitor was blocking Lck activation in 
CLL cells.
We next examined the Western blots for the presence of Lyn. Thus, the 
anti-active Src antibody immunoprecipitated copious amounts of Lyn from 
lysates of resting and BCR-stimulated CLL cells (figure 3.2B). This 
confirms the results of others relating to the presence of active Lyn in CLL 
cells [132]. The presence of the Lck-inhibitor had no effect on the ability of 
the anti-active Src antibody to immunoprecipitate Lyn. These results 
suggest that the Lck inhibitor specifically acts to block Lck activity in CLL 
cells. Figure 3.2C shows that even at very high concentrations of the Lck 
inhibitor, the ability of the anti-active Src antibody to immunoprecipitate 
Lyn remained largely unaffected. Taken together, these experiments show 
that the Lck inhibitor I have employed in this study was relatively specific 
for this kinase, and justified its use for the remainder of this thesis for the 
investigation of the functional importance of Lck in CLL cells.
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3.3.2 Lck contributes to spontaneous CLL cell survival
Having demonstrated specificity of the Lck inhibitor for Lck activity, 4 
different CLL cell clones and malignant cells from 2 patients with HCL 
were treated with this inhibitor at concentrations progressively increasing 
from 32nM to 16pM. The results are shown in figure 3.3.
Thus, the survival of CLL cells was variably reduced by the Lck inhibitor 
in a concentration dependent fashion (Figure 3.3). In contrast, the survival 
of HCL cells was largely unaffected by the presence of the Lck inhibitor, 
even at the very highest concentration. The malignant cells of HCL express 
very little or no Lck (figure 2.3), but have been shown to undergo 
apoptosis in response to the general SFK inhibitor PP1 [189]. These data 
demonstrate that the Lck inhibitor has no effect on the SFKs that are 
important for HCL cell survival. When taken together with the data 
presented in Figure 3.2 showing that the Lck inhibitor does not affect Lyn 
activity, these data further suggest that the ability of the Lck inhibitor to 
reduce CLL cell viability is due to its ability to specifically affect Lck, and 
implicates a role for Lck in CLL cell cytoprotection. Since 50% viability 
inhibition was observed at around 1 pM of the inhibitor, this concentration 
was chosen for all future experiments.
In order to further explore how effective the Lck inhibitor is at reducing 
viability of CLL-cell clones belonging to the different prognostic
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Cone, inhibitor
Figure 3.3 The Lck inhibitor variably affects the survival of CLL cells
but not HCL cells The effect of the inhibitor on cell survival was analysed 
by FACS after 48 hour incubation, using the PI/DiOC6 cell viability assay 
(as detailed in methods section 3.2.6). This technique identifies the 
proportions of alive (DiOCft positive and PI negative), early apoptotic 
(DiOCe and PI negative) and dead (DiOC6 negative and PI positive) cells 
within the analysed population. The proportion of live cells at the end of 
the 48 hour incubation with the Lck inhibitor was expressed as a 
percentage difference between inhibitor-treated and untreated control cells, 
assigning the value of 100% viability to the latter cells.
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subgroups, 56 CLL-cell samples were incubated with IpM of the inhibitor. 
Again, three different HCL cell clones, which contain other SFKs but little 
or no Lck protein, were used as negative controls to confirm the specificity 
of the Lck inhibitor. Figure 3.4A shows that there was a wide variation in 
the effect of the Lck inhibitor on the survival of different CLL clones, 
ranging from 80% decrease in cell survival to no effect at all. In contrast, 
the presence of the Lck inhibitor, as expected, had largely no effect on 
HCL cell survival. Among the 56 CLL cases analysed, 27 were IgVH 
gene-mutated and 29 were unmutated. When I analysed CLL cell 
sensitivity to the Lck inhibitor in relation to IgVH status (figure 3.4B), I 
found that the malignant cells from unmutated CLL cases were generally 
more sensitive to the Lck inhibitor than were those from mutated CLL 
cases (P=0.04). Since IgVH mutation is a good predictor of disease 
progression in CLL, these data suggest that the role Lck plays in CLL cell 
cytoprotection may have more significant consequences in those cases that 
are likely to progress. This notion is supported by previous observations 
from this department [190] showing that Lck activity measured by an in 
vitro kinase assay is higher in the malignant cells from umnutated CLL 
cases than in those from mutated CLL cases, and that BCR signalling and 
ERK activation (shown in chapter 4 to involve Lck) was selectively 
important for cytoprotection of unmutated and not mutated cells. However, 
the degree of induction of apoptosis in response to the Lck inhibitor in the 
current study did not correlate with the amount of Lck protein present in
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Figure 3.4. The Lck inhibitor variably decreases spontaneous survival 
of CLL cells. Unmutated CLL cells are affected to a greater degree 
than mutated cells Cells from 56 CLL and 3 HCL cases were incubated 
for 48hours in the presence of 1/zM Lck inhibitor. Cell viability was 
assessed using a DiOC^PI apoptosis assay and is expressed as a percentage 
survival of treated relative to untreated cells. Cases with CLL-cell IgVH 
mutation below 2% are designated unmutated (UM) and those with 2% or 
above are designated mutated (M). Statistical significance was assessed by 
an unpaired T-test and the p value is displayed on each boxplot. Point 1 on 
the boxplots represents an outlier (with 21% survival). Results are the 
mean of two experiments.
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Figure 3.5. The degree of Lck inhibitor-induced apoptosis in CLL 
clones does not correlate with levels of Lck protein. Cell survival was 
assessed as for figure 3.4 in 42 CLL cases and compared to the level of 
Lck protein expression in each case. The r value is 0.006 and is therefore 
not significant. Cell survival data is the mean value of two experiments.
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each case (figure 3.5). This indicates that CLL-cell survival depends more 
on the degree of Lck activation than on the level of Lck protein.
3,3.3 Lck is also involved in cvtoprotection of CLL cells following
activation by a variety of different stimuli
Having demonstrated that active Lck is important in maintenance of the 
viability of apparently quiescent CLL cells it seemed important to see 
whether Lck also has a role in cytoprotection of these cells when exposed 
to a variety of known CLL activation stimuli.
The results of 48 hour incubation of cells from high and low Lck 
expressing CLL clones with different stimuli known to activate these cells 
or protect them from apoptosis are shown in figure 3.6. IpM Lck inhibitor 
was employed to assess the role of Lck in providing cytoprotection of these 
stimulated cells by comparing their viability when stimulated in the 
presence or absence of this inhibitor. Unstimulated cells were again 
designated as 100% viable at the end of incubation and used as a control to 
measure the changes in the viability of cells treated with activation stimuli 
and the Lck inhibitor. The cells were stimulated with anti-IgM, CD40L, or, 
via Toll-like receptors (TLRs) using CpG oligonucleotides (ODN 2006 
sequence).
Figure 3.6 shows that compared to the unstimulated control, all stimuli
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Figure 3.6 The level of Lck protein does not influence the induction of 
TLR, BCR or CD40L-induced survival. Cells from three high versus 
three low Lck expressing clones were stimulated for 48 hours with CpG at 
0.5pg/ml, anti-IgM at lOpg/ml, CD40L at 200ng/ml coupled to enhancer at 
Ipg/ml in the presence or absence of IpM Lck inhibitor. Cell survival was 
assessed using a DiCXVPI apoptosis assay and expressed as a percentage 
of untreated cell survival. Data represents the mean and error bars indicate 
the standard deviation of two experiments.
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employed caused a different degree of preservation in cell viability. This 
apparent increase in cell viability reflects the protection of stimulated cells 
from spontaneous apoptosis that took place in unstimulated cells during the 
first 24 hours of cell culture. Furthermore, figure 3.6 also shows that the 
level of Lck expression did not seem to influence the protection given to 
CLL cells by the stimuli used. However, Lck inhibition either greatly 
reduced or prevented the pro-survival effects of BCR crosslinking (p<0.1), 
CD40 ligation (p<0.05) and TLR stimulation (p<0.05). This suggests that 
Lck activation is more important than expression in tenns of providing 
cytoprotection to CLL cells, particularly with respect to the context of the 
pro-survival stimuli used in this study. The signalling pathways employed 
by BCR crosslinking, CD40 ligation and TLR stimulation to promote CLL 
cell survival are distinct from each other with respect to the different 
combinations of protein interactions and post-translational modifications 
within their respective signalling pathways. That Lck inhibition blocks the 
pro-survival effects of all these stimuli would suggest that the 
cytoprotective effect of Lck cannot be compensated by the presence of 
other pro-survival signals.
3.3.4 The mechanism of the prevention of apoptosis of CLL cells bv
Lck
The experiments described so far in this Chapter strongly suggest that Lck 
in both unstimulated and stimulated CLL cells plays a cytoprotective role.
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The principal mechanism of cytoprotection in cells involves the 
maintenance of the balance of expression of proteins involved in the 
induction and prevention of apoptosis, with an emphasis on the expression 
of proteins involved in prevention. These proteins that are involved in the 
prevention of apoptosis belong to either anti-apoptotic Bcl-2 family 
proteins, or a family of proteins collectively known as inhibitors of 
apoptosis proteins (lAPs). Which of these proteins protects cells from 
apoptosis depends on upstream signals as well as on the circumstances in 
which the cells become prone to die and therefore require cytoprotection.
For the analysis of the anti-apoptotic effects of Lck I chose B-cell 
lymphoma extra long (Bcl-xL) and Mcl-1 as representatives of anti- 
apoptotic Bcl-2 family proteins, and cIAPl, cIAP2 and X-linked inhibitor 
of apoptosis protein (XIAP) as representatives of lAPs. It was assumed that 
changes in the expression of these proteins would be most informative, 
because all have been reported to be involved in cell cytoprotection of CLL 
cells [191-193].
3.3.4.1 CLL cell incubation with the Lck inhibitor causes conversion of
Bcl-xL into a 17-18kDa proteolytic fragment
Figure 3.7 shows the changes in Bcl-xL expression in unstimulated CLL 
cells (A) and HCL cells (B) during 20 hours incubation with or without the 
Lck inhibitor. HCs were employed as a negative control since they did not
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Figure 3.7. Inhibition of Lck causes Bcl-xL degradation in CLL cells.
CLL cells (CLL8) (A) or HCs (B) were incubated for 20 hours in the 
presence or absence of the Lck inhibitor (IpM. The Bcl-xL protein was 
then visualised by Western blotting with a polyclonal anti-Bcl-xL antibody 
(Cell Signaling). (C) Three more CLL cases were either pelleted 
immediately post-thawing (TO) or cultured in the presence of untransfected 
fibroblasts (NT-L) or fibroblasts transfected with CD40 ligand (CD40L-L) 
for 48 hours. Equal quantities of the cell line K562 were loaded as a 
positive control. (D) One CLL case was pelleted immediatley post-thawing 
(TO) or cultured for 24 hours in the presence or absence of 50nM bryostatin 
of 10//g/ml F(ab')2 anti IgM. U937 and K562 cell lines were included as a 
positive control. The blot was then either probed with an anti-Bcl-xL 
anrtibody from Cell Signalling or one purchased from Santa Cruz. Results 
are representative of at least two experiments.
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express Lck. The different molecular weight forms of Bcl-xL were 
visualised by Western blotting with a specific polyclonal antibody
A comparison of Bcl-xL expression in cell lysates of Jurkat T cells and 
CLL cells shows that the level of Bcl-xL at the expected molecular weight 
of 30kDa is considerably less in CLL cells than in Jurkat T cells (Figure 
3.1 A). Similar results were obtained when Bcl-xL expression in CLL cells 
was compared to that in a myeloid cell line, K562 (Figure 3.7C). Bcl-xL 
expression in CLL cells could be induced by culturing the cells on CD40L- 
expressing fibroblasts (Figure 3.7C). Interestingly, CLL cell lysates 
showed the presence of an extra band at 120kDa that was reactive with the 
Bcl-xL antibody we used (from Cell Signaling). This band was not present 
in either T cells or in K562 cells, and its presence in CLL cell lysates was 
not affected by culture of CLL cells on CD40L-expressing fibroblasts. 
Considering that Bcl-xL is known to spontaneously form dimers and 
tetramers [194, 195], the presence of the 120kDa band in CLL cell lysates 
suggests the presence of Bcl-xL tetramers, and that Bcl-xL expression in 
these cells is almost exclusively in this format.
I attempted to confirm that the 120kDa band was a tetrameric form of Bcl- 
xL by using other Bcl-xL-directed antibodies. Figure 3.7 shows a sample 
Western blot comparing Bcl-xL expression in CLL cell lysates using 
antibodies from two different manufacturers, Cell Signaling and Santa
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Cruz. Both antibodies were able to detect the 30kDa Bcl-xL band in CLL
and other cell lysates, and confirm that this band is likely to be Bcl-xL. 
However, only the antibody from Cell Signaling was able to detect the 
additional 120kDaband in CLL cell lysates. The antibody from Santa Cruz 
reacted with a variety of major bands corresponding to different molecular 
weights, and the pattern of reactivity was not consistent between the lysates 
derived from different cell types used on the Western blot. Thus, the 
identity of the 120kDa band could not be confirmed as a definite tetramer 
of Bcl-xL. Nevertheless, the fact that the Cell Signaling antibody primarily 
reacts with only two bands in Western blots of CLL cell lysates and only a 
single (30kDa) band in Western blots of other cell types indicates that Bcl- 
xL specificity can be assigned to the Cell Signaling antibody, and further 
suggests that the 120kDa band could be tetrameric Bcl-xL.
When I treated CLL cells with the Lck inhibitor, the pattern of antibody 
reactivity on Western blots of CLL cell lysates was completely altered 
(Figure 3.7A) The 120 kDa tetrameric as well as the 30kDa monomeric 
fonns of Bcl-xL were almost completely absent and the only clear 
immunoreactive band was a new 17kDa protein previously identified as a 
pro-apoptotic proteolytic fiagment of Bcl-xL [196].
In contrast to CLL cells, HCL cells contain primarily Bcl-xL monomer 
(Figure 3.7B). HCL cell lysates, like CLL cells, also contained the 120kDa
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band associated with the Bcl-xL tetramer, however, an additional band 
corresponding in molecular weight to a 60kDa dimer of Bcl-xL was also 
present. However, these additional bands in the HCL cell lysates were 
weak in comparison to that of the Bcl-xL monomer. This suggests that if 
the 60 and 120kDa bands are Bcl-xL oligomers, the process of formation 
of these oligomers is different between CLL and HCL cells. That is, CLL 
cells favour the formation of tetrameric forms of Bcl-xL, whereas HCL 
cells favour the maintenance of the monomeric form. An additional 
difference between HCL and CLL cells was that incubation of HCL cells 
with the Lck inhibitor failed to induce expression of the 18kDa Bcl-xL 
degradation product. Since HCL cell viability is unaffected by the Lck 
inhibitor whereas CLL cell viability is reduced, the results of this 
experiment suggest that the appearance of the 18kDa Bcl-xL degradation 
product is likely associated with the induction of cell death. Finally, in the 
experiment represented by this Figure (Figure 3.7B) a reduced amount of 
Jurkat T-cell lysate was employed for control in order to avoid the 
excessive sample loading seen in Figure 3.7A.
To investigate further the mechanism of the conversion of Bcl-xL to the 
18kDa fragment in the presence of the Lck inhibitor, CLL cells were 
additionally cultured with Z-Val-DL-Ap-fluoromethylketone (Z-vad). Z- 
vad inhibits protein degradation caused by caspases, and therefore could
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allow identification of what causes the degradation of Bcl-xL in these 
cells.
3.3.4.2 Bcl-xL degradation caused by Lck inhibition is caspase-
mediated.
Figure 3.8 shows an experiment in which CLL cells were incubated with 
the Lck inhibitor alone or in combination with the caspase inhibitor Z-vad.
As already seen in Figure 3.7A, inhibition of Lck resulted in the 
appearance of an 18kDa fragment of Bcl-xL and a reduction in the 
intensity of the 30kDa and 120kDa Bcl-xL bands. Co-incubation of CLL 
cells with Z-vad inhibited this effect of the Lck inhibitor. Both the 
fonnation of 18kDa fragment of Bcl-xL as well as the reduction in 
intensity of the 30kDa and 120kDa Bcl-xL bands caused by the presence of 
Lck inhibitor was completely blocked by Z-vad. This indicates that in the 
absence of Lck cytoprotection, apoptosis may be activated by a pro- 
apoptotic protein which can be neutralised by caspase inhibition. The most 
likely candidate for such a protein is the second mitochondrial activator of 
caspases/direct TAP binding protein with low pi (smac/DIABLO) which 
promotes apoptosis by binding to lAPs and preventing them from 
inhibiting caspases [197]. It is conceivable that some leakage of this 
protein from mitochondria occurs also in quiescent cells where it is 
neutralised and directed to proteasomal degradation by a sufficiently high
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Figure 3.8 Degradation of Bcl-xL is caspase-dependent. The cells from 
3 CLL cases were incubated for 48h in the presence or absence of either 
the Lck inhibitor (IpM) or Z-vad (500nM), or both. The figure shows Bcl- 
xL degradation (indicated by the appearance of 18kDa fragment and 
disappearance of the 30kDa and 120kDa Bcl-xL bands). This figure is 
representative of the same experiment perfonned on an additional 4 CLL 
cases with the same overall result.
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concentration of lAPs [198]. Thus, Lck inhibition likely results in the 
lowering of the lAPs concentration to the level where they are fully 
neutralised by smac, allowing caspases to exert their apoptotic effect. This 
caspase involvement is supported by the absence of Bcl-xL degradation 
when samples treated with the Lck inhibitor also contained the caspase 
inhibitor Z-vad, confirming that this degradation is caused by caspases, 
most likely caspase 3, when lAPs are inhibited by smac. Thus the 
experiment in Figure 3.8 suggests that the contribution of Lck to CLL cell 
cytoprotection may be based on the participation of Lck in cell signalling 
pathways that stimulate synthesis of lAPs resulting in a change in the 
balance between pro-apoptotic smac and anti-apoptotic lAPs in favour of 
the latter.
3.3.4.3 Lck inhibition stimulates caspase activation and induces a
reduction in XIAP, Mcl-1 and C-IAP2 expression in CLL cells.
In an attempt to provide experimental evidence for the proposal that the 
stimulation of IAP production may play a role in cytoprotection of CLL 
cells by Lck, I first examined the effect of Lck inhibition on the proteolytic 
cleavage of poly-(ADP-ribose) polymerase (PARP). PARP is a substrate of 
caspase 3, and proteolytic cleavage of PARP is seen as a marker of caspase 
3 activation and induction of apoptosis [199, 200]. Figure 3.9A shows that 
incubation of CLL cells with the Lck inhibitor induced the appearance of 
the lower molecular weight band that is associated with caspase 3-
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Figure 3.9 Lck inhibition induces PARP cleavage as well as reduction 
of XIAP, cIAP2 and Mcl-1 protein levels. CLL cells were treated for 48h 
in the presence or absence of either the Lck inhibitor (IpM) or Z-vad 
(500nM), or both. A) Western blots were probed for the presence of the 
indicated proteins. This figure is representative of the same experiment 
perfonned on 7 different CLL cases. B - E) Quantitative representation of 
expression for the indicated proteins in CLL cell lysates relative to the 
level of P-actin. n=7 for each antibody used. Statistical significance was 
established using a Student’s t-test for paired data.
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mediated cleavage of PARP. Furthermore, this figure also shows that the 
presence of Z-vad inhibited the formation of this band. These data suggest 
that Lck inhibition induces the activation of caspase 3 in CLL cells.
I next investigated the effect of Lck inhibition on IAP expression in CLL 
cells. Figure 3.9 shows that treatment of CLL cells with the Lck inhibitor 
led to small but significant reductions in expression of XIAP and cIAP2, 
but not cIAPl. Mcl-1 is a Bcl2 family protein whose expression in CLL 
and other cells is linked to apoptosis resistance. When I investigated the 
effects of Lck inhibition on the levels of this protein in CLL cells I found a 
similar reduction in expression (Figure 3.9A and C). The difference 
between Mcll and IAP proteins became apparent when I additionally 
treated the CLL cells with Z-vad. The presence of Z-vad in Lck-inhibited 
CLL cells reversed the reduction in Mcll expression (Figure 3.9C), but 
was without significant effect on the reduction of XIAP (Figure 3.9B) and 
cIAP2 (Figure 3.9E) expression. These results suggest that Lck may 
regulate the expression of Mcll and XIAP/cIAP2 through different 
mechanisms.
Taken together, the results of this section demonstrate that Lck inhibition 
in CLL cells results in the activation of caspases leading to the cleavage of 
proteins such as PARP and Mcl-1. Furthermore, these results also suggest 
that caspase activation in CLL cells may be caused by changes in Lck-
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mediated induction of XIAP and cIAP2 expression. Thus, Lck inhibition 
leads to a reduction in XIAP and cIAP2 levels in CLL cells, and this results 
in CLL cells becoming more sensitive to the induction of apoptosis by 
smac/DIABLO.
3.3.4.4 Lck inhibition stimulates increased expression of Bim in CLL
cells.
An important mediator of the intrinsic apoptosis pathway is the BH3-only 
protein Bim [201]. This member of the Bcl2 family of proteins binds to 
Bcl2 and allows the release of BAX and BAK, which are then able to 
promote permeabilization of mitochondrial membranes to result in the 
release of proteins such as smac/DIABLO and cause caspase activation and 
induction of apoptosis. Thus, controlling Bim expression may be important 
to the mechanism of cell cytoprotection provided by Lck.
Figure 3.10A shows that incubation of CLL cells for 48h led to a 
spontaneous increase in the levels of BimEL and BimL in two out of the 
three CLL cases shown. Treatment of CLL cells with the Lck inhibitor 
over this time frame induced a significant further increase in Bim, in 
particular BimEL, expression (Figure 3.10A and B). Taken together, these 
results suggest that Lck cytoprotection of CLL cells is at least partially 
regulated through the control of Bim expression.
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Figure 3.10 Lck inhibition induces an increase in BimEL expression in 
CLL cells. CLL cells were incubated for 48h in the presence and absence 
of Lck inhibitor (IpM). A) Western blot analysis of Bim expression in 
CLL cell lysates. This figure is representative of the same experiment 
performed on 4 additional CLL cell clones. B) Quantitative assessment of 
BimEL expression in CLL cells. Statistical significance was assessed using 
a Student’s t-test for paired data (n=7).
3.3,4.5 The role of Lck in the activation of ERK by constitutive stimuli
activated in CLL cells during prolonged in vitro culture
An important mechanism controlling the level of Bim expression in cells is 
the post-translational modification of this protein by ERK which results in 
its destruction by the cell proteosome. In this section I investigated the role 
of ERK because of the known role of this pathway in CLL cell 
cytoprotection, and because, in T cells, Lck is known to participate in 
signalling via this pathway [202-204].
It has been known for some time and now confirmed in figure 3.11 that in 
vitro unstimulated CLL cells contain phosphorylated ERK that varies in a 
case-dependent manner [205]. This was more recently followed by studies 
employing MEK inhibitors to demonstrate importance of this ERK 
phosphorylation/activation for CLL cytoprotection under various 
conditions [53,206].
The present studies of the role of Lck in the activation of ERK were 
preceded by studies in our laboratory demonstrating that active ERK is 
differentially expressed in prognostically different subgroups of CLL, and 
that different cells respond differently to BCR stimulation as regards ERK 
phosphorylation and preservation of cell viability [161]. It was therefore of 
interest to see whether activation of ERK is responsible for the
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improvement in cell viability of BCR stimulated cells and whether this 
activation of ERK depends on Lck.
The contribution of Lck to the activation of ERK in CLL cells was first 
explored in unstimulated cells cultured in the presence or absence of the 
Lck inhibitor for up to 24 hours. The results are shown in figure 3.11.
Figure 3.11 shows that immediately ex vivo (Ohr), cells from different CLL 
cell cases contain different levels of phosphorylated ERK ranging from 
very strong (CLL12) to almost undetectable (CLL23). It was assumed that 
this activation of ERK is a consequence of in vivo cell stimulation. This 
assumption is supported by decrease of phosphorylated ERK in the first 2 
hours of in vitro incubation when the cells are deprived of in vivo stimuli. 
The comparatively low and relatively constant level of ERK 
phosphorylation seen during subsequent 8 to 24 hom*s of culture may 
represent the background level of ERK activation required for 
cytoprotection of quiescent cells. The Lck inhibitor had little or no effect 
on this low-level phosphorylation suggesting that it is maintained by a 
process that does not require Lck activity. However, in cases CLL1, 
CLL 12 and CLL8 ERK became again variably rephosphorylated during 
this period, and this rephosphorylation was inhibited by the presence of the 
Lck inhibitor.
129
CLL1 CLL12
Ohr 1 8 24 Ohr 1 8 24
U i U i U i U i U i U i
- : zzz ~ T S* pERK
—: • i
 ii •« zzzz ERK
Ohr 1 
U i
CLL23
8 24
U i U i
CLL8
Ohr 1 8 24
U i U i U i
pERK
Figure 3.11 Reappearance of ERK phosphorylation in short term 
culture in some CLL cells is Lck-dependent In order to determine 
changes in ERK phosphorylation/activation in CLL cells during 24 hours 
culture, the stored frozen cells were thawed, washed and lysed to estimate 
the degree of ERK phosphorylation in cells tested immediately ex vivo 
(TO). The remaining cells were then suspended in the culture medium and 
left to recover for 1 hour at 37°C before addition of the Lck inhibitor (i) to 
1 aliquot of the cell suspension leaving the other aliquot untreated (U) to 
serve as a control for each of the timepoints. The cell culture was then 
continued for 24 hours taking the samples of the treated and untreated cells 
at indicated times. Results are representative of three repeats.
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This rephosphorylation of ERK was unexpected and raised the question 
whether initial dephosphorylation and subsequent rephosphorylation 
always take place under these culture conditions, whether 
rephosphorylation persists beyond 24 hour incubation and whether in all 
cases requires active Lck (as for CLL12).
For the estimation of changes in ERK phosphorylation in the presence or 
absence of the Lck inhibitor during an extended 72 hour culture, the cells 
were equally treated as described in the legend of figure 3.11. Figure 3.12 
shows that the degree of ERK phosphorylation at time 0 varied from case 
to case. In three of the cases shown in figure 3.12A this is followed by 
rapid dephosphorylation during the first hour of incubation, regardless of 
whether or not the samples contained the Lck inhibitor. In these three cases 
ERK became rephosphorylated again between 8 and 24 hours as already 
seen in figure 3.11. From then on in untreated cells ERK remained 
phosphorylated until the end of the 72 hour* incubation period, but in the 
inhibitor treated cells this phosphorylation was strongly inhibited. In 
contrast, in the three cases shown in figure 3.12B, ERK did not become 
initially dephosphorylated, the phosphorylation was maintained throughout 
the incubation at a relatively constant level. This level of activation was 
either not affected by the Lck inhibitor or slightly decreased in some 
samples at a very early stage of incubation (up to 8 hours).
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Figure 3.12 The Lck inhibitor decreases the reappearance of ERK 
phosphorylation in some CLL cases. Western blots showing the changes 
in ERK phosphorylation and expression of p21 and p27 in 6 different CLL 
clones cultured in the presence or absence of the Lck inhibitor for up to 72 
hours. Results are representative of three experiments.
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These results suggest that CLL cases can be split into 2 groups. In the first 
group the rephosphorylation of ERK at 24 hours is dependent on the 
activity of Lck (Figures 3.11 and 3.12A), whereas Lck does not contribute 
to the rephosphorylation of ERK in the second group (Figure 3.12B). To 
investigate the mechanism of ERK phosphorylation in this second group of 
CLL cases, I used the general SFK inhibitor PPL Figure 3.13 shows that 
the presence of PP1 inhibited the reappearance of phosphorylated ERK in 
all cases. This suggests that a Src kinase other than Lck is responsible for 
rephosphorylation of ERK in the malignant cells from this second group of 
CLL.
3.3.4.6 The role of Lck expression in determining CLL cell survival in
prolonged in vitro culture
The data in the above sections suggest that Lck may be important for CLL 
cell cytoprotection through a mechanism involving activation of ERK and 
maintenance of low levels of Bim. If this model is correct then it is likely 
to depend on either Lck activity or expression levels, or a combination of 
both.
In Chapter 2 I show that CLL cells from different cases can express widely 
ranging levels of Lck. To test whether the level of Lck expression plays a 
role in CLL cell survival, I incubated CLL cells for 72, 96 and 120 hours
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Figure 3.13. Comparison of the general Src family kinase inhibitor 
PP1 and the Lck inhibitor on rephosphorylation of ERK in CLL cells.
Western blots showing the changes in ERK phosphorylation in CLL cells 
incubated with the Lck inhibitor (IpM) or with the general Src family 
kinase inhibitor PP1 (10pM) for 24 hours. Results are representative of 
four repeats.
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and measured the percentage of viable cells remaining in these cultures. 
Figure 3.14 shows that the percentage of viable cells remaining in culture 
after these incubation times was significantly lower for CLL cells 
expressing low levels of Lck than for those cells expressing high levels of 
Lck. These results suggest that Lck protein levels are an important factor 
for Lck-mediated cytoprotection of CLL cells.
I next examined whether Lck protein expression was important for ERK 
rephosphorylation and Bim expression in CLL cells that had been cultured 
for 72h. Figure 3.15 shows a Western blot analysis of Bim and pERK 
expression in CLL cells from clones bearing low levels of Lck (Figure 
3.15A) and from clones bearing high levels of Lck (Figure 3.15B). BimEL 
expression was upregulated in 4 of the 6 low Lck expressing CLL cases I 
analysed. However, the increase in Bim expression was not always 
associated with low levels of pERK. In the high Lck expressing CLL cell 
clones, Bim expression showed upregulation in 5 of the 8 cases analysed, 
and, like with low Lck expressing CLL cell clones, the increase in Bim 
expression did not always correlate with low levels of pERK. The only 
difference between high and low Lck expressing CLL clones seemed to be 
the level of pERK. The density of the pERK bands seemed to be higher in 
CLL cases bearing high levels of Lck protein. Thus, there appears to be no 
relationship between ERK rephosphorylation and expression of Bim in
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Figure 3.14 Levels of Lck correlate with spontaneous apoptosis of CLL 
clones. CLL cells from five low (■) and five high (■) Lck expressing 
clones were seeded at 4xl06 cells/ml and cultured for 72, 96 or 120 hours 
prior to the measurement of viability. CLL cell viability was assessed by 
FACS analysis of the percentage of DiOC6 positive / PI negative cells (live 
healthy cells). The data is presented as mean±SD of 2 experiments. 
Statistical analysis was analysed using a Mann-Whitney U test where 
p<0.05 is considered statistically significant.
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Figure 3.15 Bim levels at 0 and 72 hours of culture in low versus high 
Lck expressing cases. 14 CLL cases were thawed and resuspended at 
4xl06 cells/ml. 1ml was either pelleted immediately (0) or cultured 
unstimulated for 72 hours (72). Cells were pelleted, protein determination 
carried out and 10/ig total protein subjected to Western blotting for Bim, 
phosphorylated and total ERK or /3-actin as a loading control. Results are 
representative of two experiments.
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CLL cells. Taken together with the survival data, these results suggest that 
the survival advantage given to high Lck expressing CLL clones may be 
due to higher levels of constitutive ERK activation rather than control of 
Bim expression. Finally, because Lck inhibition stimulates Bim expression 
in CLL cells (Figure 3.10), the results presented here implicate additional 
mechanisms, perhaps involving other signalling pathways, in the 
cytoprotection provided by Lck to CLL cells.
3.4 Discussion
The work in this chapter was the first to assign some specific functional 
role of Lck in CLL cells. In the study which first demonstrated Lck 
expression in CLL cells [4], it was suggested that this expression indicates 
the B-l cell origin of CLL cells, and that in B-l cells, Lck plays a role in 
the self renewal of these cells. However the nature of the mechanism by 
which this enzyme could contribute to this self renewal and whether Lck 
has a parallel role in self renewal of CLL cells has not been established. 
Therefore in order to detennine whether Lck has some specific non- 
redundant functional role in CLL cells, siRNA knockdown of Lck mRNA 
was attempted to inhibit Lck protein production in these cells.
siRNA was already successfully used in our laboratory to suppress 
production of some proteins, such a c-Abl, which rapidly turn over in 
quiescent cells [177] and this was repeated in this study. However this
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technique did not result in the significant down-regulation of Lck during 
the cell culture period when these non-proliferating cells are still viable. It 
was therefore decided to use a specific inhibitor to explore Lck fiinction(s) 
which are not shared by other SFKs in quiescent as well as stimulated CLL 
cells.
In the current study a recently developed compound, 4-Amino-5-(4- 
phenoxyphenyl)-7H-pyrrolo[3,2-d]pyrimidin-7-yl-cyclopentane, has been 
employed because it is supposed to have higher specificity for Lck than 
other previously used inhibitors [188]. Nevertheless, it was thought to be 
necessary to carry out an experiments to demonstmte the specificity of this 
inhibitor for Lck relative to that for Lyn (figure 3.2), because the latter 
enzyme is highly expressed in CLL cells where it has many functions 
equivalent to the functions of Lck in T cells. In addition, HCs which do not 
express Lck and whose viability is affected by the general SFK inhibitor 
PP1, served as a useful negative control for the specificity of the Lck 
inhibitor. As expected, this inhibitor had no effect on functional responses 
of HCs (figures 3.2) although these responses were strongly affected by 
PP1, a general inhibitor of SFKs (previous unpublished work from this 
department and [189]).
The Lck inhibitor was first employed at a range of concentrations to 
explore the potential role of Lck in in vitro survival of CLL cells and HCs.
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In all CLL cells, but not in HCs, a different degree of decrease in viability 
was seen after 48 hours incubation with increasing concentrations of the 
inhibitor, generally reaching 50% change in viability at concentrations of 
about 1 fiM. When 56 different clones of CLL cells with either mutated or 
umnutated IgVH genes were then incubated with 1 gM of this inhibitor and 
cell viability measured at 48 hours incubation, the unmutated cells showed 
a significantly larger decrease in viability than the mutated cells, while the 
viability of HCL controls again remained unchanged.
Previous work has shown that unmutated cells contain phosphorylated 
ERK and that this phosphorylation further increases in response to BCR 
stimulation which also prolongs in vitro survival of these cells. In contrast, 
mutated cells show strongly reduced response to BCR stimulation which in 
addition has little effect on the survival of these cells [161]. Since the 
activity of Lck in umnutated quiescent CLL cells was found to be several 
fold higher than in mutated cells [190], it seemed possible that the 
differences in the effect of Lck inhibitor on mutated and umnutated cells 
reflect the involvement of active Lck in a cytoprotective pathway activated 
through BCR stimulation that may involve ERK.
To examine whether Lck is involved in cytoprotection provided by 
stimulation of CLL cells via a number of other receptors besides BCR, the 
cells were stimulated with anti-IgM, CD40L and CpGs. These stimuli
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protected cell viability to a variable degree. The ability of these stimuli to 
provide pro-sumval signals was not dependent on Lck levels, but on Lck 
activity because the presence of the Lck inhibitor either completely or 
almost completely abolished the pro-sumval effects of these stimuli. Thus, 
Lck activity is important with respect to its provision of cytoprotective 
effects to CLL cells. This notion is supported by previous work from this 
Department showing that the activity level of Lck in unmutated quiescent 
CLL cells is several fold higher than in mutated cells [190], and by the data 
presented in this thesis showing that unmutated CLL cells are more 
susceptible to Lck inhibition than are mutated CLL cells.
The relevance of these observations for the well established relationship 
between the presence or absence of IgVH gene mutation and disease 
prognosis is currently unclear. The present in vitro study only indicates that 
Lck is likely to be involved in cytoprotection of the cells in vivo. However 
since the effect of Lck on CLL cells involves ERK activation, Lck may 
also participate in cell proliferation that clearly takes place in the in vivo 
microenviromnents which so far have not been successfully reproduced in 
vitro.
Recent studies of the in vivo CLL-cell turnover [207] suggest that the 
proliferative component (cell birth rate) is higher in active, progressive 
disease, which is generally observed in cases with unmutated IgVH genes
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and unfavourable disease prognosis. This study indicates that in this group 
of patients, not only proliferation of the malignant cells, but also their 
survival might be particularly dependent on Lck-dependent signals 
triggered by stimulation of BCR and TLRs by in vivo antigens.
B cell survival depends on the activity of several pathways, the principal 
ones being ERK, Akt, NFkB and NF-AT. Each of these pathways might be 
differentially activated depending on the stage of cell maturation and the 
conditions under which the cells are protected. This raised a question of 
whether, as suggested previously [190], this cytoprotection involves ERK. 
Therefore, it was first examined whether CLL cells during prolonged in 
vitro culture contain phosphorylated/ activated ERK and whether this ERK 
phosphorylation in any way depends on active Lck. The results of the 
experiments designed to answer these questions showed that all CLL cells 
when examined directly ex vivo contain variable amounts of 
phosphorylated ERK which in most cases is not seen after 2 hours of cell 
culture where the cells are deprived of external stimuli. However in most 
cases phosphorylated ERK reappeared in the cells, usually between 8 and
24 hours of culture and, with regards to the role of Lck, this ERK
reactivation showed two distinct patterns. In some cells the ERK
rephosphorylation was inhibited by the Lck inhibitor, but in other cases 
this inhibitor had no effect. Surprisingly, inhibition of ERK
phosphorylation using the MEK inhibitor had little or no effect on cell
142
viability measured at 48 hours, whereas the samples containing the Lck 
inhibitor always had a smaller number of viable cells than the untreated 
control, regardless of whether or not the Lck inhibitor affected ERK 
phosphorylation. Therefore it is possible that the principal cytoprotective 
effect of Lck either does not involve ERK activation, or that this activation 
proceeds by a MEK-independent pathway. Alternatively, Lck may rescue 
cells from apoptosis thorough Akt or NFkB-dependent mechanisms, while 
activation of ERK might serve another function such as decreasing the 
sensitivity of the cells to the level most appropriate for interaction with self 
antigens and thus protecting the cells from negative selection by these 
antigens [30].
In this chapter, the mechanism of cytoprotection of CLL cells by active 
Lck has been studied by analysis of Bcl-xL degradation following 
prolonged CLL cell incubation with the Lck inhibitor. The amount of Bcl- 
xL is generally decreased during apoptosis in parallel with the caspase 3- 
dependent generation of a 17-18kDa pro-apoptotic AN Bcl-xL fragment. 
During the present study this fragment was seen in unstimulated cells in 
the presence of the Lck inhibitor. This suggested that Lck protects CLL 
cells from apoptosis by a mechanism leading to the inhibition of an 
activator of caspases. The principal candidate protein with these properties 
is smac/DIABLO which binds lAPs and prevents them from inhibiting
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caspases. This then further suggests that Lck may be involved in synthesis 
of lAPs that bind smac/DIABLO and direct it to proteasomal degradation.
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Chapter 4
Role of Lck in BCR signalling in CLL cells
4.1. Introduction
The work in Chapter 3 showed that Lck functions in a cytoprotective role 
in CLL cells by modulating the balance between proteins involved in the 
induction and prevention of apoptosis. However, this might not be the only 
function for this SFK in these cells. Importantly, the major function of Lck 
in T cells is the regulation of TCR signalling where it phosphorylates 
ZAP70, among other proteins, to stimulate activation of downstream 
molecules. ZAP70 expression is also observed in the malignant cells from 
a subset of CLL cases. Here, the role of ZAP70 has been shown to 
potentiate BCR signalling in CLL cells. Since ZAP70 is a substrate of Lck 
in T cells, it seemed logical that it should also be a substrate of Lck in CLL 
cells. Thus, Lck may have a role to play in BCR signalling in CLL cells. 
The aim of this Chapter was to investigate this possibility.
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4.2. Materials and methods
4.2.1 Cell isolation and culture
CLL samples were obtained and cultured as described in methods section
2.2.1
4.2.2 CD5 crosslinking
CD5 antibodies (BD Biosciences clone L17F12 or Santa Cruz 
Biotechnology clone UCH-T2) were washed in PBS to remove the 0.1% 
sodium azide included as a preservative as this would be cytotoxic and 
therefore affect the survival of CLL cells independent of any CDS 
crosslinking specific affect. Antibodies were spun through an Ultracell 
YM-50 filter system (Millipore) at 14,000rpm, the sodium azide buffer was 
discarded and the antibody (which remains in the filter column) was 
reuspended in PBS. Antibodies were either coated onto 24 well tissue 
culture plates for 12 hours at 4°C, washed and the cells then added to these 
wells or incubated directly with the cells at a final concentration of 5pg/ml. 
Survival of the CLL cells after 48 hours of incubation was assessed using 
the DiOCe/PI apoptosis assay detailed in methods section 2.2.7.
4.2.3. Inhibitors and stimuli
All inhibitors were dissolved in DMSO, aliquoted and stored at -20°C. The 
The Lck inhibitor (4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2-
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d]pyiimidin-7-yl-cyclopentane) was used at IpM, U0126 was used at 
10pM? lactacystin at 5pM, PD98059 at lOpM, RO-32-432 at lOpM and 
bisindolylmaleimide I at IpM or lOpM, and all were purchased from 
Calbiochem. The caspase inhibitor (Z-Val-DL-Ap-fluoromethylketone) 
used at 500nM was purchased from Bachem (St Helens, UK).
F(ab’)2 fragments of goat anti-human IgM (Jackson ImmunoResearch 
Laboratories, were used at a final concentration of 10pg/ml for 
crosslinking/stimulating the BCR. CpG stimulation utilised Spg/ml 
ODN2006 (5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’) oligonucleotides 
for human Toll-like receptor 9 (TLR9) stimulation (InvivoGen; Autogen 
Bioclear, Caine, UK).
4.2.3 Western blotting
As described in 2.2.3. In addition, blots were blocked in 5% milk dissolved 
in TBST for analysing the expression of proteins, or 5% BSA in TEST for 
analysis of phosphorylated proteins. Antibodies were prepared in TBST 
containing either 5% milk powder or 5% BSA as for blocking of blots.
The following primary antibodies were used (all at 1:1000): anti-Lck 
mouse monoclonal, anti-pERK mouse monoclonal, anti ERK rabbit 
polyclonal, anti pY551-Btk rabbit polyclonal and rabbit anti-Mcl-1 
polyclonal (Santa Cruz Biotechnology). Anti-pSer473Akt mouse
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monoclonal, anti-pIKK rabbit polyclonal, anti-pY319 ZAP70 rabbit 
polyclonal, anti-pY525-Syk rabbit polyclonal and anti-pY323-Syk rabbit 
polyclonal antibodies were purchased from Cell Signaling Technology. 
The total ZAP70 antibody was purchased from Signal Transduction 
laboratories. The following secondary antibodies were used: Goat anti­
rabbit horseradish peroxidise (HRP) conjugated antibody, goat anti-mouse 
HRP-conjugated antibody (Santa Cruz Biotechnology). Tyrosine 
phosphorylation was assessed in immunoprecipitates using an anti- 
phosphotyrosine antibody (PY20) purchased from ICN Biomedicals (Ohio, 
U.S.A).
4.2.4. Immunoprecipitation
As detailed in methods section 3.2.5. The CD5 immunoprecipitating 
antibody (cloneUCH-T2) and the Lck immunoprecipitating antibody 
(mouse monocolonal, clone 3A5) were purchased from Santa Cruz 
Biotechnology, hnmunoprecipitation buffers used are detailed in the 
appendix.
4.2.5. FACS analysis of CP25 levels
CD25 levels in response to CDS crosslinking were assessed by FACS 
analysis as detailed in methods section 2.2.6 using an antibody from BD 
Bio sciences.
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4.3. Results
4.3.1 Examination of a potential role for Lck in the downreguiation of
BCR-induced signalling through association with CDS
The current paradigm explaining BCR signal transduction in CLL cells 
involves the activation of the SFK Lyn and, further downstream, of the 
tyrosine kinase Syk [208]. These signals are then further processed by CLL 
cells to transduce pro-survival and anti-apoptotic responses. A similar role 
for Lck could also be proposed within the BCR signaling cascade because 
of the known role of this SFK in the TCR signaling cascade. However, 
such a role for Lck in B cells has not been established. Rather, because Lck 
expression in B cell lineages is normally restricted to B-l cells [4], and 
because B-l cells also express CDS [209] which is a known substrate of 
Lck in T cells [210] that serves as a scaffold for the protein tyrosine 
phosphatase SHP-1 [123], it is thought that Lck is responsible for the 
downreguiation of BCR signaling. Support for this role of Lck in B-l cells 
is provided by studies that show CDS expression is linked to negative 
regulation of BCR signals in B-l cells [162], and that show Lck expression 
in B-l cells is necessary for this hyporesponsiveness to BCR engagement 
[109]. Since CLL cells express both CDS and Lck, it seemed logical to 
assume that a function of Lck in these cells may be in conjunction with 
CDS. This possibility was therefore next examined.
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Previous work by others has shown that CDS crosslinking induces 
apoptosis of CLL cells [211,212]. I attempted to repeat these experiments. 
However, I found that CLL cell viability was unaffected by the presence of 
CDS antibodies (Figure 4.1 A). Similar’ results were generated in 
experiments using either different antibodies, or different concentrations 
of the same antibody. Furthermore, I found that CDS crosslinking had no 
effect on the viability of CLL cells matching the phenotypic criteria of 
those used in a previous study showing the pro-apoptotic effect of this 
stimulus.
I next tested whether I could show that CDS antibodies induced any type of 
response in CLL cells. It has been described that crosslinking CDS induces 
upregulation of the IL2 receptor (CD25) expression on T cells [213] and B 
cells [214]. When I examined CD25 expression on CLL cells that had been 
exposed to CDS antibodies, I found that the expression of this protein had 
been upregulated (Figure 4.IB). This result demonstrates that CLL cells do 
respond to CDS crosslinking, but that apoptosis, at least in my 
experiments, was not the result.
To investigate the role of Lck in the CDS generated signals that resulted in 
increased expression of CD25 on CLL cells I used the Lck inhibitor. Figure 
4.IB shows that CLL cells treated with the Lck inhibitor failed to 
upregulate CD25 in response to CDS crosslinking. Thus, Lck in CLL cells
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Figure 4.1 CDS crosslinking did not induce CLL cell apoptosis but can 
upregulate CD25 in an Lck-dependent manner. Four CLL cases were 
treated with 50/xg/ml anti-CD5 antibody for 48 hours and cell survival 
assesed using a DiOCe/PI apoptosis assay (A) expressed as the mean and 
standard deviation of three experiments. Two CLL cases were treated as 
for A and CD25 expression was quantified by FACS analysis (B). Results 
are representative of two experiments.
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may associate with CDS and help to transduce signals from this protein.
In T cells Lck functions to phosphorylate CDS, and this process is then 
responsible for attracting SHP-1 to CDS where it acts to downregulate 
TCR signals. A similar role for Lck in CLL cells has been suggested by 
Majolini [4]. To investigate CDS phosphorylation in CLL cells I 
immunoprecipitated this protein and then probed Western blots of the 
immunoprecipitate with antibodies recognising phospho-tyrosine. Figure 
4.2 shows that tyrosine phosphorylation of CDS in Jurkat cells increases in 
cells cultured in the presence of the phosphotyrosine phosphatase inhibitor 
mpV(pic). This increase was most convincingly demonstrated in 
experiments using TX-100 lysis buffer, but was also observed in 
experiments using other buffers. However, I was unable to conclusively 
show that CDS was tyrosine phosphorylated in CLL cells. The bands 
present in the CLL immunoprecipitates either migrated to a different 
position on the gel, or were too faint to allow analysis despite using IxlO7 
cells. Thus, the role of Lck in CDS phosphorylation could not be 
investigated in CLL cells in this study.
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Figure 4.2 CDS phosphorylation can be induced in the Jurkat cell line, 
but not in CLL cells, by MPV stimulation. Immunoprecipitation of CDS 
from the Jurkat cell line or one CLL clone which expressed high levels of 
CDS protein and then analysis of its tyrosine phosphorylation status (A) or 
validation that CDS had been immunoprecipitated (B) was carried out 
using three different immunoprecipitation buffers (RIPA/ TX-100 or a TX- 
100 buffer containing 1% SDS). CLL cells were treated for 30 minutes 
with 10/ig/ml F(ab')2 anti-IgM and lOOnM mpV(pic) (MPV) was used in 
both cell types as a positive control to induce CDS phosphophorylation. 
Results are representative of two experiments.
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4.3.2 Examination of a potential positive role for Lck in BCR-induced
signalling in CLL cells
4.3.2.X Role of Lck in BCR-mediated activation of MAPK, PI3K and
NFkB signalling
The work describing a role for Lck in the modulation of BCR signals in B- 
1 cells is controversial. One study comparing BCR signals between 
peritoneal and splenic B-l cells suggests that the hyporesponsiveness of 
peritoneal B-l cells to BCR engagement is due to Lck expression [109]. 
However, another study has suggested that Lck expression enhances BCR 
signals in B-l cells [126], while a third suggests that Lck has no role to 
play at all [127]. From these studies it is difficult to hypothesise a possible 
role for Lck in this context. However, data from Chapter 3 show that the 
pro-survival effects of BCR crosslinking can be blocked by treating CLL 
cells with the Lck inhibitor (Figure 3.4). Moreover, these data also show 
that BCR crosslinking induces changes to the activation of Lck (Figure 
3.2). Considering that ZAP70 is expressed in the malignant cells of a 
subgroup of CLL cases, that ZAP70 is a predominant Lck substrate in T 
cells undergoing antigen receptor signalling, and that the function of 
ZAP70 in CLL cells is to enhance BCR signals, it seemed reasonable that 
Lck may function in CLL cells to enhance antigen receptor signals.
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BCR crosslinking of CLL cells induces activation of several pathways 
including the MAPK, PI3K, and NFkB pathways. Activation of these 
particular pathways is characterised by the phosphorylation of the key 
kinases ERK, Akt and IKK, respectively. To assess the impact of Lck 
activity on BCR-induced signals in CLL cells, I used the Lck inhibitor and 
investigated its effects on BCR-mediated activation of ERK, Akt and IKK.
I first investigated the effects of the Lck inhibitor at different 
concentrations. Figure 4.3 shows the effect of increasing concentrations of 
Lck inhibitor on BCR-induced ERK, Akt and IKK phosphorylation. From 
this experiment, it seemed that the induction of IKK phosphorylation was 
particularly sensitive to Lck inhibition, whereas the induction of Akt and 
ERK phosphorylation required higher concentrations of Lck inhibitor 
before any effect could be seen. Because IpM Lck inhibitor was the 
minimum concentration that produced maximum inhibition of BCR- 
induced ERK, Akt and IKK phosphorylation, this concentration was used 
for the rest of this study.
I next compared the effect of the Lck inhibitor on BCR and TLR 
signalling. Figure 4.4 shows that the presence of IpM Lck inhibitor 
strongly reduced the increase in pERK levels that were stimulated by BCR 
crosslinking of CLL cells, and completely blocked BCR-induced
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Figure 4.3 BCR crosslinking-induced ERK, Akt and IKK 
phosphorylation are inhibited by the Lck inhibitor. A dosage response 
of the effect of the Lck inhibitor on phosphorylation at 40nM, 200nM or 
lOOOnM (IpM as used for the rest of this chapter). Densitometry was 
performed and is represented in the bar charts. Results are representative of 
three experiments.
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Figure 4.4.A. Phosphorylation of IKK, Akt or ERK by BCR 
crosslinking, 0.5/tg/ml or 5/ig/ml CpG stimulation in three CLL cases.
Results are representative of three experiments.
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Figure 4.4.B. Phosphorylation of IKK, Akt or ERK by BCR 
crosslinking, 0.5/ig/ml or Spig/ml CpG stimulation as assesed by 
densitometry. The phosphorylated to non-phosphorylated protein ratio 
(mean +/- standard deviation) of three experiments is displayed.
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activation of Akt and IKK. In contrast, the presence of the Lck inhibitor 
had largely no effect on CpG-induced activation of IKK and ERK. In this 
experiment CpG did not induce an increase in Akt phosphorylation. These 
results suggest that the Lck inhibitor acts within the pathway of BCR- 
mediated signals leading to the activation of ERK, Akt and IKK, and that 
this pathway is distinct from the pathway used by TLRs to activate ERK 
and IKK. Considering our data showing that the Lck inhibitor reduced Lck 
but not Lyn activity (Figure 3.2), the above data therefore also suggest that 
Lck may be central to BCR-induced activation of CLL cells.
4.3.2.2 Role of Lck protein expression levels in BCR responsiveness of
CLL ceUs.
That Lck may be central to BCR-stimulated activation of CLL cells 
implies that Lck expression levels may have an important role to play in 
the signalling pathway resulting from this stimulation. Thus, CLL cells 
expressing high levels of Lck should respond to BCR crosslinking with 
greater increases in ERK, Akt and IKK phosphorylation than do CLL cells 
with low levels of Lck. However, Figure 4.5 shows that there is no 
significant difference in the degree of Akt, ERK or IKK phosphorylation 
that is induced by BCR stimulation between CLL cases with high levels of 
Lck and those with low levels of this protein. This suggests that the 
contribution of Lck to BCR signalling in CLL cells may be tempered by 
additional other factors.
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Figure 4.5. Phosphorylation of Akt, ERK and IKK in response to BCR 
crosslinking in three low versus three high Lck expressing clones.
2xl06/ml cells were stimulated with/without lOpg/ml final concentration of 
F(ab)2 anti-IgM for 15 minutes. lOpg total protein was subjected to 
Western blotting for phosphorylated or total Akt, ERK or IKK (A). Results 
are representative of two experiments. B; representation of the fold 
induction in phosphorylation in the low versus high Lck expressing clones 
as determined by densitometry normalised to the amount of total, non- 
phosphorylated, protein (mean +/- standard deviation).
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4.3.2.3 BCR stimulation of CLL cells induces ZAP70 phosphorylation
by Lck.
The effect of Lck on activation of signalling components more proximal to 
the BCR and upstream of those investigated above was studied next. 
Antibodies that detect phosphorylation of activating tyrosine residues of 
Btk, Syk and ZAP70 were utilised in CLL clones stimulated with anti-IgM 
in the presence of the Lck inhibitor. Tyrosine phosphorylation of Y551 
within Btk primes this protein for full activation, and is mediated by SFKs 
when Btk translocates to the membrane of cells undergoing activation 
[215]. Tyrosine phosphorylation of Syk on Y323 is mediated by SFKs, but 
is involved in downregulating Syk activity. In contrast, Y525 in Syk is a site 
of autophosphorylation, phosphorylation on this site is generally seen as a 
marker of kinase activation [216]. Phosphorylation of Y319 within ZAP 70 
can be catalysed by Lck, and is a marker of activation for this enzyme .
Figure 4.6 shows the results of this analysis. BCR crosslinking led to an 
increase in ZAP70 phosphorylation in all 3 CLL cases used, and the 
presence of the Lck inhibitor blocked this increase. However, BCR 
crosslinking did not induce increases in the levels of either pY551-Btk or 
pY -Syk. That these antibodies recognised their epitopes is shown in the 
last two lanes on the right. Here, the lysates of CLL cells cultured with 
irradiated fibroblasts prior to BCR crosslinking were probed with the 
phospho-specific antibodies to Btk, Syk and ZAP70. Thus, these cells 
showed constitutive activation of Btk and ZAP70 regardless of BCR
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Figure 4.6. Phosphorylation of tyrosine 319 of ZAP70 in response to 
BCR crosslinking is Lck dependent. Three CLL clones were stimulated 
for 15 minutes with 10pg/ml F(ab’)2 anti-IgM (BCR-XL) in the presence 
or absence of 1 fiM Lck inhibitor (Lck-i). A fourth CLL clone was cultured 
in the presence of non-transfected (NT cultured) fibroblasts with or without 
lOpg/ml F(ab’)2 anti-IgM as a positive control for phosphorylation of Btk, 
Syk and ZAP70. Results are representative of two experiments.
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engagement, whereas the induction of pY525-Syk required BCR 
stimulation. Interestingly, there appeared to be detectable levels of pY323- 
Syk present in the CLL cell lysates from all cases used, including the CLL 
cells cultured with the irradiated fibroblasts, and BCR crosslinking did not 
seem to affect the degree of phosphorylation in any case. The lysates used 
in Figure 4.6 are the same as those used to analyse pERK, pAkt and pIKK 
in Figure 4.4, thus, the fact that pY551-Btk and pY525-Syk are not observed 
does not indicate that signals from the BCR were not being transmitted. 
Taken together, the above results suggest that Lck is able to phosphorylate 
ZAP70 in CLL cells, and that this may be responsible for the downstream 
signals to the ERK, PI3K and NFkB pathways.
4.4. Discussion
In this chapter I investigated the potential role of Lck in the induction of 
signalling in CLL cells undergoing BCR engagement. First, I investigated 
a potential role for Lck in conjunction with CDS on the basis that this 
association may downregulate BCR signals. I found that crosslinking CDS 
on CLL cells induced an upregulation of CD25 expression, and that was 
dependent on active Lck. However, further investigation of Lck association 
with CDS was not possible. Second, I investigated a potential role for Lck 
in BCR signalling. Here I found that Lck activity was important for BCR-
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induced activation of ERK, Akt, and IKK, and that this might be mediated 
by the ability of Lck to phosphorylate ZAP70.
I initially investigated a possible role for Lck in CLL cells by examining 
the potential of these cells to undergo apoptosis in response to CD5 
crosslinking. This phenomenon in CLL cells has been previously reported, 
however, I was unable to repeat these experiments. This was not because 
the CD5 antibody was without effect, because my experiments showed that 
treatment of CLL cells with this antibody led to increased CD25 
expression. The lack of response was also not due to the CLL subtype used 
because I specifically chose CLL cell clones whose phenotype matched 
that which was reported to undergo apoptosis in response to CDS 
crosslinking in another study [212]. Other studies have implicated CDS in 
providing pro-survival signals to CLL cells [166, 217], however, my 
results showed that CDS crosslinking had no significant effect on CLL cell 
viability. Thus, from my experiments no definitive conclusion can be 
drawn about the function of Lck in CLL cells with respect to the induction 
of apoptosis or cell survival.
Nevertheless, I did find that crosslinking CDS on CLL cells upregulated 
the expression of CD25, and that this response was dependent on Lck. This 
result confirms previous work by others [213], and extends this work to 
show that CDS on CLL cells operates in a similar way as it does on T cells.
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The Lck dependence of CD25 expression by CD5 crosslinking also 
suggests that Lck may be in association with CD5 in CLL cells. That CDS 
may be a target for Lck-mediated phosphorylation in CLL cells is 
supported by studies demonstrating that this is the case in T cells [164, 
210, 218], and by implication in studies of B cells where B-l cells and 
anergic B cells have been shown to express both CDS and Lck [219, 220]. 
In CLL cells, CDS is reported to be constitutively phosphorylated [166], 
and this is thought to regulate the expression of a specific set of genes 
important for the survival of these cells. In my experiments I probed 
immunoprecipitated CDS for the presence of phospho-tyrosine residues. I 
did not observe CDS phosphorylation in CLL cells under any condition, 
however, CDS phosphorylation could be induced in Jurkat T cells 
following treatment with the tyrosine phosphatase inhibitor mpV(pic). The 
best result was observed when I used lysis buffers containing only Triton 
X-100, presumably because this preserved the secondary and tertiary 
structures of CDS that are necessary for efficient immunoprecipitation with 
the antibody I used. The reasons for my failure to observe CDS 
phosphorylation in CLL cells could be due to a failure of CDS to 
immunoprecipitate from Triton X-100 solubilised CLL cells; CDS has 
been demonstrated to associate with a Triton X-100 insoluble fraction of T 
cells that have been stimulated with CDS antibodies [221]. Whatever the 
reason, this lack of a response in CLL cells meant that I was unable to
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investigate the effect of the Lck inhibitor and assess the role of Lck in this
process.
I next investigated a potential role for Lck in BCR signalling. The work in 
this chapter shows that Lck contributes to signalling in response to BCR 
engagement. I found that BCR-induced phosphorylation / activation of 
ERK, Akt and IKK in CLL cells was inhibited by the Lck inhibitor. 
Activation of the signalling pathways leading to phosphorylation of ERK 
(the MAPK pathway), and, in particular, of Akt (the PI3K pathway) and 
IKK (the NFkB pathway) is central to the pro-survival effects provided by 
BCR crosslinking on CLL cells [222-224]. Thus, BCR-mediated activation 
of Lck may be critical for the induction of CLL cell survival.
The paradigm of BCR-induced signalling in normal B cells involves the 
activation of Lyn as one of the most proximal events following antigen 
engagement of the receptor [68]. This role for Lyn in BCR signalling is 
also accepted with respect to CLL cells because Lyn is overexpressed in 
CLL cells [132], and because crosslinking the BCR on CLL cells induces 
translocation of this receptor into lipid raft domains where Lyn is also 
present [161, 225]. Lyn is reported to be constitutively active in CLL cells 
[132], and the data I present in Chapter 3 showing that Lyn can be 
immunoprecipitated from lysates of resting CLL cells using antibodies 
directed against active Src confirms this result. Thus, my observation that
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the Lck inhibitor has no effect on Lyn activity in CLL cells, even when it is 
used at very high concentrations, indicates that the role of Lck in CLL cells 
responding to BCR engagement may be more important than previously 
thought and require a change in paradigm. In this new model of BCR 
signalling, it is Lck which mediates the membrane proximal events 
following antigen binding to receptor on CLL cells.
Proof of this role for Lck in BCR signalling could be provided by 
knockdown of this protein in CLL cells using siRNA. However, the data 
presented in Chapter 2 of this thesis shows that Lck protein levels are not 
affected by siRNA targeting Lck mRNA. In tire absence of the ability to 
employ siRNA to reduce Lck expression in CLL cells, I resorted to using 
cases with different levels of Lck expression. I found that there was no 
difference in BCR responsiveness, in terms of the induction of pERK, 
pAkt and pIKK, between CLL cell clones expressing high levels of Lck 
and those expressing low levels of this protein. This was also true with 
respect to the induction of CLL cell survival following BCR stimulation. 
Thus, the role of Lck in BCR signalling in CLL cells, although important, 
is not governed by a simple relationship between expression level and 
response. The data presented in this thesis support this notion and show 
that Lck expression in CLL cells does not correlate with markers of poor 
disease prognosis such as IgVH mutation and ZAP70 expression. This may 
be important because the cohort of CLL cases used in this study show, in
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agreement with published data [63, 65, 226], good correlation between 
ZAP70 expression and IgVH mutation. That is, the malignant cells from 
umnutated CLL cases have high levels of ZAP70 expression whereas those 
from mutated CLL cases have low levels of ZAP70. Considering the 
established role of the BCR for CLL clonal expansion, that unmutated 
IgVH genes are important because of associated broad antigen specificity 
of the BCR [48] and that the presence of ZAP70 is an important enhancer 
of BCR signalling [168], it is easy to see why ZAP70 expression and IgVH 
gene mutation are important indicators of poor prognosis in CLL. That Lck 
expression levels do not correlate with either of these markers but is 
nevertheless still important for the transmission of BCR signals suggests 
that additional factors are important with respect to more distal events (to 
Lck) in the BCR signalling pathway.
One of these additional factors could be ZAP70 expression. I show in this 
chapter that Lck is responsible for phosphorylation of ZAP70 on tyrosine 
319 (figure 4.6). In T cells this tyrosine residue is situated within a binding 
site for the SH2 domain of Lck [227], and is required for ZAP70 activation 
and propagation of the downstream signalling cascade [119]. 
Phosphorylation of Y319 in ZAP70 was originally thought to be mediated 
by autophosphorylation, and that the contribution of Lck was to facilitate 
ZAP70 activation by phosphorylating the ITAM motifs within the 
components of the TCR that attracted ZAP70 to bind and activate this
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protein. However, it has now been shown that Y319 within ZAP70 is a 
substrate of Lck, and that its phosphorylation does not affect the enzymatic 
activity of ZAP70 but instead influences its association with other 
intracellular transducers such as Lck [227] and PLCyl [228]. The structure 
of ZAP70, including the Y319 phosphorylation site, is shown in figure 4.7.
Y Y Y
Y319
Lck phosphorylation site
Figure 4.7 The structure of ZAP70. Adapted from [229].
It has been suggested that the role ZAP70 plays in CLL pathogenesis is 
independent of its kinase activity and relies on its role as an adapter protein 
[168, 230]. This was concluded from work on ZAP70 negative CLL which 
were transfected with ZAP70 containing a mutation of K369 to alanine 
which results in a form of ZAP70 that cannot be activated. The result in 
figure 4.6 supports the role of Lck in BCR crosslinking-induced signalling 
as Lck can phosphorylate Y319 and lead to an increase of ZAP70 binding to 
signalling components that could contribute to its pathogenesis in CLL as 
an adapter protein.
169
The fact that the Lck inhibitor affects CLL clones with unmutated IgVH 
genes to a greater extent than those with mutated sequences supports the 
proposal that Lck contributes to CLL cell survival by phosphorylating 
ZAP70, which is expressed to a much higher degree in unmutated than in 
mutated cells. However, the Lck inhibitor also affects survival of clones 
with mutated IgVH sequences. This suggests that Lck has additional roles 
in CLL cells other than just phosphorylation of ZAP-70 Y319, as mutated 
cases contain low to absent levels of ZAP70 protein.
The role of Syk (p72Syk) kinase activity has been suggested to be more 
important for CLL pathogenesis than the kinase activity of ZAP70. Syk has 
an analogous role in B cells to the role of ZAP70 in T cells. Syk is 
recruited to phosphorylated ITAMs of CD79a and CD79b of the BCR 
complex leading to activation of Syk and increased downstream signalling 
[68]. The presence of ZAP70 and its role as an adapter protein is thought to 
contribute to increased activation of Syk which has a 100-fold greater 
kinase activity in CLL cells in vitro than does ZAP70 [231, 232]. 
Therefore future studies of the role of Lck in CLL antigen receptor 
signalling would also have to include the potential role of Lck in the 
activation of Syk. Figure 4.6 suggests that Lck is not involved in the 
phosphorylation of Y323 or Y525. Y323 in Syk can be phosphorylated either 
by Syk itself, or by SFKs, including Lyn [216]. Phosphorylation of Syk at 
this site is associated with downregulation of Syk activity and expression
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though association with Casitas B-lineage lymphoma (Cbl) family 
proteins, as well as with activation of PI3K through association with the 
p85a subunit. In my experiments, presence of the Lck inhibitor did not 
affect pY323-Syk levels in CLL cells, suggesting that Lck is not responsible 
for phosphorylation of Syk at this site. Y525 in Syk is located within the 
activation loop of the kinase, and is a site of autophosphorylation that is 
thought to be important for initial activation of the kinase [216]. In my 
experiments BCR stimulation did not result in an increase in pY525-Syk 
levels. The reasons for this are not clear, but are not due to a failure of the 
phospho-specific antibody to recognise pY525-Syk since this antibody did 
recognise this epitope under appropriate conditions of BCR activation in 
the positive control lanes. Nevertheless, phosphorylation of Syk at Y525 did 
not seem to be necessary for distal signalling to take place because BCR 
crosslinking activated the MAPK, PI3K and NFkB pathways within these 
cells.
Taken together, the results of this Chapter suggest an important role for 
Lck in transmitting BCR signals in CLL cells. However, the exact nature 
of this role remains to be further clarified.
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Chapter 5
General discussion and future work
The aim of the work described in this Thesis was to gain some insight into 
the expression and function of the protein tyrosine kinase Lck in the 
malignant cells of CLL. So far this enzyme has been extensively studied 
only in T lymphocytes where it plays a key role in the cell response to 
various stimuli that regulate selection, clonal expansion and function of 
these cells.
Although initially thought to be a T cell-specific protein, Lck was later 
found in a number of other normal and malignant cells, including normal 
B-l cells and CLL cells [4]. Since in normal B cells Lyn plays an 
equivalent role to that of Lck in T cells, this raised the question of whether 
SFKs expressed in CLL cells could have important specific roles or be 
largely redundant. The published studies carried out to answer this question 
show that these highly homologous enzymes are likely to have both 
specific and shared roles, but such roles of Lck in CLL cells have yet to be 
described.
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Other questions of particular relevance for normal B cells and malignant 
CLL cells are those related to the regulation of expression and function of 
Lck in different subsets of normal B cells which are at different stages of 
maturation and activation as well as in cells from prognostically distinct 
sub-groups of CLL.
For the pmposes of the project described in this Thesis, it was assumed that 
the expression of Lck is another phenotypic marker of CLL cells 
supporting their origin from B-l cells that have been positively selected by 
a restricted set of T-independent auto antigens but can also react with 
structurally similar microbial products. However in contrast to normal B-l 
cells that are responsible for natural antibody production, CLL cells are 
arrested at the pre-plasma cell stage of differentiation and remain 
chronically stimulated by cognate antigens by being unable to produce 
significant levels of antibodies that could neutralize and initiate clearance 
of these antigens.
In the Chapter concerned with the regulation of Lck expression, attention 
was paid to all three stages of this regulation, namely transcription, 
translation and post-translational modification. During lymphocyte 
development Lck expression is regulated at the level of transcription by 
signals generated through cell stimulation by antigens and/or LPS [3]. 
Antigen receptor cross-linking on normal mature lymphocytes in the
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presence of IL-2 also results in an increase in Lck mRNA [113], but these 
mature cells activate different promoters from that activated in immature 
cells [3]. Moreover, the promoters responsible for Lck mRNA transcription 
in malignant cells are again different from those utilized by their normal 
counterparts. It was therefore decided to analyse all transcripts that could 
possibly be generated in CLL cells through activation of both proximal 
(type I) and distal (type II) promoters with the aim that this could provide 
insights into whether Lck expression in these cells reflects the state of their 
maturation or activation, or it is only a consequence of their malignant 
transformation.
CLL cells contained both Type I and Type II transcripts, the Type II 
transcript - which is in normal mature lymphocytes associated with antigen 
receptor signalling - was the dominant product of Lck transcription in these 
malignant cells. The malignant nature of these cells was further 
underscored by expression of variable levels of type la and lb transcripts 
which are normally associated with cells undergoing malignant 
transformation. This analysis of Lck mRNA transcripts therefore supports 
the generally accepted notion that CLL cells are mature, antigen-activated 
malignant cells.
The study of Lck transcription levels in different CLL clones by qRT-PCR 
showed that all cells expressed a high level of Lck mRNA in comparison 
to normal B cells and the malignant cells of HCL. The levels of Lck
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mRNA in the different CLL clones studied were similar to the levels in
normal T cells.
At the onset of the work described in this thesis the presence of Lck in 
CLL cells was still questioned in some publications. However, the work in 
this department clearly showed that in the limited number of clones 
studied, all contained functional Lck protein which was detectable by 
Western blotting and had clear protein tyrosine activity in an in vitro assay 
[190]. Nevertheless at that stage it was still not clear whether Lck is 
expressed in all CLL cells belonging to different subgroups of the disease, 
or only in some cells as demonstrated in mice through comparison of B-l 
cells from peritoneum and spleen. In addition, it has been already shown 
that Lck expression can depend on the stage of cell maturation as well as 
on the degree of cell activation, but whether different CLL cells differ in 
these regards was also still unknown.
The study presented here demonstrates that CLL cells, belonging to by 
now well characterised disease subgroups, all contain variable amounts of 
Lck ranging from barely detectable to as high as in T cells and that this Lck 
does not originate from contaminating T cells. In 42 CLL clones where the 
malignant cells were purified by removing contaminating T cells, 
monocytes/macrophages and NK cells the amount of Lck varied greatly
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but did not correlate with any disease prognosis markers such as IgVH 
gene mutation or ZAP70 expression.
When the levels of Lck mRNA were compared to the level of Lck protein 
present in each case, it was shown that there was no correlation. Thus, 
despite an almost 10-fold difference in protein expression, Lck mRNA 
levels were relatively constant. This indicates that the level of Lck protein 
present in each case is the result of regulation at the post-transcriptional 
level. It also indicates that the half life of the protein is very long, and 
suggests a reason why siRNA targeting Lck mRNA did not result in a 
reduction of protein levels.
In normal B cells, Lck expression can be induced by BCR crosslinking and 
IL-2 [113] but these stimuli failed to up-regulate Lck expression in CLL 
cells. Thus the pathway that in normal B cells leads to increased Lck 
expression in response to BCR stimulation and IL-2 seems to be defective 
in CLL cells, although other results in this thesis show that BCR 
stimulation effectively activates Lck. However since Lck expression could 
be potentially induced by a number of other stimuli, and since all CLL 
cells are thought to be arrested at a similar level of maturation, it still seems 
likely that Lck expression varies with the degree of cell activation by a 
mechanism that remains to be identified.
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The post-translational regulation of Lck protein levels in T cells is well 
described. In response to TCR engagement or PKC activators Lck is 
activated and then serine phosphorylated, which causes a shift on SDS- 
PAGE analysis. I show in this thesis that Lck in CLL cells undergoes 
similar post-translational modifications. BCR crosslinking and 
PMA/Bryostatin stimulation result in a shift in molecular weight of Lck 
corresponding to the appearance of the p60 band. Moreover, I also show 
that this is due to phosphorylation of Lck, most likely on the S42 and S59 
residues that are targeted by PKC and MAPKs.
In T cells, phosphorylated Lck is then targeted for proteasomal degradation 
by polyubiquitinylation [96]. The results presented in this thesis suggest 
that this level of post-translational regulation of Lck protein levels in CLL 
cells may differ from the process in T cells. There was some evidence of 
ubiquitinylation of Lck in response to CLL cell activation by BCR 
engagement or bryostatin stimulation. However, the analysis of the fate of 
the p60 band of Lck was complicated by the sensitivity of CLL cells to the 
cytotoxic effects of the proteasomal inhibitor lactacystin and by the 
transcriptional inhibitors flavopiridol and actinomycin D within the 12 - 
24h culture times of the experiments I performed. Nevertheless, because 
flavopiridol (at a 4h time point where CLL cell viability was unaffected) 
caused a quantitative reduction in Mcll levels while Lck was unaffected, I 
can say that Lck protein levels are not rapidly turned over in the cell, even
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when the cells have been stimulated with bryostatin. Here, the data support 
a notion that phosphorylated Lck in CLL cells is turned over at a far slower 
rate than it would in T cells, and that the reappearance of the p56 band in 
CLL cells on prolonged culture is likely to be the result of 
dephosphorylation.
The regular presence of Lck in CLL cells posed the question of the 
functional role of this enzyme and whether it contributes to the 
pathogenesis of the disease. Since survival of CLL cells undoubtedly 
contributes to their clonal expansion and can be measured in vitro, the next 
step was to examine the effect of Lck inhibition on the in vitro survival of 
unstimulated and variously stimulated CLL cells. Attempts to use siRNA 
to block Lck production in CLL cells did not result in the desired lowering 
of Lck protein. Therefore it was necessary to use a pharmacological 
inhibitor of Lck in all experiments designed to determine its effects on cell 
survival, the signalling pathways involved and the underlying mechanism 
responsible for the change in the balance between cell survival and cell 
death caused by these signals. Firstly, I confirmed that the Lck inhibitor 
acted to inhibit the activity of Lck and not the activity of Lyn, as this latter 
protein is highly expressed and constitutively active in CLL cells [132]. To 
determine whether Lck is involved in preservation of cell viability, 
unstimulated CLL cells from 4 different patients were incubated with a 
range of concentrations of the Lck inhibitor for 48 hours and their viability
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then determined using a DiOC6/PI apoptosis assay. HCs do not contain 
demonstrable amounts of Lck protein, and were therefore used as negative 
controls. The results of this experiment showed that the viability of all CLL 
cell clones tested, but not of HCs, was variably decreased by the Lck 
inhibitor, with 50% of this decrease occurring at around 1 pM in the most 
sensitive cases.
When the number of different CLL cells tested was increased to include 27 
IgVH mutated and 29 unmutated clones it was found that the Lck inhibitor 
at IpM concentration had a considerably larger pro-apoptotic effect on 
unmutated than mutated cells while HC viability was not affected at all. A 
previous study from our department has shown that unmutated cells more 
readily respond to BCR cross-linking by an increase in cell viability 
accompanied by ERK activation [190]. Therefore these observations 
together with the above effects of the Lck inhibitor suggest that Lck may 
be participating in the preservation of cell viability by being a component 
of a signalling pathway that is activated by cognate antigens and also 
includes activation of ERK. However since many alternative stimuli and 
signalling pathways that protect CLL cells from apoptosis were proposed 
in the literature, the viability of CLL cells and the effect of the Lck 
inhibitor were also determined in cells stimulated not only by anti-IgM but 
also CD40L or CpG oligonucleotide (ODN 2006).
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The results of these experiments showed that BCR crosslinking, CD40 
engagement and TLR signalling induced increased CLL cell survival, and 
that the presence of the Lck inhibitor blocked this increase regardless of the 
stimulus. This suggests that the role of Lck in CLL cell cytoprotection is 
not restricted to a single pathway, and that Lck may be involved in the 
regulation of anti-apoptosis proteins. I therefore next investigated the effect 
of the Lck inhibitor on the expression of Bcl2 family and IAP family 
proteins in CLL cells. I found that the presence of this agent in CLL cell 
cultures reduced the expression of XIAP and cIAP2. This reduction of 
expression in XIAP and cIAP2 was not rescued by the presence of zVAD, 
suggesting that Lck inhibitor did not promote caspase cleavage of these 
proteins, but was likely involved in the maintenance of high expression 
levels. I also found that the presence of Lck inhibitor in CLL cell cultures 
resulted in an increase in Bim protein levels. Thus, the combination of 
increased pro-apototic Bim and decreased anti-apoptotic XIAP likely 
stimulated mitochondrial depolarisation resulting in caspase activation and 
cleavage of anti-apototic Mcll and Bcl-xL to further facilitate the process 
of apoptosis.
In order to determine which pathway(s) are involved in Lck-dependent 
cytoprotection, F(ab')2 anti-IgM or CpG oligonucleotide stimulated CLL 
cells were examined for the presence of phosphorylated (activated) ERK, 
Akt and lKKa/[3, in the presence and absence of the Lck inhibitor.
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I found that the presence of the Lck inhibitor profoundly blocked BCR- 
mediated activation of ERK, Akt and IKK, whereas its effects on CpG 
stimulation were negligible. This result matches the survival data because 
the Lck inhibitor had a greater effect on blocking the pro-survival effects of 
BCR crosslinking than it did on those of TLR stimulation. These results 
therefore strongly indicate that Lck may be central to BCR signalling in 
CLL cells. This role of Lck in BCR signalling is supported by my 
experiments showing that BCR-induced ZAP70 phosphorylation is 
blocked by the presence of the Lck inhibitor. ZAP70 is an important 
substrate of Lck in T cells. The exact role of Lck in this process requires 
further studies. Because in vivo, CLL cells are exposed to a large 
combination of different stimuli and their response to these stimuli may 
differ in phenotypically different subgroups of cells, it was necessary to 
concentrate on one single aspect of Lck involvement in the biology of 
these cells and leave the rest for the future work. The aspect chosen as a 
natural follow up of the work already earned out in this department and the 
work discussed above was the role of Lck in ERK activation and the 
possible link of this activation to the mechanism of cytoprotection.
In conclusion, this work was an attempt to explore still controversial 
questions of the tissue specificity and redundancy of different Src family 
kinases using CLL cells as a suitable model cell for such exploration. 
Differences between normal B cells and CLL cells belonging to different
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subgroups with regal'd to the expression and function of antigen receptor 
suggests a possibility of the involvement of an alternative Src family 
kinase in the cellular processes of CLL cells that in normal B cells involve 
Lyn. This work is the first to demonstrate a cytoprotective mechanism in 
CLL cells that could specifically involve Lck and might be relevant for 
survival and clonal expansion of these cells. Like Lyn in normal B cells, 
Lck in CLL cells seems to be involved in several cytoprotective pathways 
that are activated through BCR stimulation. With regard to the importance 
of these studies for the pathogenesis and treatment of CLL, the most 
relevant future studies are likely to be those aimed at clarification of 
whether or not Lck cytoprotection is equally relevant for all different 
subgroups of the disease.
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APPENDIX
Table 1.2 Clinical details of CLL cases studied.
Case no (a) WBC (b) CD38 (c) Binet (d) Rai (e) VH% (f) Gene usage (g) Class (h)
1 167 4 C III - - -
2 98 82 A I 1.02 3-07/D P-54 M
3 - - - - 0.34 3-07/D P-54 M
4 33 87 C IV 0 1-69/D P-10 M
5 310 16 c IV 0.42 5-51/DP-73 M
6 57 43 c IV 3.38 3-23/D P-47 M
7 57 43 c IV 3.38 3-23/DP-47 M
8 129 43 c IV 3.38 3-23/DP-47 M
9 84 43 c IV 3.38 3-23/DP-47 M
10 48 10 A l 0 1-69/DP-10 M
11 46 14 - - 4.67 4-30.1/DP-65 M
12 80 64 c IV 0 3-30/DP-46 G
13 163 14 c IV 0 3-21/DP-77 M
14 21 14 B I 1.09 3-66/8-1B+ M
15 57 13 A 0 2.8 3-21/DP-77 M
16 122 - B I 0 1-69/D P-10 M
17 427 98 B II 0 1-18/D P-14 M
18 192 - C III 0 5-51/DP-73 M
19 134 - B 0 0.35 1.46/D P-7 M
20 125 - - - 0 1-69/D P-10 -
21 129 4 B II 8.06 4-34/D P-63 G
22 155 - - - 5.37 4-34/D P-63 G
23 330 - C IV 2.46 3-30.3/DP-46 M
24 33 - A 0 3.7 3-07/D P-54 M
25 128 - C III 10.47 3-30/D P-49 M
26 18 7 A 0 3.64 3-73/YAC-9 M
27 132 53 - - 0 4-b*01 M
28 170 - C II 2.46 3-30.3/DP-46 M
29 158 - c III 8.93 4-34/D P-63 M
30 240 97 - - 0 5-51*01 A
31 285 98 B II 0 1-18/D P -14 M
32 19 - B I 0 VH3-30/DP-49 M
33 382 - - - 0 DP8+ M
34 105 27 B I 0 1-24*01 M
35 142 - - - 0.4 3-48/ M
36 118.5 - - - 3.6 3-73/ M
37 242 - - - 12.3 3-53/ G
38 126.5 - C - 0.0 3-09/ M
39 184 - - - 0.0 3-30/ M
40 183 - - - 0.3 2-70/ M
41 23.3 - A - 1.35 3-48/ M
42 412 - - - 0 DPS M
43 86.8 - B - 1.09 3-66/ M
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Case no (a) WBC (b) CD38 (c) Binet (d) Rai (e) VH% (f) Gene usage (g) Class (h)
44 49.3 0 A - - - -
45 215 low A 0 4.47 4-43/ M
46 128 - - - 3.2 3-48/ M
47 116 - A - 6.1 3-23/ G
48 24.7 - A 0 8.5 3-13/ M
49 66.4 low C - 11.11 3-48/ M
50 124.7 - - - 0.0 1-69/ M
51 147 60 A - 0 4-34/ M
52 124 - B - 6.12 V3-49 G
53 110.7 - - - 8.9 4-34/ G
54 187 - B - 0.0 4-31/ M
55 182 - B - 6.45 1-69/ M
56 266 - - - 0.3 3-49/ M
57 - 25 - - 0.35 1.46 M
58 210 - B - 8.6 3-09/ M
59 165 - - - 4.6 4-34/ M
60 127 - - - 0.0 1-69/ M
61 165 - A - 4.56 4-34/ M
62 71.5 - - - - - -
63 165 - - - 4.6 4-34/ M
64 54 - - - 6.12 3-72/ M
65 196 - - - 3.1 3-30/ M
66 127 - B - - - -
67 150 - - - 5,2 3-48/ M
68 - - - - - -
69 98.8 - A - 4.4 3-07/ M
70 175 - - - 6.6 1-69/ M
71 174 - A - 1.75 4-59/ M
72 105 - - . 1.8 4-59/ M
73 77 - B II 1.7 4-61/ M
74 105 - - - 2.6 3-48/ M
75 152 - - - 0 - -
a. Case number used in this thesis
b. White blood cell count (xl 09/L)
c. % CDS 8 positive cells
d. Binet clinical staging
e. Rai clinical staging
f. IgVH gene % deviation from germ line sequence
g. IgVH gene segment usage
h. Class of immunoglobulin
Case numbers 2/3, 6-9 and 21/22 are subsequent rebleeds of the same patient.
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Lck mRNA sequences
NM 001042771.1 LCK, transcript variant 1, mRNA
GTGTGAATTTACTTGTAGCCTGAGGGCTCAGAGGGAGCACCGGTTTGGAGCT
GGG ACCCCCT ATTTT AGCTTTT CT GT GGCTGGTG A AT GGGG AT CCC AGG AT CT
CACAATCTCAGGGACCATGGGCTGTGGCTGCAGCTCACACCCGGAAGATGAC
TGG AT GG AA AAC ATCG AT GT GT GT G AG AACTGCC ATT AT CCC AT AGT CCC ACT
GGATGGCAAGGGCACGCTGCTCATCBPAAK K»( I ( I G A( .GlfliGGGACCCA
CTGGTTACCTACGAAGGCTCCAATCCGCCGGCTTCCCCACTGCAAGACAACCT
GGTT AT CGCTCT GC AC AGCT ATG AGCCCTCT C ACG ACGG AG AT CT GGGCTTT G
AGAAGGGGGAACAGCTCCGCATCCTGGAGCAGAGCGGCGAGTGGTGGAAGG
CGCAGTCCCTGACCACGGGCCAGGAAGGCTTCATCCCCTTCAATTTTGTGGCC
AAAGCGAACAGCCTGGAGCCCGAACCCTGGTTCTTCAAGAACCTGAGCCGCA
AGGACGCGGAGCGGCAGCTCCTGGCGCCCGGGAACACTCACGGCTCCTTCCT
CATCCGGGAGAGCGAGAGCACCGCGGGATCGTTTTCACTGTCGGTCCGGGAC
TTCGACCAGAACCAGGGAGAGGTGGTGAAACATTACAAGATCCGTAATCTGG
ACAACGGTGGCTTCTACATCTCCCCTCGAATCACTTTTCCCGGCCTGCATGAA
CTGGTCCGCCATTACACCAATGCTTCAGATGGGCTGTGCACACGGTTGAGCCG
CCCCTGCCAGACCCAGAAGCCCCAGAAGCCGTGGTGGGAGGACGAGTGGGA
GGTTCCCAGGGAGACGCTGAAGCTGGTGGAGCGGCTGGGGGCTGGACAGTTC
GGGG AGGTGTGGATGGGGT ACT ACAACGGGCACACGAAGGTGGCGGTGAAG
AGCCTGAAGCAGGGCAGCATGTCCCCGGACGCCTTCCTGGCCGAGGCCAACC
TCATGAAGCAGCTGCAACACCAGCGGCTGGTTCGGCTCTACGCTGTGGTCAC
CCAGGAGCCCATCTACATCATCACTGAATACATGGAGAATGGGAGTCTAGTG
GATTTTCTCAAGACCCCTTCAGGCATCAAGTTGACCATCAACAAACTCCTGGA
CATGGCAGCCCAAATTGCAGAAGGCATGGCATTCATTGAAGAGCGGAATTAT
ATT C AT CGT G ACCTTCGGGCT GCC AAC ATT CT GGT GT CTG AC ACCCTG AGCT G
CAAGATTGCAGACTTTGGCCTAGCACGCCTCATTGAGGACAACGAGTACACA
GCCAGGGAGGGGGCCAAGTTTCCCATTAAGTGGACAGCGCCAGAAGCCATTA
ACTACGGGACATTCACCATCAAGTCAGATGTGTGGTCTTTTGGGATCCTGCTG
ACGGAAATTGTCACCCACGGCCGCATCCCTTACCCAGGGATGACCAACCCGG
AGGTGATTCAGAACCTGGAGCGAGGCTACCGCATGGTGCGCCCTGACAACTG
TCCAGAGGAGCTGTACCAACTCAT$*AGGC I (j IGCTGGAAC.G \|CGCCCAGAG
GACCGGCCCACCTTTGACTACCTGCGCAGTGTGCTGGAGGACTTCTTCACGGC
CACAGAGGGCCAGTACCAGCCTCAGCCTTGAGAGGCCTTGAGAGGCCCTGGG
GTT CT CCCCCTTT CT CT CC AGCCTG ACTT GGGG AG AT GG AGTT CTT GT GCC AT
AGTCACATGGCCTATGCACATATGGACTCTGCACATGAATCCCACCCACATGT
GACACATATGCACCTTGTGTCTGTACACGTGTCCTGTAGTTGCGTGGACTCTG
CACATGTCTTGTACATGTGTAGCCTGTGCATGTATGTCTTGGACACTGTACAA
ggtacccctttctggctHBIMBBBBMMHBgagagaggggagaa
GCCT GGG ATTG AC AG AAGCTTCT GCCC ACCT ACTTTT CTTT CCTC AG AT CAT C 
C AG AAGTTCCTC AAGGGCC AGG ACTTT AT CT A AT ACCT CT GT GTGCTCCT CCT 
TGGTGCCTGGCCTGGCACACATCAGGAGTTCAATAAATGTCTGTTGATGACTG 
TTGTAAAAAAAAAAAAAAAAAAA
NM 005356.3 LCK, transcript variant 2, mRNA
AGTCAGGGTGGGACGTGGGCGCGGGGAGACAGGTGGTGGCTACGACGGCGA
AGGGAGCTGAGACTGTCCAGGCAGCCAGGTTAGGCCAGGAGGACCATGTGA
ATGGGGCCAGAGGGCTCCCGGGCTGGGCAGGGACCATGGGCTGTGGCTGCAG
CTCACACCCGGAAGATGACTGGATGGAAAACATCGATGTGTGTGAGAACTGC
CATTATCCCATAGTCCCACTGGATGGCAAGGGCACGCTGCTCATdM^M
Bi^H^^HiGGGACCCACTGGTTACCTACGAAGGCTCCAATCCGCCGGC
TT CCCC ACT GC A AG AC AACCT GGTT AT CGCT CT GC AC AGCT AT G AGCCCTCT C
ACGACGGAGATCTGGGCTTTGAGAAGGGGGAACAGCTCCGCATCCTGGAGCA
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GAGCGGCGAGTGGTGGAAGGCGCAGTCCCTGACCACGGGCCAGGAAGGCTT
CATCCCCTTCAATTTTGTGGCCAAAGCGAACAGCCTGGAGCCCGAACCCTGGT
TCTTCAAGAACCTGAGCCGCAAGGACGCGGAGCGGCAGCTCCTGGCGCCCGG
GAACACTCACGGCTCCTTCCTCATCCGGGAGAGCGAGAGCACCGCGGGATCG
TTTTCACTGTCGGTCCGGGACTTCGACCAGAACCAGGGAGAGGTGGTGAAAC
ATTACAAGATCCGTAATCTGGACAACGGTGGCTTCTACATCTCCCCTCGAATC
ACTTTTCCCGGCCTGCATGAACTGGTCCGCCATTACACCAATGCTTCAGATGG
GCTGTGCACACGGTTGAGCCGCCCCTGCCAGACCCAGAAGCCCCAGAAGCCG
TGGTGGGAGGACGAGTGGGAGGTTCCCAGGGAGACGCTGAAGCTGGTGGAG
CGGCTGGGGGCTGGACAGTTCGGGGAGGTGTGGATGGGGTACTACAACGGGC
ACACGAAGGTGGCGGTGAAGAGCCTGAAGCAGGGCAGCATGTCCCCGGACG
CCTTCCTGGCCGAGGCCAACCTCATGAAGCAGCTGCAACACCAGCGGCTGGT
TCGGCTCTACGCTGTGGTCACCCAGGAGCCCATCTACATCATCACTGAATACA
TGGAGAATGGGAGTCTAGTGGATTTTCTCAAGACCCCTTCAGGCATCAAGTTG
ACCATCAACAAACTCCTGGACATGGCAGCCCAAATTGCAGAAGGCATGGCAT
T C ATT G AAG AGCGG AATT AT ATTC ATCGT G ACCTTCGGGCT GCC AAC ATT CT G
GTGTCTGACACCCTGAGCTGCAAGATTGCAGACTTTGGCCTAGCACGCCTCAT
TGAGGACAACGAGTACACAGCCAGGGAGGGGGCCAAGTTTCCCATTAAGTGG
ACAGCGCCAGAAGCCATTAACTACGGGACATTCACCATCAAGTCAGATGTGT
GGTCTTTTGGGATCCTGCTGACGGAAATTGTCACCCACGGCCGCATCCCTTAC
CCAGGGATGACCAACCCGGAGGTGATTCAGAACCTGGAGCGAGGCTACCGCA
TGGTGCGCCCTG AC A ACT GTCC AG AGG AGCT GT ACC A ACT C AT|G AGC i( TGT< I
CTGGAGGACTTCTTCACGGCCACAGAGGGCCAGTACCAGCCTCAGCCTTGAG 
AGGCCTTGAGAGGCCCTGGGGTTCTCCCCCTTTCTCTCCAGCCTGACTTGGGG 
AGATGGAGTTCTTGTGCCATAGTCACATGGCCTATGCACATATGGACTCTGCA 
C ATG AATCCC ACCC AC AT GT G AC AC AT ATGC ACCTTGT GT CT GT AC ACGT GT C 
CTGTAGTTGCGTGGACTCTGCACATGTCTTGTACATGTGTAGCCTGTGCATGT 
ATGTCTTGGACACTGTACAAGGTACCCCTTTCTGGCT^^——■ 
B^iGAGAGAGGGGAGAAGCCTGGGATTGACAGAAGCTTCTGCCCACCTAC 
TTTTCTTTCCTCAGATCATCCAGAAGTTCCTCAAGGGCCAGGACTTTATCTAA 
T ACCT CT GT GT GCTCCT CCTT GGT GCCT GGCCT GGC AC AC ATC AGG AGTT C AA 
T AAAT GT CT GTTG ATG ACT GTT GT AAA AA AA AA AA AA A A A AA A
RT-PCR forward primers
R i PC R reverse primer
qRT-PCR forward prime!
ciRT-PCR reverse primer
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Buffers
TBST
Tris (pH 7.4) 150mM
Sodium chloride 50mM
Tween-20 0.1%
Rumiing gel buffer (4x)
Tris (pH 8.8) 1.5M
SDS 0.4%(w/v)
Running gel
Acrylamide Varied (usually 10%)
4x Running gel buffer 25%
TEMED 0.01%
Ammonium persulphate 0.04%(w/v)
Made up to 100% with dEhO
Stacking gel buffer
Tris (pH 6.8) 0.5M
SDS 0.4%(w/v)
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Stacking gel
Acrylamide 4%
Stacking gel buffer 25%
TEMED 0.1%
Ammonium persulphate 0.08%(w/v)
Made up to 100% with dEEO.
Transfer buffer
Bought from Geneflow Ltd (Fradley, UK)
Electro buffer
Tris
Glycine
SDS
25mM 
192mM 
0.1%(w/v)
Western blot stripping buffer 
SDS 2%(w/v)
Tris (pH6.7) 62.5mM
jS-mercaptoethanol 1 OOmM
Laemelli buffer (2x)
Tris (pH6.8) 
Glycerol
125mM
20%
188
SDS
/3 -mercaptoethanol 
Bromophenol blue
Clear lysis buffer
SDS 
Glycerol 
Tris (pH6.8)
EDTA
4%(w/v)
10%
0.006%(w/v)
l%(w/v)
10%
50mM
5mM
Phosphate Buffered Saline TPBS)
NaCl
KC1
Na2HP04
KH2PO4
150mM 
3mM 
4.3mM 
1.5mM
Purification buffer
PBS
BSA 0.1%(w/v)
EDTA 2mM
Degassed overnight prior to use.
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